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SUMMARY   
 
     Cellular glucose metabolism involves the conversion of glucose into CO2 and 
H2O via glycolysis and oxidative phosphorylation to produce ATP and into 
numerous metabolites that are critical for biosynthesis of organic molecules as 
well as for a number of protein modifications. Cellular glucose metabolism is 
known to be deregulated in pathological conditions, particularly in cancer and 
diabetes. HIF-1 and Txnip are two major regulators of cellular glucose 
metabolism. HIF-1 promotes the glycolytic pathway during hypoxia by 
upregulating genes encoding glucose transporters and a series of glycolytic 
enzymes while inhibiting mitochondrial oxidative phosphorylation. Txnip acts as 
a negative regulator of glucose uptake, thus leading to a decrease in cellular 
glucose utilization. To gain further insights into the regulation of cellular glucose 
metabolism, we investigated how HIF-1 is regulated by mitochondrial activity 
as well as the mechanism through which Txnip regulates cellular glucose uptake.  
     HIF-1 protein stabilization is known to be dependent on a functional 
mitochondrial electron transport chain. It has been suggested that mitochondrial 
electron transport promotes HIF-1 protein stabilization by either decreasing the 
cellular oxygen availability or by producing and releasing reactive oxygen species 
that originate from complex III. In our study, we found that ROS production by 
mitochondrial complex III is not required for hypoxia-induced HIF-1 
stabilization. This conclusion is based on a number of results. For instance, 
reestablishing mitochondrial oxygen consumption in the presence of a complex III 
inhibitor using an artificial electron donor to complex IV or by overexpressing 
xii 
 
Ciona intestinalis alternative oxidase results in HIF-1 protein stabilization in 
hypoxia. Furthermore, five inhibitors that target different sites of the 
mitochondrial electron transport chain have similar effects on the HIF-1 protein 
half-life in hypoxia but vary in their effects on mitochondrial ROS production. 
Finally, ROS do not regulate prolyl hydroxylase activity directly. Our results 
suggest that mitochondria modulate the cellular hypoxic response by regulating 
cellular oxygen availability. 
     In the second part of the study, we studied the mechanism through which the 
-arrestin proteins Txnip and Arrdc4 inhibit cellular glucose utilization. It has 
been reported that Txnip regulate cellular glucose utilization indirectly by 
promoting mitochondrial function. However, we show that inhibition of cellular 
glucose utilization by Txnip and Arrdc4 was sustained when the mitochondrial 
ETC was inhibited. Our results indicate that the -arrestin proteins compromise 
glycolytic ATP production. We also show that Txnip and Arrdc4 inhibit glucose 
consumption but not the glycolytic cascade since the -arrestin proteins lowered 
the cellular concentrations of fructose-2,6-bisphosphate and glucose-6-phosphate 
without affecting the enzyme activities of phosphofructokinase-2 and hexokinase. 
These results suggest that Txnip and Arrdc4 inhibit glucose utilization by 
inhibiting glucose uptake. Indeed, we observed a markedly reduced plasma 
membrane localization of glucose transporter GLUT1 upon Txnip or Arrdc4 
overexpression. Contrary to a recent report, our results indicate that Txnip and 
Arrdc4 do not appear to promote internalization of GLUT1 but instead inhibit 
GLUT1 trafficking to the plasma membrane. In conclusion, our results suggest 
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that -arrestin proteins inhibit cellular glucose uptake by preventing anterograde 
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Cellular glucose metabolism  
     Glucose is the primary fuel used by cells and glucose can be derived from 
breakdown of dietary sugars and digestible carbohydrates consumed by the body. 
The generated glucose can be metabolized in cells by either the glycolytic 
pathway or pentose phosphate pathway to produce energy and biomaterials for 
cellular survival. 
     Glycolysis is the breakdown of glucose via ten enzymatic catalyzed steps to 
form  two molecules of pyruvate. The first five steps of glycolysis constitute the 
energy investment phase and the next five steps are the energy production phase 
[Akram, 2013]. Upon entering cells, glucose is phosphorylated by hexokinase to 
form glucose-6-phosphate. The phosphorylated hexose is converted by 
phosphoglucoisomerase into fructose-6-phosphate. Fructose-6-phosphate is 
phosphorylated by phosphofructokinase to form fructose 1,6-bisphosphate. 
Aldolase then cleaves fructose 1,6-bisphosphate into glyceraldehyde 3-phosphate 
and dihydroxyacetone phosphate. Dihydroxyacetone phosphate is converted by 
triose phosphate isomerase into glyceraldehyde 3-phosphate.  Thus in total two 
molecules of glyceraldehyde 3-phosphate are generated from one glucose 
molecule in the energy investment phase.  In addition, two ATP molecules are 
utilized by hexokinase and phosphofructokinase in this phase.  In the next five 
steps of glycolysis or the energy production phase, four ATP molecules and two 
molecules of NADH are produced from processing two molecules of  
glyceraldehyde 3-phosphate. Firstly, glyceraldehyde 3-phosphate is converted by 
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glyceraldehyde 3-phosphate dehydrogenase to form 1,3-bisphosphoglycerate and 
NADH. Next, an ATP molecule is formed when 1,3-bisphosphoglycerate is 
converted to 3-phosphoglycerate by phosphoglycerate kinase. 3-phosphoglycerate 
is then converted into 2-phosphoglycerate by phosphoglycerate mutase. Enolase 
enzyme catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate. 
In the final step of glycolysis, pyruvate kinase catalyzes the transfer of a 
phosphate group from phosphoenolpyruvate to form pyruvate and an ATP 
molecule . Therefore, there is a net gain of two ATP molecules from glycolysis.   
The fate of pyruvate is determined by the absence or the presence of oxygen. In 
the absence of oxygen, pyruvate is reduced to lactate and this reaction is catalyzed 
by lactate dehydrogenase in the presence of NADH. The regenerated NAD
+
 is 
then utilized by the upstream glyceraldehyde 3-phosphate dehydrogenase to 
maintain glycolysis. In the presence of oxygen, pyruvate is converted into acetyl-
CoA in the mitochondria by pyruvate  dehydrogenase to fuel the citric acid cycle.  
NADH and FADH2 generated from the cycle are used as electron donors to 
generate more ATP molecules via oxidative phosphorylation. 
Oxidative phosphorylation is carried out by the electron transport chain located in 
the inner mitochondrial membrane. The electron transport chain is made up by 
four mitochondrial respiratory complexes namely NADH:ubiquinone 
oxidoreductase (complex I), succinate dehydrogenase (complex II), cytochrome c 
reductase (complex III) and  cytochrome c oxidase (complex IV). Mitochondrial  
complex I accepts electrons transferred from NADH while mitochondrial 
complex II accepts electrons from FADH2. Electrons from both complex I and II 
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are then transferred to the downstream complex III via the mobile electron carrier 
ubiquinone. Cytochrome c, another electron carrier then carries electrons from 
complex III to complex IV.  Electrons from complex IV are transferred to oxygen 
that acts as the final electron acceptor of the electron transport chain. During the 
electron transport, protons are pumped out from the mitochondrial matrix into the 
intermembrane space by complex I, III and IV. The generated proton gradient is 
utilized by the ATP synthase or complex V  to produce ATP from ADP and 
inorganic phosphate. Therefore if glycolysis is linked to oxidative 
phosphorylation, breakdown of glucose will theoretically yield a total of 38 ATP 
molecules.  
     The pentose phosphate pathway is an alternative pathway for glucose 
metabolism. In this pathway, glucose that is converted to glucose-6-phosphate 
will undergo two stages to synthesize ribose 5-phosphate and NADPH reducing 
equivalents [Stanton, 2012].  Firstly, glucose-6-phosphate is oxidized to 6-
phosphoglucono--lactone by glucose-6-phosphate dehydrogenase. 6-
phosphoglucono--lactone is then converted to 6-phosphogluconate by lactonase. 
Ribulose 5-phosphate is generated from 6-phosphogluconate by the activity of 6-
phosphogluconate dehydrogenase.  In the second stage, ribulose 5-phosphate is 
changed into ribose 5-phosphate by phosphopentose isomerase. Ribose 5-
phosphate is utilized by cells to synthesize nucleic acids. In addition, 2 NADPH 
molecules are generated during reactions catalyzed by glucose-6-phosphate and 6-
phosphogluconate dehydrogenase in the pentose phosphate pathway. The 
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generated NADPH plays a role in fatty acid synthesis and antioxidant defense [ 
Jiang et al., 2014; Zhang et al., 2010]. 
 
     Glucose metabolism is regulated by various hormones. However control of 
glucose metabolism is primarily mediated by insulin and glucagon. These 
hormones regulate glucose metabolism via various transcription factors and 
signaling intermediates. Two important regulators of glucose metabolism are 
transcription factors hypoxia inducible factor and the -arrestin protein 
thioredoxin interacting protein.    
In this study, we characterized the function and regulation of these two mediators. 
1.1 Hypoxia inducible factor (HIF) 
     Hypoxia is defined as a condition when oxygen demand exceeds the supply 
[Taylor, 2008]. It occurs in both normal physiological and pathological conditions 
such as during embryonic development, adaptation to high altitudes, ischemic 
diseases or cancer. Cells respond to hypoxia conditions by activating the 
transcription factors hypoxia-inducible factors (HIF), including HIF-1 and HIF-2, 
to induce genes (e.g. erythropoietin, vascular endothelial growth factor, glucose 
transporter1, glycolytic enzymes) that allow cells to adapt to low oxygen 
condition and the resulting cellular metabolic consequences. 
1.1.1 Discovery of Hypoxia inducible factor-1 (HIF-1) 
     Hypoxia inducible factor-1 (HIF-1), a member of the human HIF family, was 
originally discovered through the investigation of human erythropoietin (EPO) 
gene expression in the early 90s. It is known that EPO gene is overexpressed in 
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fetal liver and in kidney during adulthood when subjected to hypoxia to stimulate 
production of erythrocytes.  However the molecular mechanism in controlling 
EPO gene expression was unknown. In 1991, Semenza and colleagues identified 
that DNA sequences in the 3’ flanking region of the EPO gene are essential for 
enhancing its transcription [Semenza et al., 1991].  The identified DNA region 
that functions as a hypoxia-inducible enhancer, contains a 50bp hypoxic response 
element (HRE) [Semenza et al., 1992], which was further characterized by the 
same group of researchers. This led to the discovery of a nuclear factor designated 
HIF-1 and its binding site within the HRE of the EPO gene. Before HIF-1 can 
bind to the HRE, it must undergo de novo protein synthesis induced by hypoxia. 
Subsequent studies revealed that HIF-1 not only binds to DNA in EPO-producing 
cells but also to reporter genes containing HIF-1 binding sites in non-EPO-
producing cells [Wang and Semenza, 1993]. This suggested that other than 
regulating EPO gene expression, HIF-1 also possibly regulates a range of oxygen-
sensitive genes. These were subsequently identified as vascular endothelial 
growth factor (VEGF),  glucose transporter 1 (GLUT-1),  aldolase A (ALDA), 
phosphoglycerate kinase 1 (PGK-1), pyruvate kinase (PK) and lactate 
dehydrogenase A (LDH-A) [Shweiki et al., 1992; Goldberg and Schneider, 1994; 
Ebert et al., 1995;  Firth et al., 1994; Semenza et al., 1994]. HIF-1 was then 
purified biochemically via DEAE ion-exchange and DNA affinity 
chromatography from cellular nuclear extracts previously subjected to hypoxia or 
treated with hypoxic mimetic, cobalt chloride.  Further analysis of this 
transcription factor revealed that it is a basic helix-loop-helix-(bHLH)-PAS 
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heterodimeric complex consisting of 2 subunits, HIF-1 and HIF-1 [Wang and 
Semenza, 1995; Wang et al., 1995]. Properties of both subunits will be briefly 
elaborated in the following sections.  
1.1.2 Structure and function of Hypoxia Inducible factor –  (HIF-)  
     Hypoxia inducible factor– (HIF-) is an oxygen-regulated subunit of HIF. 
Three isoforms of this subunit (HIF-1, HIF-2 and HIF-3) are identified, with 
HIF-1 being best characterized.   
1.1.2.1 HIF-1 
    HIF-1 is a 120kDa polypeptide that contains multiple domains including a 
basic helix-loop-helix (bHLH) followed by a Per-ARNT-Sim (PAS) domain at its 
N-terminal region [Wang and Semenza, 1995; Wang et al., 1995] (Figure 1). The 
bHLH domain is responsible for both the dimerization of HIF-1 with the HIF-1 
subunit and binding of the formed complex (HIF1) to the HRE of the target gene. 
The dimerization is further strengthened by both A and B domains of the PAS 
motif.   
    The HIF-1 subunit also contains other domains such as oxygen dependent 
degradation domain (ODDD), two transactivation domains (N-terminal-TAD and 
C-terminal-TAD) and two nuclear localisation signals (NLS). The ODDD is an 
important region within HIF-1 that determines its protein stability by controlling 
degradation via the ubiquitin-proteasome system [Huang et al., 1998].  The N-
terminal-TAD (N-TAD) that is located in the ODDD.  Both the N-TAD and the 
C-terminal-TAD (C-TAD) are involved in promoting the transcriptional activity 
7 
 
of HIF1 when HIF-1 stabilized in low oxygen conditions [Ruas et al., 2002]. In 
between both TADs lies an inhibitory domain (ID) that inhibits the transcriptional 
activity of the TADs during normoxia [Jiang et al., 1997]. The two NLSs which 
are located at both C and N terminal regions (NLS-N, NLS-C) serve to translocate 
the stabilized HIF-1 protein to the nucleus during low oxygen conditions [Kallio 
et al., 1998].  
1.1.2.2 HIF-2 
    Unlike HIF-1, which is expressed ubiquitously, HIF-2 is only present in 
specific cell lines derived from different organs such as brain, lung, liver, heart, 
kidney, pancreas and intestine [Wiesener et al., 2003]. Since it has a 48% 
similarity in its amino acid sequence compared to HIF-1, it has a similar domain 
structure and similar biochemical properties compared to HIF-1 [Ema et al., 
1997; Tian et al., 1997]. Like HIF-1, HIF-2 also dimerizes with HIF-1 to 
form HIF-2 to transactivate its target genes. 
1.1.2.3 HIF-3 
    HIF-3 is the third HIF- subunit to be identified.  It shares 57% and 53% 
amino acid identity with HIF-1 and HIF-2, respectively, in both the bHLH and 
PAS domains [Gu et al., 1998]. HIF-3 contains an N-TAD and ODDD, however 
a C-TAD is absent. HIF-3 has been shown to be a possible negative regulator of 
both HIF-1 and HIF-2 in human kidney since it competes to dimerize with 
HIF-1 to form HIF-3. HIF-3 will bind to HRE sequence to prevent transcription 
8 
 
of HIF-1 and HIF-2 inducible genes. However more research must be done to 
elucidate the function of HIF-3 [Hara et al., 2001].   
    Two splice variants of HIF-3 also play a part in negatively regulating HIF-1 
and HIF-2 mediated transcription. The first HIF-3 splice variant, Inhibitory-
PAS domain protein (IPAS), forms a nonfunctional complex with HIF-1 within 
the nucleus to prevent HIF-1 from binding to HRE and transactivating VEGF 
gene in mouse cornea [Makino et al., 2001]. The second HIF-3 splice variant, 
neonatal and embryonic PAS (NEPAS), negatively regulates the expression of 
HIF-1 and HIF-2 target genes in the same manner as HIF-3 by forming a 
complex with HIF-1. This reduces the availability of HIF-1 to form functional 
transcriptional factors like HIF-1 and HIF-2 during embryonic and neonatal phase 
[Yamashita et al., 2008]. Given their transcriptional upregulation under conditions 
of hypoxia, HIF-3 and its splice variants (IPAS and NEPAS) play an important 
role in providing negative feedback regulation of the transcriptional activities of 
both HIF-1 and HIF-2 subunits at different stages of a mammalian’s life. 
1.1.3 Structure and function of hypoxia inducible factor-1 (HIF-1) 
    Unlike the HIF- subunits, the HIF-1 subunit is constitutively expressed and 
has a molecular weight of 94kDa. HIF-1, also known as aryl hydrocarbon 
nuclear translocator (ARNT), has b-HLH-PAS domains and a NLS, which 
enables it to heterodimerize with the HIF- subunits in the nucleus to form HIF-1, 
HIF-2 or HIF-3 to regulate hypoxia responsive genes (Figure1). HIF-1 also has a 
C-TAD, which enables HIF-1 or HIF-2 to induce genes that allow cells to adapt to 
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hypoxia [Kobayashi et al., 1997]. In addition, HIF-1 also interacts with other 
non-hypoxic binding partners that include aryl hydrocarbon receptor to 







Figure 1. Structure of HIF-1 and HIF-1. (Modified from Mazure et al., 
2004; Brahimi-Horn and Pouysségur, 2009) HIF-1 and HIF-1β contain the 
following domains as depicted in the figure:  a basic helix-loop-helix (bHLH) 
motif, Per-ARNT-Sim (PAS) domain, oxygen dependent degradation domain 
(ODDD), N-terminal activation domain (N-TAD), C-terminal activation domain 
(C-TAD), nuclear localization signal (NLS). Domains at the N-terminus 
participate in dimerization and binding of both HIF-1 and HIF-1β subunits to 
DNA, while domains at the C-terminus serve in regulatory and transactivation 
functions of the subunits. Hydroxylation of proline 402/564 (P402/564) promotes 
ubiquitination and degradation of HIF-1 during normoxia. In addition, 
hydroxylation of Asparagine 803 (N803) prevents interaction of HIF-1 with the 
transcriptional coactivators p300 and CREB-binding protein (CBP). Both N-TAD 
10 
 
and C-TAD in HIF-1 are involved in transcriptional activity of HIF-1 during 
hypoxia. 
 
1.1.4  Regulation of HIF-1 activity 
    The activity of HIF-1 is tightly regulated and depends on the protein stability 
and transcriptional activity of the HIF-1 subunit which is influenced by two 
oxygen dependent hydroxylation events. 
1.1.4.1 Regulation of HIF-1 protein stability and transcriptional activity 
during normoxia 
    At normal oxygen conditions, despite continuous expression and translation, 
the HIF-1 protein is present at very low levels. This is due to very fast 
proteasome dependent degradation of the HIF-1 protein [Wang et al., 1995; 
Salceda and Caro, 1997]. The HIF-1 protein is targeted for proteasome 
dependent degradation mediated through oxygen-dependent ubiquitination via the 
pVHL-ElonginB/C-Cul2 E3 ubiquitin ligase. The von Hippel-Lindau protein 
(pVHL) acts as the substrate-recognition subunit of the E3 ubiquitin ligase and 
recognizes either of the hydroxylated conserved proline residues (Pro402/564) 
within the (ODDD of the HIF-1 subunit [Masson et al., 2001; Jaakkola et al., 
2001, Huang et al., 1998]. The prolyl hydroxylation is carried out by a family of 
oxygen-dependent prolyl-4-hydroxylase domain enzymes (PHD1, PHD2 and 
PHD3) in the presence of iron as their cofactor. Upon recognizing the 
hydroxylated HIF-1, the pVHL-ElonginB/C-Cul2 E3 ubiquitin ligase catalyzes 
the conjugation of a polyubiquitin chain onto the HIF-1 protein with the aid of 
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an E2 enzyme. The polyubiquitinated hydroxylated HIF-1 then undergo rapid 
proteasomal degradation.  
    As a second line of oxygen dependent regulation, HIF-1 transcriptional 
activity is controlled by another oxygen and iron dependent dioxygenase enzyme, 
asparaginyl hydroxlase known as factor inhibiting HIF-1 (FIH-1). During 
normoxia, FIH-1 hydroxylates an asparagine residue (Asn 803) within C-TAD of 
HIF-1 [Lando et al., 2002a; Lando et al., 2002b]. Asparagine hydroxylation 
prevents the interaction of HIF-1 with coactivators such as p300 and CREB-
binding protein (CBP), thus inhibiting transcription of HIF-1- target genes (Figure 
2). 
1.1.4.2 Regulation of HIF-1 protein stability and transcriptional activity 
during hypoxia 
    During hypoxia, lack of oxygen inactivates PHDs and hydroxylation of the 
HIF-1 subunits is inhibited. The non-hydroxylated HIF-1 subunits that are not 
recognized by pVHL escape from ubiquitination and proteasomal degradation. 
Thus, HIF-1 subunits will rapidly accumulate and translocate into nucleus. 
Within the nucleus, HIF-1 heterodimerizes with HIF-1 to form HIF-1. Since 
FIH-1 is not functional in the absence of oxygen, this permits the binding of 






Figure 2. Schematic diagram of HIF-1 protein stabilization and 
transcriptional activity during normoxia and hypoxia.  During normoxia, HIF-
1 is hydroxylated by both the oxygen dependent PHD2 and FIH-1 enzymes at 
Proline 402/564 (Pro) and Aspargine 803 (Asn), respectively. Hydroxylation of 
Pro 402/564 creates a motif that is recognized by pVHL, a substrate recognition 
subunit of the Cullin2 (Cul2)-based E3 ubiquitin ligase. Thus, upon binding of 
pVHL HIF-1 is targeted for polyubiquitination and proteasomal degradation. In 
addition, hydroxylation of Asn prevents the interaction of HIF-1 with p300/CBP 






leads to inactivation of both PHD2 and FIH-1.The non-hydroxylated HIF-1 
translocates into the nucleus and heterodimerizes with HIF-1β to form HIF-1. In 
the absence of Asn hydroxylation, HIF-1 binds to p300/CBP to promote 
transcription of HIF-1 target genes. 
 
 
1.1.5 Role of HIF-1 in regulating cellular glucose metabolism during hypoxia 
and cancer 
    HIF-1 has been shown to increase glycolytic rates during hypoxia in both 
normal cells and cancer [Semenza, 2009; Semenza, 2007].  HIF-1 increases 
cellular glucose utilization via two mechanisms. Firstly, HIF-1 functions by 
transactivating genes involved in glucose uptake and glycolysis. Secondly, HIF-1 
also concurrently represses mitochondrial oxidative phosphorylation.  
1.1.5.1 Role of HIF-1 in regulating glucose metabolism in normal cells 
    In order to survive oxygen deprivation, normal cells induce HIF1 to upregulate 
genes encoding proteins involved in the Pasteur effect (e.g. glucose transporters, 
glycolytic enzymes, lactate dehydrogenase A (LDHA) and Pyruvate 
dehydrogenase kinase 1 (PDK1)) and NADH dehydyrogenase (ubiquinone) 1 
alpha subcomplex subunit 4-like 2 gene (NDUFA4L2). The Pasteur effect refers 
to inhibiting mitochondrial oxidative phosphorylation while increasing rate of 
anaerobic glycolysis to maintain adenosine triphosphate (ATP) production [Bunn 
et al., 1996].  
    Since under hypoxic conditions oxygen is unavailable to act as the final 
electron acceptor in the mitochondrial electron transport chain (ETC), cells will 
abandon oxidative phosphorylation for ATP production. Inhibition of oxidative 
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phosphorylation is achieved by transactivating both PDK1 and NDUFA4L2 [Kim 
et al., 2006; Tello et al., 2011].  HIF1 inhibits conversion of glucose-derived 
pyruvate to acetyl-Coenzyme A (acetyl-CoA) through induction of PDK1 [Kim et 
al., 2006]. HIF-inducible PDK1 inactivates pyruvate dehydrogenase (PDH) to 
suppress pyruvate metabolism to fuel tricarboxylic acid (TCA) cycle and 
downstream oxidative phosphorylation. HIF-1 also prevents mitochondria from 
carrying out oxidative phosphorylation through upregulation of NDUFA4L2. 
NDUFA4L2 is a subunit of mitochondrial ETC complex I. Upon upregulation, the 
NDUFA4L2 inhibits the activity of complex 1, leading to lower oxidative 
phosphorylation rates. 
     HIF also induces the expression of proteins such as glucose transporters, 
glycolytic enzymes and LDHA, which are involved in producing ATP via 
anaerobic glycolysis. Since conversion of glucose to lactate produces far less ATP 
than oxidative phosphorylation, the rates of both glucose uptake and glycolysis 
are increased to sustain the cellular ATP requirement in hypoxic cells. 
1.1.5.2 Role of HIF-1 in regulating glucose metabolism in cancer cells 
    In cancer cells, the Warburg effect or aerobic glycolysis is adopted as one of 
the mechanisms to promote continuous cell proliferation and mediate adaptation 
to hypoxic conditions. There are several reasons for cancer cells to choose 
glycolysis over the more effective mitochondrial oxidative phosphorylation for 
energy production even when there is sufficient oxygen to support mitochondrial 
functions. Firstly, increased flux into the glycolytic cascade and the pentose 
phosphate pathway promotes biosynthesis of cellular metabolites, which is 
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necessary for continuous cell proliferation. Thus, intermediates derived from 
glucose metabolism are involved in the synthesis of nonessential amino acids and 
nucleotides. Secondly, lowering the dependence on mitochondria for ATP 
production confers resistance to intermittent hypoxia, which is frequently 
observed as a result of rapid tumor growth. It has also been suggested that the 
increased lactate production and excretion from the cell promotes the invasion of 
the cancer cells [Vander Heiden et al., 2009; Lunt and Vander Heiden, 2011]. 
 Similarly to hypoxic cells, HIF-1 in cancer cells transactivate a series of genes to 
upregulate glycolysis and promote survival and proliferation. Increased 
expression of glucose transporters (e.g GLUT1, GLUT3 and GLUT4) [Zhao et 
al., 2007; Chen et al., 2001; Gleadle et al., 1997] enhances glucose uptake within 
cancer cells. To retain maximal amounts of glucose intracellularly, the incoming 
glucose is phosphorylated by HIF1-inducible hexokinase 2 (HK2). Glucose-6-
phosphate (G6P) will be channeled into glycolysis when there is increased 
expression of a series of glycolytic enzymes (e.g. PGI, PFK-1, aldolase, TPI, 
GAPDH, PGK, PGM, endolase, PK) to form pyruvate.  Accumulation of the 
glycolytic end product pyruvate slows down the glycolytic rate, thus pyruvate is 
converted into lactate via HIF-1 inducible LDHA. Regenerated NAD
+
 derived 
from the reduction of pyruvate is used by GAPDH to allow continuous cycles of 
glycolysis. To avoid toxic intracellular acidosis, excess lactate is transported out 
of cancer cells via monocarboxylate transporter 4 (MCT4) that is also upregulated 
by HIF1 [Ullah et al., 2006].  
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    In order to lower overproduction of toxic mitochondrial ROS, HIF-1 
downmodulates mitochondrial activities in cancer cells such as VHL-deficient 
cell lines and neuroblastoma cells [Papandreou et al., 2006; Fredlund et al., 2008]. 
Lack of oxygen as the final acceptor of the mitochondrial ETC has been 
suggested to increase the amount of superoxide generated as a result of electron 
leakage from mitochondrial complex III [Kim et al., 2006]. To downregulate 
mitochondrial activities and hence ROS production, cancer cells upregulate the 
HIF-1 inducible PDK1 and NDUFA4L2 to inhibit PDH and complex 1. HIF-1 
also regulates different subunits of cytochrome c oxidase subunit IV (COX4) to 
improve the electron transfer efficiency within the electron transport chain to 
decrease mitochondrial ROS generation in hypoxic CCRC cells [Fukuda et al., 
2007; Hervouet et al., 2008]. By decreasing the expression of COX4-1 isoform 
while increasing expression of both COX4-2 isoform and LON mitochondrial 
protease that degrades the COX4-1 isoform, cytochrome c oxidase is able to carry 
out mitochondrial respiration more efficiently at low oxygen conditions. As a 
result, lower amounts of mitochondrial ROS would be produced, which may 
promote the survival of cancer cells when the surrounding oxygen level is low. 
1.2 Thioredoxin Interacting Protein (Txnip) 
     Thioredoxin Interacting Protein (Txnip) also known as VDUP1 (vitamin D3 
up-regulated protein) or TBP2 (thioredoxin-binding protein 2) is a member of the 
human -arrestin protein family. The -arrestin protein family also have five 
other members namely Arrestin Domain Containing 1-5 (Arrdc1-5) [Alvarez, 
2008]. Similar to the other members of the -arrestin family Txnip has two 
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arrestin domains (N-terminal arrestin domain and C-terminal arrestin domain), an 




Figure 3.  Thioredoxin interacting protein (Txnip) and the -arrestin protein 
family.  (Modified from Masutani et al., 2012) Txnip and other - arrestin protein 
members contain the following domains as depicted in the figure : arrestin N-
terminal domain, an interdomain connecting hinge, arrestin C-terminal domain 
and a C-terminal tail. 
 
 
1.2.1 Discovery of Txnip 
     Txnip was first reported as VDUP1 because its gene expression was found to 
be upregulated in Human promyelocytic leukemia HL-60 cells treated with 1, 
25-dihydroxyvitamin D3 [Chen and Deluca, 1995]. Through yeast two-hybrid 
screening, a protein identical to the VDUP1 gene product was found to interact 
with reduced thioredoxin and termed TBP-2 [Nishiyama et al., 1999]. Txnip is the 
only member of the -arrestin protein family that binds to thioredoxin (TRX), as 
18 
 
demonstrated by both Oka and Patwari [Oka et al., 2006; Patwari et al., 2006]. 
Both groups have shown that three other -arrestin protein members (Arrdc2-4) 
with the closest amino acid sequences to Txnip are unable to bind to TRX. [Oka 
et al., 2006; Patwari et al., 2006].  Txnip forms a disulfide bond between its 
Cysteine -247 residue and the conserved Cysteine-32 residue that lies within the 
catalytic sites of the reduced TRX [Patwari et al., 2006]. Through this interaction, 
Txnip acts as a negative regulator of TRX activity [Nishiyama et al., 1999; 
Yamanaka et al., 2000]. 
1.2.2 Txnip is implicated in cancer 
     Txnip, a negative regulator of TRX, plays a part in inhibiting cancer initiation. 
This has been supported by the frequent downregulation or loss of Txnip 
expression observed in a wide range of tumor tissues and cancer cell lines such as 
lung cancer, breast cancer, gastrointestinal cancer, prostate cancer, bladder cancer, 
acute myeloid leukemia and etc [Butler et al., 2002; Ikarashi  et al., 2002, Zhou et 
al., 2011]. Txnip promotes apoptosis and inhibits cell proliferation to prevent 
uncontrolled cell growth and has been proposed to function as a candidate tumor 
suppressor. In support, Txnip deficient mice have dramatically increased 
incidence of spontaneous hepatocellular carcinoma [Sheth et al., 2006]. Txnip’s 
proapoptotic function is achieved via both cellular redox regulation and apoptosis 





1.2.2.1 Txnip promotes apoptosis by inhibiting redox function of thioredoxin 
     Early studies have shown that Txnip interacts with TRX to inhibit its redox 
function, thus exerting proapoptotic effects. Txnip plays a crucial role in 
regulating cellular redox status through its interaction with TRX.  TRX is a small 
ubiquitous protein with two highly conserved redox-active cysteine residues 
(C32/C35) in its catalytic site Cys-Gly-Pro-Cys [Holmgren et al., 1968]. Together 
with thioredoxin reductase and NADPH, it forms the thioredoxin system to 
regulate the cellular redox balance [Nordberg et al., 2001]. NADPH dependent-
thioredoxin reductase maintains TRX in a reduced form. Reduced TRX then acts 
as an antioxidant by reducing disulfide bonds in substrate proteins such as 
peroxiredoxins while becoming oxidized itself [Kang et al., 2005; Björnstedt et 
al., 1994] The reduced catalytic active peroxiredoxins can then detoxify excess 
amount of hydrogen peroxide to control the level of cellular oxidative stress and 
protect cells against  apoptosis.  
     In contrast to TRX which lowers cellular ROS levels, Txnip has the opposite 
effect. Txnip binds to the reduced TRX, thus preventing TRX from recycling 
peroxiredoxins. The inactivation of peroxiredoxins allows the accumulation of 
excessive ROS. Thus, Txnip disrupts the redox balance by suppressing the 
antioxidant function of TRX and rendering cells to be more vulnerable to 





1.2.2.2 Txnip promotes apoptosis through interacting with Apoptosis signal-
regulating kinase-1 (ASK-1) 
     Txnip is also capable of mediating cell death directly through its interaction 
with TRX that is part of the apoptosis signal-regulating kinase-1 (ASK-1) 
signalosome. The ASK-1 signalosome is a multicomponent complex that exists in 
either an inactive or an active form depending on specific activating stimuli. 
Under normal conditions, the signalosome consists of an ASK-1 homo-oligomer, 
TRX, 14-3-3 protein and additional unidentified factors. Upon exposure to stress, 
TRX and 14-3-3 proteins are replaced by either tumor necrosis factor receptor-
associated factor 2 (TRAF2) or TRAF6 [Noguchi et al., 2005] to form a larger 
complex.  
     Under basal conditions, ASK-1, a serine/threonine protein kinase, is negatively 
regulated by both TRX and 14-3-3 proteins [Saitoh et al., 1998; Goldman et al., 
2004]. The two ASK-1 subunits of the homo-oligomer are far apart from each 
other as their N-terminal regions are bound by reduced TRX. This leads to 
inhibition of the kinase activity of ASK-1 to prevent activation of downstream c-
Jun N-terminal kinase (JNK) and p-38 MAPK signaling pathways to protect cells 
from apoptosis.  TRX bound ASK-1 is also targeted for polyubiquitination and 
proteasomal degradation to inhibit ASK-1 mediated apoptosis. Upon exposure to 
ROS, Txnip competes with ASK-1 homo-oligomer to bind with TRX proteins. 
Once TRX is dissociated, the uninhibited N-terminal regions of ASK-1 subunits 
are then free to interact with each other.  This homophilic interaction is further 
promoted by the binding of the positive regulators TRAF2/6 to form the higher 
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molecular weight signalosome. Close proximity of two ASK-1 subunits allows 
autophosphorylation of ASK-1 at threonine 838 in the human protein to activate 
its kinase activity.  Activated ASK-1 then in turn triggers the activation of both 
the JNK and p-38 pathways and lead to apoptosis. Therefore, as a negative 
regulator of TRX, Txnip acts as a proapoptotic protein by reversing the inhibitory 
effect of TRX on ASK-1-induced apoptosis. 
1.2.2.3 Txnip inhibits proliferation by blocking cell cycle progression  
     In cell culture studies, Txnip has been shown to inhibit cell proliferation by 
blocking cell cycle progression [Elgort et al., 2010; Han et al., 2003].  Txnip 
induces cell cycle arrest at different phases by regulating the abundance of 





  and cyclin A2.  
     Txnip arrests cells at G0 phase by maintaining high levels of p27
kip1
 in the 
nucleus. p27
kip1 
is a cell cycle inhibitor protein that controls the progression of cell 
cycle at G1 phase via its cellular abundance. In normal cells, it
 
remains at high 
levels to maintain cells at quiescence state (G0). However, upon exposure to 
mitogenic signals, p27
kip1
 translocates from the nucleus into cytoplasm. 
Cytoplasmic p27
kip1
 subsequently undergoes polyubiquitination and proteasomal 
degradation [Tomoda et al., 2002]. A reduced p27
kip1
 level permits cells to exit 
G0 phase and reenter into G1 and S phase.  As a tumor suppressor, Txnip 
prevents p27
kip1
 from being translocated to cytoplasm [Jeon et al., 2005]. As a 
result, the stable nuclear p27
kip1
 accumulates to high levels and traps cells in the 
quiescent state to inhibit uncontrolled cell growth.  
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     Txnip also prevents cells from progressing through both S phase and G2/M 
transition by forming a transcriptional repressor complex to suppress cyclin A 
promoter activity [Han et al., 2003].  Cyclin A2 is a member of the cyclin family 
that plays essential roles in somatic cell cycle progression. When cyclin A2 is 
associated with cyclin dependent kinase 2 (CDK2), it promotes the initiation and 
progression of DNA synthesis. On the other hand, when cyclin A2 binds to 
CDK1, it activates cyclin B1-CDK1 complex, also known as M phase-promoting 
factor (MPF), to trigger the onset of M phase [Pagano et al., 1992; Fung et al., 
2007]. To prevent cells from proliferating uncontrollably, Txnip interacts with 
transcriptional corepressors such as promyelocytic leukemia zinc finger, Fanconi 
anemia zinc finger and histone deacetylase 1 to form a transcriptional repressor 
complex. Formation of this transcriptional repressor complex inhibits 
transcription of cyclin A and traps cells in the G0/G1 phase. Therefore, Txnip can 
also acts as a tumor suppressor by arresting cells at G0/G1 phase to prevent 









2.  MATERIALS AND METHODS 
2.1 MATERIALS     
Cell lines - Stably transfected Human kidney epithelial HEK293T cell line that 
expresses Ciona intestinalis Alternative oxidase (AOX) under a tetracycline-
inducible promoter was a generous gift from Dr. Howard Jacobs (University of 
Tampere, Finland).  HEK293 cells, HEK293T cells, Human osteosarcoma 143B 
cells, Human colon carcinoma HCT116 and Human breast adenocarcinoma 
MCF7 were purchased from ATCC and invitrogen. 
Chemicals and reagents - All chemicals were reagent grade and were obtained 
from Sigma-Aldrich Co. (St. Louis, USA) unless otherwise stated. Glutathione 
Sepharose, enhanced chemiluminescence (ECL), Hybond ECL nitrocellulose 
membrane (0.2µM) and hyperfilm ECL were from Amersham, GE Healthcare 
UK Limited (Buckinghamshire, UK). Acrylamide/Bis-Acrylamide Solutions, 
BioRad protein assay dye reagent and laemmli sample buffer, Tris/glycine/SDS 
(TGS) running buffer, prestained broad range protein marker, BioRad 
nitrocellulose membrane (0.2µM) were obtained from BioRad (Hercules, CA, 
USA).  Pierce ECL western blotting substrate was purchased from Thermo 
Scientific (Rockford, IL USA) (Peptone, yeast extract and Bacto-agar were 
purchased from BD Bioscience (San Jose, CA, USA). DETA-NONOate was from 
Alexis Biochemicals, Enzo Life Sciences (Boulevard Farmingdale, NY, USA). 
Compound C was from Calbiochem, EMD millipore (Billerica, MA, USA). 
Genejuice transfection reagent, Bugbuster plus Lysonase Kit were purchased from 
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Novagen, EMD millipore (Billerica, MA, USA), BL21 chemically competent 
cells, DH5 competent cells, DMEM (Dulbecco’s modified Eagle’s medium), 
RPMI (Roswell Park Memorial Institute) 1640 medium were from Invitrogen, 
Life Technologies (Carlsbad, CA, USA).  Trypsin, L-Glutamine and Penicillin-
streptomycin mixture obtained from GibcoBRL, Life Technologies (Carlsbad, 
CA, USA). Steady-Glo luciferase assay reagent was obtained from Promega 
(Madison, USA). DNA gel extraction kit and plasmid miniprep extraction were 
from QIAGEN (Hiden, Germany). Complete Protease Inhibitor Cocktail Tablets 
and restriction enzymes were obtained from Roche Diagnostics (Penzberg, 
Germany). Site directed mutagenesis kit was from Stratagene, Agilent 
Technologies (Santa Clara, CA, USA). Fetal bovine serum (FBS) was purchased 
from Hyclone, Thermo Scientific (South Logan, UT, USA). Restriction enzymes, 
DNA ladders (100bp, 1kb) and prestained protein ladder were obtained from 
Fermentas, Thermo Scientific Life Science. Vectashield mounting media with 
4′,6-diamidino-2-phenylindole (DAPI) was purchased from Vector Laboratories 
(Burlingame, CA, USA). 
Antibodies for immunoblotting - Primary antibody against soybean alternative 
oxidase (AOX) was a gift from Dr. James Whelan (The University of Western 
Australia, Australia). Primary antibody against Ciona intestinalis AOX was a 
generous gift from Dr Howard Jacobs (University of Tampere, Finland)  Primary 
antibody again clathrin heavy chain (CHC) was a generous gift from Dr Frederic 
Bard (IMCB, Singapore).The following primary antibodies were obtained 
commercially: mouse anti V5-Tag (AbD serotec; Kidlington, Oxford, UK), goat 
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anti-GST (Amersham Biosciences; Buckinghamshire, UK), rabbit anti-catalase, 
rabbit anti-GLUT1, mouse  anti-clathrin heavy chain (X-22) (Abcam; Cambridge, 
MA, USA), rabbit anti-PDH-E1 (pSer293) (Calbiochem, EMD millipore, MA, 
USA) (goat anti-lactate dehydrogenase (Fitzgerald; North Acton, MA, USA),  
mouse anti-PFKFB3 (Novus Biological; Littleton, Co, USA) mouse anti-HIF-1, 
mouse anti-VHL, and mouse anti--tubulin (BD Transduction Laboratories; San 
Jose, CA, USA), rat anti-HA (Roche Diagnostics; Mannheim, Germany), goat 
anti-Thioredoxin (IMCO Corporation; Stockholm, Sweden),  Mouse anti--actin 
and mouse anti-FLAG (Sigma-aldrich; St. Louis, USA), mouse anti-GAPDH (US 
Biological; Salem, MA, USA) The following secondary antibodies were obtained 
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA. USA): goat anti-mouse IgG 
HRP, rabbit anti-goat IgG HRP, goat anti-rabbit IgG HRP, goat anti-rat IgG HRP. 
Secondary antibodies for immunofluorescence - Donkey anti-mouse secondary 
antibody tagged with FITC, goat anti-mouse secondary antibody tagged with 
TRITC, goat anti-rabbit secondary antibody tagged with TRITC were purchased 
from Molecular Probes, Life Technologies (Carlsbad, CA, USA). 
2.2 METHODS    
 
2.2.1 Plasmids - Retroviral expression vector Puro-MaRX was a kind gift from 
Dr David Beach (Institute of Cell and Molecular Science, London, United 
Kingdom). Soybean alternative oxidase cDNA (AOX1a pGem3zf+) was a 
generous gift from Dr. James Whelan (Plant Energy Biology, ARC Centre of 
Excellence, The University of Western Australia, Australia) pVHL-V5pcDNA3, 
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PHD2-V5pcDNA3.1/Zeo, Ubc4-HApcDNA4/TO were previously constructed by 
Assoc. Prof. Thilo/ members of the lab. 
2.2.1.1 Plasmid construction and mutagenesis - Soybean AOX1a-V5 puro-
MaRX and Soybean AOX1a-V5 pcDNA4/TO were created when AOX1a cloned 
from soybean AOX1a cDNA was inserted in pcDNA3 expression vector with a 
C-terminal V5-tag before inserting into the retroviral expression vector both Puro-
MaRX and pcDNA4/TO respectively. Cytosolic catalase (CYTO catalase Puro-
MaRX) was created when murine catalase was PCR-amplified from I.M.A.G.E. 
clone (ID 4241333) and inserted in the Puro-MaRX. Mitochondrially targeted 
catalase (MITO-CAT-V5 Puro-MaRX) was generated from cytosolic catalase by 
including a N-terminal mitochondrial targeting sequence of SOD2 (comprising 
the sequence corresponding to residues 1–28). Wild-type GST-HIF-1 (521-652)-
V5 pGEX-KG was generated by subcloning HIF-1 (521-652)-V5 into a 
modified N-terminal GST tagged pGEX-KG vector. P564A mutant GST-HIF-1 
(521-652)-V5 pGEX-KG] were constructed by site-directed mutagenesis using 
wild-type GST-HIF-1 (521-652)-V5 pGEX-KG as template with the following  
PCR primers. It was then subcloned into a modified  N-terminal GST tagged 
pGEX-KG vector. Mouse Txnip and human Arrdc4 were amplified from MGC 
I.M.A.G.E. clones (ID 3591421 and 30345612) and subcloned into modified C-
terminal Flag tagged pcDNA3 and N-terminal Flag tagged pcDNA4/TO, 
respectively. PDK1 DNA sequence was amplified from HEK293 cell cDNA and 
subcloned into modified C-terminal V5 tagged pcDNA3. The wild-type Flag-
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PFKFB3 and V5-PFKFB3 constructs were generated by inserting human 
PFKFB3, amplified from Addgene clone (ID 23668), into modified N-terminal 
FLAG tagged pcDNA3.1 or V5 tagged pcDNA3.1/zeocin. S461A Flag-
PFKFB3plasmid was generated by site-directed mutagenesis using fusion PCR 
and wild-type Flag-PFKFB3 as a template. S461E mutant PFKFB3 was generated 
by site-directed mutagenesis using wild-type Flag-PFKFB3 as template and 
inserted into N-terminal V5 tagged pcDNA3.1/zeocin to obtain S461E V5-
PFKFB3 plasmid. Human GLUT1 (NM_006516) was cloned from HEK293T 
cDNA and inserted into modified C-terminal EGFP-HA tagged pcDNA3.1 to 
generate GLUT1-EGFP-HA. GLUT1-EGFP-HA-pcDNA4/TO was generated by 
subcloning the GLUT1-EGFP-HA into a pcDNA4/TO  plasmid.  
2.2.2 siRNA-mediated gene silencing - Cells with 20-30% confluency prepared 
in 12 well plate were transfected siRNA duplexes at final concentrations of 20nM 
using Lipofectamine RNAiMax transfection reagent (Invitrogen) for three days. 
The 2 human PFKFB3 siRNAs (Integrated DNA Technologies) used in the knock 
down experiments were HSC.RNAI.N004566.12.9 (PFKFB3#1) and 
HSC.RNAI.N004566.12.2 (PFKFB3 #2) (Table 1). Briefly, appropriate volume of 
siRNA targeted to human PFKFB3 or negative control siRNA was added to 50µl 
of serum free medium. Next, 2.5µl of Lipofectamine was added to 50µl of serum 
free medium. The contents of both tubes were mixed well before adding the 
diluted siRNA  to the diluted Lipofectamine. The prepared mixture was incubated 












Table 1.  Target sequences of human PFKFB3 siRNAs 
 
2.2.3 Cell lines and culture - All cell lines used in the research were grown under 
5% CO2 at 37
o
C. HEK293, HEK293T and Trex293 were cultured in DMEM 
medium while 143B, HCT116 and MCF7 were cultured in RPMI medium. Both 
media were supplemented with 10% heat inactivated fetal bovine serum, 2mM L-
glutamine, and 1% penicillin-streptomycin. To induce the expression of Soybean 
AOX1a in Tet-on HEK293 cells and Ciona intestinalis AOX expression in 
HEK293T, 1µg/ml tetracycline or 2mM of pyruvate was added overnight 
respectively. 
2.2.3.1 Generation of Cell lines - 
(a) 143B cells stably expressing Soybean Aox1a or HEK293 cells expressing  
tetracycline-inducible Soybean Aox1a 
Soybean Aox1a retroviral particles were generated by transfecting  2µg AOX1a-
V5 puro-MaRX or enhanced  GFP (control)  Puro-MaRX expression vector and 
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0.3µg vesicular stomatits virus-G (VSVG) plasmid into 293-gag-pol cells using 
gene juice according to the manufacturer's protocol. After two days of 
transfection, the retroviral particles in the cell culture medium were harvested and 
centrifuged at 900g to remove any cells.  400µl of retroviral particles containing 
supernatant was used to infect 143B cells growing in DMEM media 
supplemented with 8µg/ml polybrene. Once the retroviral infected 143B cells 
reached full confluency, protein expression was assessed by immunofluorescence 
(enhanced GFP) before the cells were trypsinized and neutralized with DMEM 
media. A low volume of the cell suspension was introduced into a 60mm plate 
containing 5ml DMEM media and 2g/ml puromycin was added 24 hours later to 
select 143B cells that express Soybean Aox1a-V5.  The cells were grown until 
visible single puromycin resistant colonies were observed and subsequently 
expanded in mutli-well plates. Protein expression of Soybean Aox1a-V5 in 
individual 143B cell clones was assessed by immunoblotting with V5-Tag 
antibody. 
HEK293 cells expressing  tetracycline-inducible Soybean Aox1a were generated 
by transfecting  Tet-on HEK293 cells  with Soybean Aox1a under a tetracycline-
inducible promoter (Soybean AOX1a-V5 pcDNA4/TO). After two days of 
transfection, the cells were trypsinized and neutralized with DMEM media. Low 
volume of the cell suspension was introduced into a 60mm plate containing 5ml 
DMEM media and 400g/ml zeocin was added 24 hours later to select Tet-on 
HEK293 cells that express Soybean Aox1a-V5.  The cells were grown until 
visible single zeocin resistant colonies were observed. Protein expression of 
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Soybean Aox1a-V5 in Tet-on HEK293 cells was assessed by immunoblotting 
with V5-Tag antibody. 
(b) Human osteosarcoma 143B cells expressing cytoplasmic catalase (CYTO 
catalase) or mitochondrial catalase (MITO-CAT-V5) 
Catalase retroviral particles were generated by transfecting 0.8µg CYTO catalase 
Puro-MaRX or MITO- CAT-V5Puro-MaRX expression vector and 0.3µg VSVG 
plasmid into 293-gag-pol cells using gene juice according to the manufacturer’s 
protocol. The cells were generated according to methods described for the 
generation of Soybean AOX1a stably expressing 143B cells. Protein expression 
of CYTO catalase or MITO-CAT-V5 was assessed by immunoblotting with 
catalase or V5-Tag antibody. Functionality of both types of catalase was tested 
with determining the hydrogen peroxide scavenging capacity of the catalase 
overexpressing cells (refer to section 2.2.13). 
2.2.4 Transient Transfection - Transfection of appropriate plasmid DNA into 
cell lines was performed with gene juice transfection reagent (2.7µl/µg DNA) 
according to the manufacturer’s instructions. The seeded cells were at least 25% 
confluent before transfection was carried out. Briefly, the appropriate amount of 
genejuice was added to serum free media and followed by incubation for 5 
minutes before addition of specific plasmid DNA. The transfection mixture was 
incubated for at least 20 minutes and then added in a dropwise manner to each 
well or petri dish. After two days of transfection, the cells were harvested. 
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2.2.5 Hypoxia incubations - Cells were subjected to at least 3 hours of hypoxic 
condition (1% O2, 94% N2, and 5% CO2) by incubating them in either a Pro-ox in 
vitro chamber attached to a Pro-ox 110 oxygen controller (BioSpherix, Redfield, 
NY) or a hypoxia workstation (Coy Laboratories , Grass Lake, Michigan, USA)). 
The workstation was used when cells required drug treatment at several time 
points without introducing atmospheric oxygen. 
2.2.6 Measurement of Oxygen Consumption - Oxygen consumption of cells at 
a density of 1.6 X 10
8
/ml or of 0.5 mg/ml freeze thawed mouse liver mitochondria 
was measured with a Clark-type oxygen electrode (Oxygraph; Hansatech) in 
either Krebs buffer (118mM NaCl, 4.8mM KCl, 1.2mM KH2PO4, 1.2mM MgSO4, 
1mM CaCl2, 25mM Hepes pH7.4, 25mM Tris pH7.5) supplemented with 10mM 
glucose or mitochondria isolation buffer (280mmol/L of sucrose, 10mmol/L of 
Tris pH7.4, 1mmol/L EDTA), respectively, with substrates and other additions as 
indicated in the figure legends. 
2.2.7 Sample preparation - 
(a) Whole cell lysate preparation 
Cells were rinsed once with ice-cold phosphate-buffered saline (PBS) and lysed 
with triton lysis buffer (25mM Tris pH7.5, 2.5mM EDTA, 2.5mM EGTA, 20mM 
Sodium Fluoride, 1mM Sodium orthovanadate, 100mM NaCl, 20mM Sodium -
glycerophosphate, 10mM Sodium pyrophosphate, 0.5% triton) supplemented with 
complete protease inhibitor cocktail and 0.1% -mercaptoethanol. The cell lysates 
were collected and centrifuged at 16,000g for 5 minutes at 4
o
C to remove cellular 
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debris and the supernatant was collected as the whole cell lysate. Protein 
concentrations of the supernatants were determined using BioRad protein assay 
dye reagent. For co-immunoprecipitation involving clathrin heavy chain (CHC), 
cells were also lysed with octyl-beta-Glucoside (β-OG) buffer (0.5% β-OG, 
30mM Tris pH7.5, 120mM NaCl, 1mM Sodium orthovanadate, 20mM sodium 
Fluoride) supplemented with complete protease inhibitor cocktail as described in 
Wu et al. [2013]. 
(b) Preparation of Mitochondria 
Mitochondria were isolated from mouse liver (Gift from Dr Sashi Kesavapany, 
NUS) by differential centrifugation in mitochondrial isolation buffer (280mM 
sucrose, 10mM Tris (pH7.4), and 1mM EDTA). In short, the mouse liver was 
rinsed and minced in 2ml of ice-cold mitochondrial isolation buffer and 
subsequently homogenized with 10 up-and down strokes using a hand-held tight-
fitting glass dounce homogenizer. The homogenate was centrifuged at 800g for 2 
minutes at 4
o
C in a refrigerated microcentrifuge (Eppendorf, Hamburg, Germany) 
to sediment nuclei, unbroken tissues and residual blood. The pellet was discarded 
while fat/lipid floating on the surface of the supernatant (postnuclear fraction) was 
cautiously aspirated out. The supernatant was then transferred to a new microfuge 
tube and spun at 9000g for 2 minutes at 4
o
C. The mitochondrial pellet was 
washed twice in the ice-cold wash buffer (280mM sucrose, 10mM Tris (pH7.4)) 
by centrifuging it at 9000g for 5 minutes. The supernatant was discarded and the 
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final pellet was resuspended in a small volume of ice-cold mitochondrial isolation 
buffer to about 25mg protein/ml.  
(c) Bacterial cell lysate preparation 
Before performing a large-scale protein extraction and purification of 
recombinant proteins expressed in E. coli  (e.g. wild-type or P564A mutant GST-
HIF-1 (521-652)-V5 pGEX-KG expressed in BL21 cells) the solubility of the 
specific recombinant proteins overexpressed in BL21 cells was determined. To 
this end, 500µl of overnight cultured BL21 cells transformed with wild-type GST-
HIF-1 (521-652)-V5 pGEX-KG were added to 5ml of LB media with 100mg/L 
Ampicillin, with and without 0.5mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) induction. The cultures were shaken at 180 rpm for 4 hours at 37
o
C before 
centrifugation at 12,000g for 5 minutes. 200µl of Bugbuster protein extraction 
reagent with 1µl of Lysonase bioprocessing reagent was added to resuspend each 
pellet. The bacterial suspensions was shaken at room temperature at 15.5 rpm for 
20 minutes to facilitate efficient lysing of bacterial cells. The bacterial suspension 
was then spun at maximum speed for 2 minutes at room temperature. Soluble 
proteins were present in the supernatant while the insoluble proteins are found in 
the pellet. Each pellet was dissolved in 40μl of 0.2% SDS. 25μl of the soluble 
fraction and 5μl of the insoluble fraction of each sample were diluted in 4X 
Laemmli sample buffer (0.25M Tris pH6.8, 6% SDS, 40% sucrose, 0.04% 
bromophenol blue) supplemented with -mercaptoethanol.  The samples were 
boiled for 5 minutes before running on 12% SDS gel and visualized with 
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coomassie blue staining (See Figure 21A). If the majority of the specific 
recombinant protein was found in the soluble fraction, it indicated that the 
bacterial expression system used was suitable.  For large scale protein extraction, 
4ml of overnight cultured BL21 cells transformed with either  wild-type or P564A 
mutant  GST-HIF-1 (521-652)-V5 pGEX-KG was added to 200ml of LB media 
with Ampicillin with or without 4 hours of  IPTG induction. The obtained 
bacterial pellet was resuspended in 6ml of PBS with 0.1mM PMSF before 
subjecting it to four rounds of sonication for a duration of 30 seconds with 10 
seconds interval. The entire sonication protocol was carried out on ice to prevent 
protein degradation by the heat generated during the process. The bacterial cell 
lysate was then spun at 12,000g for 15 minutes at 4
o
C to pellet the cell debris and 
insoluble fraction. The cleared bacterial lysate was kept frozen before purifying 
the wild-type or mutant recombinant HIF-1 protein using glutathione-sepharose 
beads (Refer to section 2.2.16). 
2.2.8 Immunoprecipitation - Anti-Flag M2 agarose or Sepharose G-beads 
loaded with specific antibody was used for immunoprecipitation. Maximum 
amounts of pre-cleared lysate prepared from transfected HEK293T cells grown in 
60mm or 100mm tissue culture petri plates were added to the beads. Cell lysate 
prepared from cells grown on 60mm or 100mm plates was used to detect a 
transfected protein or an endogenous protein of interest, respectively. The samples 
were subjected to 1 hour incubation at 4
o
C on a rotatory shaker before washing 
the beads three times in 1ml of ice cold Nonidet P-40 buffer (50mM Tris pH7.5, 
0.5% Nonidet P-40, 5% glycerol, 0.5mM EDTA, 400mM NaCl) and one time in 
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1ml ice cold 50mM Tris, pH7.5. The captured proteins were eluted from the beads 
with 0.1M acetic acid and the supernatants were neutralized with 1M NaOH. The 
resultant supernatants were then denatured in SDS-sample buffer and subjected to 
SDS-PAGE and western blotting.  
2.2.9 Sodium Dodecyl Sulfate- Polyacrylamide gel electrophoresis (SDS-
PAGE) - SDS-PAGE was carried our using gel apparatuses from Life 
Technologies (XCell SureLock™ Mini-Cell) and Biorad (Protean-III). The 
resolving gels (10-12%) were prepared with resolving buffer (1.5M Tris-HCl 
pH8.8, 0.4% SDS) and 40% acrylamide/bis-acrylamide solution. Polymerization 
of the gel was initiated by the free radicals generated from reduction of the 
catalyst, ammonium persulfate (APS) by the adjunct catalyst, N,N,N’,N’,-
tetramethylethylenediamine (TEMED). The 4% stacking gel was prepared with 
stacking buffer (0.5M Tris-HCl pH6.8, 0.4% SDS), 40% acrylamide/bis-
acrylamide solution and polymerized with APS and TEMED. 
Different samples with equal protein concentrations were diluted with Laemmli 
sample buffer supplemented with 5% -mercaptoethanol and boiled for 5 minutes 
at 100
o
C before loading into the gels. The electrophoresis was carried out under 
constant voltage with TGS running buffer. 
2.2.10 Coomassie Blue staining of SDS gel - After electrophoretic separation, 
the SDS gel was stained for 10 minutes with coomassie blue staining reagent (1% 
coomassie blue, 10% glacial acetic acid, 40% methanol, 49% H2O) with gentle 
agitation. The gel was then destained with destaining solution (5% glacial acetic 
36 
 
acid, 30% methanol, 65% H2O) with gentle agitation. The destaining solution was 
changed several times until visible protein bands and a clear background could be 
observed. 
2.2.11 Western Blotting Analysis - Proteins separated by SDS-PAGE were 
transferred to a nitrocellulose membrane overnight at a constant voltage of 25V 
with a Biorad trans-blot cell assembly and ice-cold transfer buffer (3g/L Tris, 
14.4g/L glycine, 20% (v/v) methanol).  After the transfer, the nitrocellulose 
membrane was blocked for 1 hour with 10% non-fat milk in TBST (6.67g/L 
NaCl, 10mM Tris-HCl, pH7.5, 0.06% (v/v) Tween 20) with gentle shaking and 
washed twice with TBST. Membranes were then probed with primary antibody at 
different dilution in TBST with gentle agitation. The following dilutions were 
used for the primary antibodies: mouse anti-HIF-1 (1:5000), rabbit anti-catalase 
(1:7500), rabbit anti-AOX (1:15000), mouse anti-VHL (1:6000), mouse anti-
PFKFB3 (1:7500), rabbit anti-PDH-E1(pSer293) (1:10000), goat anti-
thioredoxin (1:10000),  mouse anti GAPDH  (1:15000), mouse anti V5-Tag (1: 
10000), goat anti-GST (1: 15000), mouse anti-Flag M2 (1: 5000), rat anti-HA 
(1:7500). The membrane was washed three times with TBST before probing with 
secondary horseradish peroxidase-conjugated antibody diluted in 5% non-fat milk 
in TBST (1:15000) for an hour. Either mouse anti--actin (1:7500) or mouse anti-
-tubulin (1:7500) antibodies were used as loading controls. Chemiluminescence 
visualization was performed using an ECL-detection kit and hyperfilm according 
to the manufacturer’s instructions.  
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2.2.12 Detection of cellular superoxide - Superoxide production was estimated 
using dihydroethidium (DHE). Cells were plated in 12-well plates and grown to 
70% confluence and cotreated with 20µM DHE and mitochondrial inhibitors for 
30 minutes. Subsequently, the cells were rinsed with PBS and kept in PBS for 
analysis of fluorescence using a multiwell plate reader (Molecular Devices, 
excitation and emission wavelengths were 520nm and 610nm, respectively.) The 
validity of this assay was verified by using menadione as positive control. 
2.2.13 Flow cytometry analysis - 
(a) Measurement of ROS production in the form of  H2O2 or Superoxide 
Adherent mammalian cells were harvested by trypsinizing the cells for 3 minutes 
at 37
o
C followed by washing once with PBS. The cell pellet was resuspended at a 
cell density of approximately 1 x 10
6
 /ml in Krebs buffer containing 10mM 
glucose loaded with ROS indicator fluorescence dye (e.g. 20µM DHE to detect 
superoxide or 5µM 2'7'-dichlorodihydrofluorescein diacetate (DCFDA) to detect 
H2O2). The cells were incubated for 15 minutes at 37
o
C and analyzed immediately 
by flow cytometry. Detection with DHE was analyzed with PE-Texas red channel 
(log mode), while detection using DCFDA was analyzed with fluorescein 







(b) Detection of H2O2 scavenging capacity 
H2O2 scavenging capacity was estimated using DCFDA. 143B cells resuspended 
in  Krebs buffer containing 10mM glucose were loaded with 20µM DCFDA for 
15 mins at 37
o
C  and analyzed by flow cytometry using FITC channel (log mode) 
both before and after treating with 200µM H2O2 for 5 mins.  In each analysis, 
10,000 events were recorded. 
2.2.14 Measurement of mitochondrial Complex I activity - The assays were 
performed at 37
o
C and the contents within the quartz cuvette were kept 
homogenous by stirring at low speed. For these assays, the LS-55 fluorescence 
spectrometer (Perkin Elmer, MA, USA), which has temperature control and a 
magnetic stirring device, was used. Mitochondrial Complex I activity was 
determined by measuring the decrease in the NADH fluorescence at Ex/Em 
352nm/464nm [Birch-Machin et al, 1994]. 0.1mg/ml freeze-thawed mouse liver 
mitochondria were preincubated in 2ml of reaction buffer (120mM KCl, 5mM 
Tris-HCl pH7.4, 1mM EGTA, 64M decylubiquinone, 2mg/ml albumin) for 5 
minutes. The reaction was initiated by the addition of 1.25mM NADH, which 
acted as the substrate of mitochondrial complex I. The decrease in NADH 
fluorescence was measured for 5 minutes before adding different concentrations 
(100nM, 250nM, 500nM, and 1M) of the test compound myxothiazol. The 





2.2.15 Measurement of hydrogen peroxide generation rate by Mitochondrial 
Complex I - These assays were also performed using the LS-55 fluorescence 
spectrometer at a temperature of 37
o
C. Hydrogen peroxide (H2O2) production was 
measured using horseradish peroxidase-homovanillic acid (HRP-HVA) assay. 
0.1mg/ml mouse liver mitochondria were preincubated for 3 minutes in 2 ml of 
reaction buffer (125mM KCl, 2mM KH2PO4, 1mM MgCl2, 20mM Hepes, 0.1mM 
EGTA pH7.4) in the presence of 0.1mM HVA and 0.5µM HRP. H2O2 production 
was initiated by addition of different respiratory substrates (5mM glutamate 
+5mM malate for forward electron transfer; 10mM succinate for reverse electron 
transfer), followed by the addition of different mitochondrial inhibitors (rotenone, 
Compound C). H2O2 is generated when superoxide produced from either of the 
two electron fluxes of complex I is dismutated by the endogenous superoxide 
dismutase and released into the reaction buffer. HVA is oxidized by H2O2 in the 
presence of HRP to generate a fluorescent dimer which is a readout for the H2O2 
production. The rate of hydrogen peroxide production was measured 
fluorometrically (ex: 312nm, em: 420nm) [Barja, 2002]. The concentration of 
hydrogen peroxide was quantified using a standard curve ranging from 0.2µM to 
1.4µM H2O2 prepared in 1x PBS. 
2.2.16 pVHL Binding Assays -  
(a) Purification of wild type or P564A mutant GST-HIF-1 (521-652)-V5  
The expressed wild type or P564A mutant GST-HIF-1 (521-652)-V5 was 
purified from the sonicated bacterial lysate (refer to section 2.2.7C) by affinity 
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chromatography whereby the GST-tagged wild-type or mutant recombinant HIF-
1 protein was captured by glutathione-conjugated sepharose.  The clear bacterial 
lysate was introduced into the column packed with glutathione sepharose and 
subjected to 1 hour incubation at 4
o
C on a rotary shaker.  The column was washed 
seven times with 5ml of ice cold PBS to remove any unbound proteins.   
 (b) Prolyl hydroxylation assay 
The immobilized GST-HIF was divided equally into 1.5ml microfuge tubes 
before incubation with equal amounts of whole cell lysate from HEK293 cells 
transfected with 4µg PHD2 -V5 pcDNA3.1/Zeo and 4µg VHL-V5 pcDNA3 and 
2mM ascorbate and 2mM 2-oxoglutarate for 1 hour at room temperature.  The cell 
lysate containing PHD2 and VHL was prepared with Nonidet P-40 buffer (0.5% 
Nonidet P-40, 5% glycerol, 0.5mM EDTA, 50mM NaCl supplemented with 1mM 
DTT and complete protease inhibitor cocktail). After the assay, the cell lysate was 
removed, and the beads were washed three times using NP-40 buffer and washed 
once using PBS. pVHL bound to GST-HIF fusion protein was analyzed by 
western blotting.  
2.2.17 Cellular metabolism related assays -  
(a) Glucose uptake from media 
HEK293T cells were transfected for two days and replaced with fresh growth 
media with and without myxothiazol (1µM). After 6 hours, conditioned media 
was collected to determine the remaining glucose concentration. Glucose was 
measured as previously described [Chai et al., 2011]. Briefly, 1µl of media 
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sample was incubated in 300µl reaction buffer (1X PBS, 2mM NADP, 2mM ATP, 
10mM MgCl2). The reaction was initiated by addition of 1unit of enzyme 
hexokinase/G6PDH. Enzyme activity was measured spectrophotometrically as the 
increase in absorbance at 340nm. The glucose consumption corresponds to the 
difference between the initial glucose concentration in the medium and the 
glucose concentration after 6 hour incubation. Glucose uptake was expressed as 
percent of glucose in conditioned media of empty vector transfected HEK293T 
cells.  
(b) Lactate concentration in media 
HEK293T cells were transfected for two days and fresh phenol red free growth 
media supplemented with 10% FBS, 2mM L-glutamine and 25mM glucose was 
added in the presence or absence of myxothaizol (1µM). After 6 hours, 
conditioned media was collected to measure the lactate production. Lactate 
production in media was measured using a lactate dehydrogenase-based assay 
from Eton Biosciences Inc. and a microplate reader (SpectraMax 190, Molecular 
Devices, Sunnyvale, CA). Briefly, 50l of lactate assay solution was added to 
each well containing 50l of media diluted in water. The content was mixed well 
and incubated at 37
o
C for 30 minutes. 50l of 0.5M acetic acid was added to each 
well followed by brief gentle agitation to stop the reaction. Any air bubbles 
present in the wells were eliminated using a needle prior to measurement. The 
lactate concentration is measured as the increase in absorbance at 490nM and was 
normalized by total protein concentration and expressed as percent in conditioned 
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media of empty vector overexpressing HEK293T cells. The concentration of 
lactate was quantified using a standard curve ranging from 50M to 800M L-
lactate solution diluted in water. 
(c) ATP measurements 
ATP was extracted from transfected cells grown in 6 well plates by lysing the 
cells in 400µl of 6% perchloric acid followed by centrifugation at 16,000g for 1 
minute at 4
o
C. 360µl of the supernatant was transferred to a new microfuge tube 
and neutralized in triethanolamine buffer (0.43M TEA, 1.6M K2CO3) with 
vortexing to mix well. The mixture was sat on ice for 1 minute and centrifuged at 
16,000g for 1 minute at 4
o
C. ATP concentrations were measured from the 
resulting supernatant according to the manufacturer's instructions using 
ENLITEN ATP assay system (Promega). Briefly, 5l of sample was added to 
50l of the assay reagent and mixed well before reading of the samples with a 
luminometer (Tuner biosystems Sunnyvale, CA USA).  The concentration of ATP 
was quantified using a standard curve ranging from 45nM to 4500nM ATP 
prepared in ATP-free water provided in the kit. 
(d) Lactate Dehydrogenase activity 
Transfected cells grown in 6 well plates were lysed in hypotonic lysis buffer 
(25mM Tris (pH7.5), 2mM EDTA, 2mM EGTA) supplemented with complete 
protease inhibitor cocktail. The lysate was freeze-thawed once prior to measuring 
LDH activity according to the manufacturer's instructions by a LDH based in 
vitro toxicity assay kit (Sigma aldrich St. Louis, USA).  Briefly, 3µl of sample 
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were added to 197µl of LDH assay mixture (prepared by mixing equal volumes of 
LDH assay substrate solution, 1 x LDH assay cofactor preparation and LDH assay 
dye). LDH activity was measured as the increase in absorbance at 490nm over 
time using Varioskan Flash microplate reader (Thermo Scientific, Rockford, IL 
USA) and was normalized by total protein concentration. 
(e) Fructose, 2,6-bisphosphate measurement  
The cellular fructose, 2,6-bisphosphate (F2,6P2) concentration was measured 
using an assay described by Van Schaftingen [Van Schaftingen et al., 1982; 
Cordero-Espinoza and Hagen, 2013]. The assay is based on measuring the 
conversion rate of fructose-6-phosphate to fructose-1,6-bisphosphate by potato 
tuber pyrophosphosphate fructose-6-phosphotransferase (PPi-PFK), an enzyme 
whose activity is dependent on the F2,6P2 concentration. In the assay, cells were 
grown in individual 60mm plates and lysed in 0.1M NaOH followed by heating at 
80
o
C for 5 minutes. The samples were cooled on ice for 5 minutes and then 
centrifuged at 16,000g for 5 minutes. The supernatant was neutralized with ice-
cold 1M acetic acid in the presence of 20mM Hepes and centrifuged again. F2,6P2 
in the resultant supernatant was assayed through its ability to activate PPi-PFK. 
20µl of the neutralized extract was added to a 200µl reaction mixture (50mM 
Tris/HCl (pH8), 50mM MgCl2, 0.5mM pyrophosphate, 1mM F6P, 17.5mM G6P, 
50µg/ml aldolase, 1µg/ml triosephosphate isomerase, 10µg/ml glycerol-3-
phosphate dehydrogenase, 0.15mM NADH). The reaction was initiated with the 
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addition of PPi-PFK. PPi-PFK activity was measured as the decrease in NADH 
absorbance over time and was normalized to the total protein concentration.  
(f) Glucose- 6- phosphate concentration 
Glucose-6-phosphate (G6P) was extracted from cells using the same method as 
for the F2,6P2 extraction (see 2.2.12 section e). G6P was measured from the 
extracted samples according to a method slightly modified from [Zhu et al., 2009]. 
In this method, G6P oxidation by glucose-6-phosphate dehydrogenase (G6PD) is 
coupled to NADPH-dependent reduction of resazurin, which can be measured 
fluometrically. In the assay, 100µl of extracted sample or standard was added into 
2 x assay cocktail (40mM Tris (pH7.5), 2mM MgCl2, 200µM NADP
+
, 20µM 
resazurin). The reaction was initiated by addition of 0.1U/ml G6PD and 0.2U/ml 
diaphorase and incubated at room temperature for 30 minutes. The G6P 
concentration was measured fluorometrically (ex: 530nm, em: 590nm) and was 
normalized to the total protein concentration. The concentration of G6P was 
quantified using a standard curve ranging from 20nM to 400nM G6P prepared in 
water. 
(g) Hexokinase activity 
Cells were seeded in 12 well plates and transfected for 2 days with different 
expression plasmids. Cells were then lysed in triton lysis buffer with 100mM 
DTT and centrifuged at 16,000g for 5 minutes. Hexokinase activity was measured 
from the supernatant. The reaction was started by adding 25µl of fresh sample 
into the assay cocktail (1x PBS, 4mM ATP, 2mM NADP, 10mM glucose, 10mM 
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MgCl2, 3.75U/ml GDPD). Hexokinase activity was measured 
spectrophotometrically as the increase in absorbance at 340nm and was 
normalized to the total protein concentration. A control (fresh cell lysate of empty 
vector transfected cells and all components of assay cocktail except ATP) was 
included to determine the specificity of the assay. 
2.2.18 Immunofluorescence - Cells were grown on glass coverslips coated with 
100g/ml poly D-lysine and transfected to overexpress target protein(s) for 2 
days. Cells were fixed using 4% formaldehyde and permeabilized with 0.2% 
Triton X-100 for 10 minutes. After blocking with 5% fetal bovine serum, the 
coverslips were incubated with primary antibody, followed by specific 
fluorochrome-labeled secondary antibody. Coverslips were mounted onto glass 
slides using Vectashield (Vector Laboratories) containing 4′,6-diamidino-2-
phenylindole to label nuclei. Localization of target protein(s) was then visualized 
by fluorescence microscopy. 
2.2.19 Confocal live cell imaging - Trex 293 cells were grown on a 35mm 
imaging petri dish with a glass bottom (ibidi), coated with 100g/ml poly D-
lysine. The cells were transfected for two days to coexpress GLUT1-EGFP-HA 
pCDNA4/TO with either one of the following plasmids: empty vector pcDNA3, 
mTxnip Flag-pcDNA3, Flag-Arrdc4 pcDNA3. Cells were pretreated with both 
40µM cycloheximide and 1µg/ml tetracycline for 2.5 hours before rinsing of cells 
twice with fresh media to remove any residual cycloheximide.  The cells were 
then treated with only 1µg/ml tetracycline and the translocation of the 
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tetracycline-inducible EGFP tagged GLUT1 to plasma membrane was tracked 
overtime using confocal time-lapse microscopy with 100x objective oil lens  (Carl 
Zeiss LSM 710). All images were collected and analyzed with ZEN software. 
2.3 Statistical Analysis    
Results are expressed as mean  S.E.M. Differences in measured variables were 
assessed by one-way ANOVA. The differences were considered statistically 
significant if P <0.05 and highly significant if P <0.01.  
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3. Role of mitochondria in regulating Hypoxia Inducible Factor-1 (HIF-1α)            
protein stability 
3.1 Introduction 
     HIF-1α protein is a master regulator of the cellular response to hypoxia in both 
normal and cancerous cells. It is known to be regulated in an oxygen dependent 
manner at the level of its protein stability. Mitochondria are double membrane 
enclosed organelles with an electron transport chain (ETC) composed of complex 
I to IV, embedded in their inner membrane. The functional mitochondrial ETC 
has been proposed to play a critical role for hypoxia dependent HIF-1α protein 
stabilization. Chandel and colleagues, as well as several other groups, have 
demonstrated that 0 cells or cells depleted of mitochondrial DNA have a non-
functional mitochondrial ETC and failed to activate HIF-1 transcriptional activity 
during hypoxia [Chandel et al., 1998].  However the mechanism through which 
mitochondria regulate HIF-1α remains controversial. There are two opposing 
mechanisms as to how mitochondria might interact with the cellular oxygen 
sensor PHD, which is known to control HIF-1α protein stability. The two 





  48 
 
3.2 ROS Hypothesis    
3.2.1 Mitochondrial reactive oxygen species (ROS)  
     The mitochondrial ETC is the major source of cellular reactive oxygen species 
(ROS) in most cell types during normal aerobic metabolism. During oxidative 
phosphorylation, a significant amount of electrons "leak" from the mitochondrial 
ETC and interact with molecular oxygen (O2) resulting in the generation of 
superoxide [Turrens, 2003; Stowe and Camara, 2009]. Mitochondrial respiratory 
complexes I and III have been identified as the main sites of superoxide 
production in the ETC [St-Pierre et al., 2002]. Mitochondrial complex I generated 
superoxide is released into the matrix side of the inner mitochondrial membrane 
while complex III generated superoxide is released into both the matrix and 
cytosolic side of the inner mitochondrial membrane  [Muller et al., 2004] (Figure 
4). The released superoxide from both complex I and complex III is rapidly 
dismutated by manganese superoxide dismutase (SOD2) and copper-zinc 
superoxide dismutase (SOD1) to form hydrogen peroxide (H2O2) [Loschen et al., 
1974].  H2O2 can give rise to the highly reactive hydroxyl radicals via the Fenton 
reaction. Hydroxyl radicals oxidatively damage DNA, proteins and membranes. 
Therefore, cellular antioxidant defense systems, such as catalase and glutathione 
redox cycle, exist that can inactivate and prevent the buildup of  H2O2  [Michiels 
et al., 1994].  
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Figure 4.  Schematic diagram of Mitochondrial Electron Transport  Chain 
 
3.2.2 Increasing hypoxic ROS from mitochondrial complex III leads to HIF-
1α protein stabilization 
     According to the ROS hypothesis, increased amounts of ROS released from 
mitochondrial complex III during hypoxia are required to stabilize HIF-1α 
[Brunelle et al., 2005; Guzy et al., 2005; Mansfield et al., 2005] (Figure 5). 
Chandel et al was the first group to suggest a link between mitochondrial ROS 
and HIF-1 stabilization. They showed that functional mitochondria are required 
for the generation of ROS detected in the form of H2O2 during hypoxia. ROS 
production in wild type cells increases during hypoxia but decreases in the 
presence of antioxidants that attenuate H2O2. 
0
 cells also failed to generate ROS 
when subjected to hypoxia [Chandel et al., 1998]. Based on studies using a 
number of pharmacologic and genetic approaches, the source of ETC-derived 
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ROS in hypoxia is mitochondrial complex III and not complex I [Chandel et al., 
1998; Chandel et al., 2000]. Furthermore, Chandel et al found that inhibiting 
mitochondrial ROS production in hypoxia by different means (e.g. antioxidant 
treatment) prevented the stabilization of HIF-1α protein and the activation of the 
mRNA expression of HIF-inducible genes during hypoxia. The authors concluded 
that mitochondrial ROS are required to trigger hypoxia induced transcription.  In 
2000, the same group further demonstrated that increased ROS from 
mitochondrial complex III are also necessary to stabilize HIF-1α. Under hypoxia, 
both antioxidant-treated wild-type cells and 0 cells failed to accumulate HIF-1α 
protein [Chandel et al., 2000]. Likewise, the 0 cells were unable to induce HIF 
transcriptional activity when luciferase gene reporter assay was carried out. There 
was a marked increase in reporter activity in wild-type cells which was absent in 
0 cells during hypoxia.  In addition, when boluses of exogenous H2O2 were 
supplied to 0 cells under normoxia, HIF-1α was stabilized. These H2O2-treated 
0 cells were also able to induce HIF transcriptional activity during normoxia.  
Therefore, it was concluded that ROS generated from mitochondrial complex III 
during hypoxia lead to HIF-1 protein stabilization. 
3.2.3 The Qo site of mitochondrial complex III is required for HIF-1 protein 
stabilization via production of ROS 
     Mitochondrial complex III has been hypothesized to be the source of hypoxic 
ROS. Three subunits in complex III are involved in electron transport activity, the 
Rieske iron sulfur protein (RISP), cytochrome b and cytochrome c1. Together 
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with coenzyme Q (CoQ), a mobile electron carrier in the inner mitochondrial 
membrane, these three subunits of mitochondrial complex III form the two stage 
ubiquinone (Q) cycle. Firstly, the RISP subunit transfers electrons from reduced 
coenzyme Q or ubiquinol (carrying electrons derived from mitochondrial complex 
I or II) to the cytochrome c1 subunit. The cytochrome c1 subunit then passes an 
electron on to another electron carrier, cytochrome c, that in turn carries electrons 
from mitochondrial complex III to complex IV. The oxidation of ubiquinol 
produces highly reactive ubisemiquinone at the Qo site of complex III oriented 
towards the intermembrane space. Thus, the unstable ubisemiquinone radicals can 
donate electrons to generate ROS in the form of superoxide. The superoxide is 
being released to the cytosolic side of the inner mitochondrial membrane. 
Secondly, the cytochrome b subunit receives the second electron from the 
ubisemiquinone radicals and in turn transfers it to the oxidised coenzyme Q or 
ubiquinone at the Qi site in complex III to generate new ubiquinol. When this 
electron is passed on to RISP and subsequently to cytochrome c1, the Q cycle is 
completed. Since the Qi site is located on the side of the inner mitochondrial 
membrane that faces the mitochondrial matrix, leaked electrons from the Qi site 
will form superoxide that is released into the mitochondrial matrix [Chen et al., 
2003]. 
     Three papers employing different genetic approaches have shown that the 
source of hypoxic ROS is derived from the Qo site of mitochondrial complex III. 
Mansfield et al utilized cells lacking cytochrome c to prevent both the electron 
transfer from RISP and cytochrome c1 subunits of mitochondrial complex III and 
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subsequent formation of the unstable ubisemiquinone. This would abolish 
superoxide production from Qo site. These cells failed to increase ROS production 
and stabilize HIF-1α during hypoxia. However when cytochrome c was 
reintroduced into the cytochrome c null cells, both ROS production and HIF-1α 
induction were restored [Mansfield et al., 2005].  Two other research groups 
generated cells with defective Qo site by knocking down RISP. These cells failed 
to stabilize HIF-1 protein when subjected to hypoxic condition [Guzy et al., 
2005; Brunelle et al., 2005]. Bell et al further confirmed that it is not the Qi site of 
mitochondrial complex III that is responsible for the increased hypoxic ROS 
production [Bell et al., 2007]. This was demonstrated by using cells lacking the 
cytochrome b subunit with abolished Qi site. These cells were still able to 
generate ROS during hypoxia since the Qo site was still intact. However, when the 
Qo site in cytochrome b null cells was made defective, these cells were unable to 
generate ROS and stabilize HIF-1 protein in hypoxia. Therefore, it was 
concluded that the Qo site of mitochondrial complex III is required for HIF-1 
protein stabilization via ROS production.   
3.2.4 Increasing hypoxic ROS from mitochondrial complex III inhibits PHD 
enzyme, leading to stabilization HIF-1α protein 
     According to the ROS hypothesis, increased superoxide released from the Qo 
site of mitochondrial complex III will be converted into H2O2 to inhibit the 
activity of PHD2 enzyme (Figure 5). The enzymatic activity of PHD2 is 
dependent on the availability of both its cofactors (i.e. Fe
2+
, ascorbate) and 
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cosubstrates (i.e. oxygen, 2-oxoglutarate). H2O2 was hypothesized to oxidize the 
Fe
2+
 in the active site of PHD2 to Fe
3+ 
via Fenton chemistry. With the absence of 
Fe
2+
 cofactor, the inactive PHD2 allows HIF-1 protein to escape from 
hydroxylation and consequently proteasomal degradation. This hypothesis was 
supported by Gerald et al who demonstrated that JunD deficient cells or cells with 
compromised antioxidant capacity had increased intracellular H2O2 level that 
inhibited PHD2 activity. With inactive PHD2, HIF-1 protein accumulated under 
normoxia [Gerald et al., 2004]. The amount of HIF-1 protein could be 
diminished upon treatment of cells with ascorbate since this cofactor has the 
ability to recover the enzymatic activity of PHD2 by restoring the ferrous state of 
iron within the active site of the enzyme [Knowles et al., 2003]. Therefore, the 
stability of HIF-1 protein may be regulated through inhibition of PHD2 enzyme 
via increasing hypoxic ROS from mitochondrial complex III. However, of note, a 
recent study has reported that PHD enzymes have low sensitivity to inhibition by 
H2O2 (Masson et al., 2012). Thus, the exact contribution of H2O2 to hypoxia 
dependent HIF-1 protein stabilization remains unclear. 
3.3 Oxygen availability hypothesis 
     Hagen et al and Doege et al have suggested an alternative mechanism whereby 
the activity of the mitochondrial ETC regulates the stability of HIF-1 protein by 
determining the amount of oxygen available for PHD enzymes (Figure 5).   
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3.3.1 HIF-1 protein is destabilized when the mitochondrial ETC is 
nonfunctional 
     To investigate whether stabilization of HIF-1 protein in hypoxia is dependent 
on any mitochondrial complexes, Hagen et al and Doege et al carried out studies 
using pharmacological inhibitors (e.g. mitochondrial inhibitors and low doses of 
nitric oxide, which acts as an endogenous inhibitor of mitochondrial complex IV). 
These authors showed that inhibition of any ETC complex prevents accumulation 
of HIF-1 protein during hypoxia. Destabilization of HIF-1 is accompanied by 
increased intracellular oxygen concentrations in hypoxia, as demonstrated by 
Hagen et al [Hagen et al., 2003]. Normally, mitochondria consume the vast 
majority of the cellular oxygen and any changes in the activity of the ETC will 
result in changes in the intracellular oxygen availability. According to the oxygen 
availability hypothesis, a non-functional mitochondrial ETC prevents cellular 
oxygen consumption. This will lead to an increased intracellular oxygen 
concentration that is redistributed to the cytoplasm, making it available for non 
mitochondrial enzymes such as PHDs to regain their activities. 
3.3.2 Destabilization of HIF-1 protein due to mitochondrial inhibition is 
mediated through an increased activity of PHD2 
     To assess whether PHDs play a role in HIF-1 destabilization by 
mitochondrial inhibitors during hypoxia, both group of researchers utilized both 
pharmacological and genetic interventions.  Hagen et al transfected cells with a 
mutated HIF-1 construct that was resistant to prolyl hydroxylation and 
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proteasomal degradation. On the other hand, Doege et al inhibited PHDs activity 
by treatment of cells with dimethyloxalylglycine (DMOG), a 2-oxoglutarate 
analog.  Both groups subjected their cell models to mitochondrial inhibition under 
hypoxia and observed that stabilization of HIF-1 protein was restored when 
either HIF-1 was resistant to hydroxylated by PHD or when PHDs were 
nonfunctional [Doege et al., 2005; Hagen et al., 2003].  Taken together, the results 
suggested that destabilization of HIF-1 protein upon mitochondrial inhibition is 
mediated through an increase the activity of PHDs.  
3.3.3 Regulation of HIF-1 protein stabilization may not be dependent on 
hypoxic ROS from mitochondria 
     In addition, Hagen et al had further demonstrated the effects of inhibitors of 
mitochondrial ETC is independent of the hypoxic ROS generated since HIF-1 
stabilization is unaffected by the addition of antioxidants.    
     In summary, the regulation of HIF-1 is hypothesized to be dependent on the 
intracellular oxygen concentration which in turn is regulated by the mitochondrial 
ETC activity. Thus regulation of HIF-1 protein may be independent on the 


















Figure 5.  Schematic diagram of how mitochondria regulate HIF-1 protein 
stability according to the ROS hypothesis or Oxygen availability hypothesis.  
In the ROS hypothesis, hypoxia results in an increase in ROS in the form of 
superoxide (O2
.-
) released from mitochondrial complex III. Superoxide is 





, thus leading to HIF-1 protein stabilization. In the 
oxygen availability hypothesis, mitochondria that consume the vast majority of 
cellular O2 regulate the stability of HIF-1 protein by determining the amount of 
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3.4 Aims of the study 
     Given the importance of the cellular hypoxic response for normal cell 
physiology and the critical involvement of HIF in cancer, the aim of the study was 
to characterize the mechanism through which mitochondria regulate the HIF-1 
protein stability by validating the two proposed mechanisms, ROS hypothesis and 
oxygen availability hypothesis, using several approaches that specifically alter the 
mitochondrial oxygen consumption without affecting ROS production. To this 
end, the following specific objectives were addressed: 
1) To determine  if any specific site within the mitochondrial ETC is required 
for hypoxia dependent HIF-1 stabilization? 
2) To further establish whether the effects of mitochondrial inhibitors on 
HIF-1 are due to inhibition of mitochondrial oxygen consumption or 
inhibition of ROS production from complex III  
3) To determine whether HIF-1 stabilization is dependent on mitochondrial 
ROS from complex III  
4) To assess the role of ROS in mediating HIF-1 stabilization directly 
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3.5 Results 
3.5.1 Mitochondria are involved in regulating the hypoxic response by 
regulating the stabilization of the HIF-1 protein  
     A functional mitochondrial ETC has been reported to be involved in hypoxia-
dependent HIF-1 protein stabilization [Chandel et al., 1998]. To determine 
whether any specific sites within the mitochondrial ETC is required for HIF-1 
stabilization during hypoxia, 143B cells were incubated at 21% or 1% O2 for 4 
hours in the presence of various mitochondrial ETC inhibitors. At 1% O2, HIF-1 
protein is stabilized in the untreated cells while its accumulation was completely 
inhibited upon treatment with the different inhibitors (e.g. rotenone, myxothiazol, 
stigmatellin, antimycin A and sodium azide) at concentrations that completely 
inhibit ETC activity. (Figure 6). In addition, this effect was specific to HIF-1 
since mitochondrial inhibitors did not affect the loading protein control,  actin. 
Thus, the requirement of a functional ETC for HIF-1 stabilization is not 





















Figure 6. Effects of different mitochondrial electron transport inhibitors on 
HIF-1 protein stability. (A) 143B cells were incubated at 1% O2 for 4 hours in 
the presence of the mitochondrial inhibitors stigmatellin (1µM), sodium azide 
(2mM), myxothiazol (1µM), rotenone (0.5µM), and antimycin A (1µM), as 
indicated in (B). HIF-1 was analyzed by Western blotting.  (B) Specific 





  60 
 
3.5.2 All inhibitors of mitochondrial electron transport have similar effects 
on HIF-1 protein half-life in hypoxia 
     To explore further the effects of the mitochondrial inhibitors, we obtained a 
more quantitative measurement of the effect of mitochondrial inhibitors by 
measuring the rate at which HIF-1 protein is degraded. HEK293 cells were 
subjected to 3 hours of hypoxia followed by incubation with the protein synthesis 
inhibitor cycloheximide in the presence or the absence of inhibitors for different 
durations.  In the presence of cycloheximide, there was a slow gradual decrease in 
the HIF-1 protein concentration with a half-life of 33.0 minutes (Figure 7A and 
Figure 7B). However, in the presence of both cycloheximide and either one of the 
following mitochondrial inhibitors (rotenone, myxothiazol, antimycin A, sodium 
azide, DETA-NONOate), HIF-1 protein was degraded at a much faster rate 
(Figure 7A).  As summarized in Figure 7B, all inhibitors of the mitochondrial 
ETC decreased the HIF-1 half-life to similar degrees (rotenone t1/2 = 8.9 minutes, 
myxothiazol t
1
/2 = 10.0 minutes, antimycin A t
1
/2 = 5.7 minutes, sodium azide t
1
/2 
= 8.6 minutes, DETA-NONOate t
1
/2 = 10.7 minutes).  These results indicate that 
inhibition of any site in the mitochondrial ETC inhibits hypoxia-dependent HIF-
1 protein induction by decreasing its half life and that the requirement of 













Figure 7. Rate of HIF-1 protein degradation in the presence of different 
mitochondrial electron transport inhibitors. (A) After incubation at 1% O2 for 
3 hours in a hypoxia chamber, HEK293 cells were treated with cycloheximide 
(Chx, 40µM) and either of the mitochondrial inhibitors rotenone (0.5µM), 
myxothiazol (1µM), antimycin A (1µM), sodium azide (2mM) and DETA-
NONOate (100µM) as indicated. The inhibitors were added within the hypoxic 
chamber without introducing atmospheric oxygen, and cell lysates were obtained 
after 5, 20, 30, and 45 minutes followed by immunoblotting using HIF-1 
antiserum. (B) Summary of immunoblot analysis of HIF-1 in cell lysates under 
the same conditions as those described in Figure 7A. The band intensity, as 
determined by densitometry, was normalized to the -tubulin signal and 
expressed as percent of the HIF-1 abundance of time zero. The results shown 
represent the means + S.E. of three independent experiments. The decrease in 
HIF-1 protein expression in mitochondrial inhibitor treated versus control cells 
was statistically significant (p < 0.05) for all inhibitors at 45 minutes, for all 
inhibitors except myxothiazol at 30 minutes, for sodium azide and DETA-
NONOate at 20 minutes. 
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3.5.3 No correlation between the amount of superoxide production and the 
level of HIF-1 protein stabilization during hypoxia  
     ROS are produced to different degrees at the various complexes of the 
mitochondrial ETC.  Inhibition of different sites within the mitochondrial electron 
transport chain is known to have different effects on the mitochondrial ROS 
production. To determine the effects of the different inhibitors on ROS production 
in normoxia and hypoxia, we measured the superoxide-dependent oxidation of the 
fluorescent dye dihydroethidium. In untreated cells, there was no significant 
increase in the superoxide concentration in hypoxia compared with normoxia. Of 
the mitochondrial ETC inhibitors, only sodium azide lowered the superoxide 
production in both hypoxia and normoxia significantly.  There was no significant 
change with DETA-NONOate and a slight increase was observed with other 
inhibitors (Figure 8). Comparison of these results with those shown in Figure 6A 
suggest that there is no correlation between the effects of the various inhibitors on 
superoxide production and hypoxia-dependent HIF-1 protein stabilization, 
suggesting that superoxide may not play an important role in HIF-1 protein 















Figure 8. Effects of different mitochondrial electron transport inhibitors on 
ROS production in normoxia and hypoxia.  HEK293 cells were incubated in 
either 21% O2 or 1% O2 for 3 hours followed by treatment with mitochondrial 
inhibitors used at the same concentration as in Figure 7 and 20µM 
dihydroethidium dye (DHE) for 30 minutes to measure the cellular superoxide 
concentration. The fluorescence results shown represent the average of three 
independent experiments (mean  S.E.). Only sodium azide caused a statistically 
significant (p < 0.05) decrease in the superoxide concentration in normoxia and 
hypoxia (as indicated by an asterisk).  
 
 
3.5.4 Reestablishing oxygen consumption in the presence of mitochondrial 
complex III inhibitor restores hypoxia-dependent HIF-1 stabilization 
     To further establish whether the effects of mitochondrial inhibitors on HIF-1 
are due to inhibition of mitochondrial oxygen consumption or inhibition of ROS 
production from complex III, we investigated the effect of myxothiazol on HIF-
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1 protein accumulation in the presence of 2,2,4-trimethyl-1,3-pentanediol 
(TMPD) and ascorbate. The mitochondrial complex III inhibitor myxothiazol has 
been reported to inhibit complex III-dependent superoxide production  
[Konstantinov et al., 1987; Starkov and Fiskum, 2001]. TMPD, which is 
maintained in a reduced state by ascorbate, acts as artificial electron donor to 
donate electrons to mitochondrial complex IV via cytochrome c (Figure 9). As a 
result, the upstream mitochondrial complex III was bypassed and oxygen 
consumption was restored even in the presence of myxothiazol (Figure 10A). We 
then determined the effect of TMPD on hypoxia-dependent HIF-1 stabilization. 
TMPD alone had no effect on the HIF-1 protein concentration in hypoxia 
(Figure 10B). However, TMPD completely rescued myxothiazol-induced 
inhibition of HIF-1  stabilization. This indicates that in the presence of a 
mitochondrial complex III inhibitor, reestablishing mitochondrial oxygen 
consumption via complex IV is sufficient for HIF-1 stabilization. The result also 
suggests that both electron transport via mitochondrial complex III and 
superoxide derived from complex III are not required for HIF-1 induction. 
Therefore, the effect of myxothiazol on HIF-1 stability is likely a consequence 











Figure 9. Schematic diagram of reestablishing oxygen consumption with 
TMPD when mitochondrial complex III is inhibited. Under conditions where 
the mitochondrial ETC is inhibited by myxothiazol oxygen consumption can be 
reactivated by adding 2,2,4-trimethyl-1,3-pentanediol (TMPD). TMPD donates 
electrons directly to complex IV via cytochrome c.  
 
 




Figure 10. Under conditions of inhibition of complex III, reestablishing 
oxygen consumption with TMPD is sufficient for hypoxia-dependent HIF-1 
stabilization. (A) Oxygen consumption of 143B cells was measured using a 
Clark-type oxygen electrode at 37
o
C. The addition of myxothiazol (1µM) and 
TMPD (0.2mM) is indicated. (B) 143B cells were incubated at 1% O2 for 3 hours 
with myxothiazol in the absence or presence of TMPD. HIF-1 protein 
abundance was determined by Western blotting. 
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     Next, we repeated the HIF-1 half-life measurements with different 
mitochondrial complex III inhibitors, myxothiazol and antimycin A, in the 
presence of TMPD. As shown in Figure 11, addition of TMPD increased the HIF-
1 half-life in the presence of myxothiazol from 10.0 minutes to 28.9 minutes,  
which is similar to the untreated control (t
1
/2 = 33.0 minutes).  A very similar 
trend was observed when the experiment was repeated with another complex III 
inhibitor, antimycin A. In cells treated with antimycin A, the HIF-1 half-life 
increased from 5.7 minutes in the absence of TMPD to 23.7 minutes in the 
presence of the artificial electron donor. These results further suggest that HIF-1 
protein stabilization is dependent on mitochondrial oxygen consumption. 
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Figure 11. Half life of HIF-1 in the presence of complex III inhibitors and 
TMPD is very similar to the control. (A) HEK293 cells were incubated at 1% 
O2 for 3 hours, followed by treatment with cycloheximide (Chx, 40µM) and the 
complex III inhibitors myxothiazol (1µM) and antimycin A (1µM), as indicated, 
in the absence or presence of TMPD. Cell lysates were obtained after 5, 20, 30, 
and 45 minutes, followed by immunoblotting using HIF-1 antiserum. (B) 
Summary of immunoblot analysis of HIF-1 in cell lysates of HEK293 cells 
under the same conditions as those described in Figure 11A. The results were 
calculated and are presented as in Figure 7B (n = 3, means  S.E.). With 
antimycin A, TMPD caused a statistically significant (p< 0.05) increase in HIF-
1 protein expression at 20, 30, and 45 minutes. With myxothiazol, the TMPD-
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3.5.5 Expression of Alternative Oxidase to bypass electron transport via 
complex III 
     Alternative Oxidase (AOX) is a mitochondrial enzyme that is found in plants, 
some fungi, protists, and lower metazoa [McDonald, 2008]. It has two reported 
physiological functions: to lower the production of ROS during mitochondrial 
electron transport and to carry out thermogenesis [Maxwell et al., 1999; Dufour et 
al., 2000]. The AOX protein is an additional terminal oxidase of the ETC that 
localizes to the inner mitochondrial membrane. It accepts electrons from 
coenzyme Q and uses the electrons to reduce oxygen to water directly, therefore 
bypassing complex III and IV (Figure 12). As a consequence, electron transport 
via complex III is decreased, resulting in lower superoxide production from 
complex III via the Q cycle, while mitochondrial oxygen consumption is 
maintained. Since electron flow from coenzyme Q is less tightly coupled to ATP 
production, the resultant free energy is dissipated in the form of heat. By lowering 
mitochondrial ROS production, AOX provides protection against oxidative 
damage. The ability to bypass complex III and IV allows plant or non-plant 
species with activated AOX to overcome inhibition of electron transport and 
proton pumping when they release cyanogenic or other poisons to inhibit complex 
IV. This allows AOX expressing species to either resist pathogenic attack or to 
survive in the toxic sulfite-rich environment, respectively [McDonald 2008; 
Grieshaber and Völkel 1998]. Heat production resulting from AOX activity 
allows both plant and non-plant species to survive in freezing environments.  





Figure 12. Schematic diagram of the Alternative Oxidase (AOX) pathway in 
the mitochondrial ETC.  AOX is an additional terminal oxidase of the ETC that 
localizes to the inner mitochondrial membrane. It accepts electrons from 
coenzyme Q (CoQ) and uses the electrons to reduce oxygen to water directly, 
therefore bypassing complex III and IV. As a consequence, electron transport via 
complex III is decreased, resulting in lower superoxide production from complex 
III via the Q cycle. 
 
     AOX is found in all plant species studied to date. We chose to overexpress the 
enzyme derived from soybean (Glycine max) in mammalian cells (i.e.143B, 
HEK293), since soybean cotyledons are non-thermogenic plants that have 
relatively high amounts of AOX protein expression and activity [Moore and 
Siedow 1991]. In addition, it was previously reported that AOX dependent 
electron transport remains unaffected by NO concentrations that completely 
inhibit cytochrome c oxidase during soybean embryo development, since these 
embryo continue to respire in the presence of this complex IV inhibitor [Caro and 
Puntarulo 1999]. There are two isoforms of AOX, namely AOX1 and AOX2. 
AOX1, which is activated by stress conditions, is hypothesized to play a role in 
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the stress defense response whereas the not stress-induced AOX2 is constitutively 
active and is hypothesized to serve as a housekeeping protein in respiration 
[Considine et al 2002]. Therefore, expressing AOX1a in mammalian cells is more 
suitable for our aim to genetically determine whether HIF-1α stabilization is 
dependent on mitochondrial ROS originating from complex III. 
3.5.5.1 Plant AOX is non-functional in mammalian cells 
     To determine whether soybean AOX is expressed, is successfully imported 
into mitochondria of mammalian cells and is functional, immunofluorescence, 
and polarographical measurement of respiration via the alternative pathway were 
performed. As shown in Figure 13A, the TRITC-labeled soybean AOX 
colocalized with mitochondrial protein Apoptosis inducing factor (AIF) when 
143B cells were transiently transfected with both C-terminally V5-tagged AOX 
and GFP-tagged AIF. Although soybean AOX was translocated into mitochondria, 
only little myxothiazol-resistant respiration was observed in the soybean AOX 
expressing 143B stable cell line (data not shown). The oxygen consumption 
measurement was repeated using another AOX expression system (i.e. soybean 
Aox1a tetracycline-inducible HEK293 cells with well expressed AOX, see Figure 
13B).  However, similar observations were made. Taken together, AOX derived 
from soybean proved to be non-functional when expressed in mammalian cells. 
This could be due to the fact that the AOX protein with the plant origin is 
evolutionally too remote from mammalian cells 
 






Figure 13. Determining localization and expression of plant AOX protein.  (A) 
Immunofluorescent images of cells transfected with C-terminally V5-tagged AOX 
i) Transfection with AIF-GFP which localizes to mitochondria ii) Transfection of 
AOX-V5 (stained with V5 primary antibody and TRITC-labeled secondary 
antibody) iii) Overlay: Colocalization of AIF and AOX indicates that plant AOX 
is successfully targeted to mitochondria in mammalian cells (143B). (B) Plant 
AOX-overexpressing tetracycline-inducible HEK293 cells were treated overnight 
in the presence or absence of 1µg/ml tetracycline, followed by immunoblotting to 
determine the expression of AOX protein. 
 
3.5.5.2 Lower metazoa AOX is functional in mammalian cells  
     In 2006, Hakkaart et al demonstrated that AOX derived from Ciona 
intestinalis is well tolerated in mammalian cells. This lower metazoa AOX 
remains functional by conferring resistance to inhibition of respiration by 
complex III and complex IV inhibitors both in cultured human cells and in vivo in 
Drosophila [Hakkaart et al.,  2006;  Dassa et al., 2009; Fernandez-Ayala et al., 
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2009]. Therefore, expressing Ciona intestinalis AOX in HEK293T cells would be 
a suitable approach to genetically determine whether HIF-1 stabilization is 
dependent on mitochondrial complex III derived ROS. We obtained a stably 
transfected HEK293T cell line that expresses Ciona intestinalis AOX under a 
tetracycline-inducible promoter from Dr. Howard Jacobs (University of Tampere, 
Finland). We first compared the respiratory properties of wild type and AOX-
expressing HEK293T cells by comparison of their oxygen consumption. As 
shown in Figure 14A, AOX is well expressed in HEK293T cells after overnight 
pyruvate treatment. Pyruvate is known to activate AOX by promoting the inactive 
dimer to the more active monomeric state. [McDonald, 2008; Umbach et al., 2006; 
Hoefnagel et al., 1997].  When subjected to myxothiazol and rotenone, respiration 
of the wild type cells was inhibited by 75.7% and 84.6%, respectively (Figure 
14B). However, in the AOX-expressing cells, respiration was inhibited by only 
42.8% when myxothiazol was present (Figure 14B). Subsequent addition of 
rotenone resulted in similar inhibition (78.5%) as observed in control cells. Thus, 
the AOX-expressing cells still consume oxygen even in the presence of 
myxothaizol, due to their ability to bypass both complex III and IV and utilize 













Figure 14. Determining oxygen consumption of Ciona Intestinalis AOX 
overexpressing cells. Both HEK293T wild-type and Ciona Intestinalis AOX-
overexpressing cells were treated overnight in the presence of 2mM pyruvate (an 
AOX activator to ensure maximum AOX activity), followed by (A) 
immunoblotting to determine the expression of AOX protein or (B) measurement 
of oxygen consumption in the presence of mitochondrial inhibitors myxothiazol 
(1µM) or rotenone (1µM), as indicated. 
 
     Next, we determined the effect of AOX protein expression on the cellular 
superoxide concentration in the presence of different mitochondrial ETC 
inhibitors. AOX expression lowered the superoxide production in the presence of 
the complex III inhibitors myxothiazol and antimycin A but had no effect on 
superoxide when the complex I inhibitor rotenone was present (Figure 15). Thus, 
as expected, AOX only inhibits complex III-dependent superoxide production.  




Figure 15. Effect of AOX protein expression on the cellular superoxide 
concentration in the presence of different mitochondrial ETC inhibitors.  
HEK293T wild type (open bars) and AOX-overexpressing (filled bars) cells were 
treated with the mitochondrial inhibitors rotenone (0.5µM), myxothiazol (1µM), 
and antimycin A (1µM) and 20µM dihydroethidium dye (DHE) for 1 hour to 
measure cellular superoxide concentrations. The fluorescence results shown are 
expressed as relative fluorescence units (RFU) and represent the average of two 
independent experiments (mean  S.E.).  
 
3.5.5.3 AOX-dependent oxygen consumption is sufficient to reactivate the 
hypoxia response  when complex III  is inhibited 
     To investigate whether reestablishing oxygen consumption under conditions 
where complex III is inactive is sufficient for hypoxia-dependent HIF-1 
stabilization, we treated wild-type and AOX-expressing HEK293T cells with 
mitochondrial inhibitors under hypoxic conditions. In wild-type cells, HIF-1 
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protein accumulation was prevented in the presence of inhibitors of complex I, III, 
and IV (Figure 16). In AOX-expressing cells, HIF-1 induction was also 
inhibited with the complex I inhibitor rotenone. This result is expected because 
rotenone inhibits electron transport upstream of AOX. In contrast, antimycin A 
and sodium azide had no inhibitory effect on HIF-1 expression in AOX-
expressing cells. These cells still consume oxygen via the AOX protein, but do 
not produce increased superoxide because electron transport via complex III is 
inhibited. These results suggest that the mitochondrial ETC regulates HIF-1   
protein stability by controlling the intracellular oxygen but not ROS concentration.      
     Unexpectedly, HIF-1 expression was significantly inhibited when AOX-
expressing cells were treated with myxothiazol. Myxothiazol is a complex III 
inhibitor. Therefore, its inhibitory effect on hypoxia-dependent HIF-1 
accumulation is expected to be reversed when AOX is expressed and oxygen can 
be consumed independently from complex III.  
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Figure 16. Effects of different mitochondrial electron transport inhibitors on 
HIF-1 protein stability in AOX-overexpressing cells. HEK293T wild type 
and AOX-overexpressing cells were exposed to 1% O2 for 3 hours in the presence 
of the mitochondrial inhibitors myxothiazol (1µM), antimycin A (1µM), sodium 
azide (5mM), and rotenone (0.5µM). HIF-1 was detected by Western blotting.  
 
 
 A possible explanation for the inhibitory effect of myxothiazol on HIF-1 
expression is that at a concentration of 1µM myxothiazol also functions as 
complex I inhibitor. Mitochondrial complex I is also known as NADH:ubiquinone 
oxidoreductase. Normally electrons derived from the complex I substrate NADH 
are transferred to the flavin mononucleotide (FMN) prosthetic group of the 
complex to produce FMNH2. These electrons are transferred to the iron-sulfur 
clusters within the complex and subsequently to the mobile electron carrier 
ubiquinone and complex III. Like the complex I inhibitor rotenone, myxothiazol 
is structurally similar to ubiquinone. By occupying the ubiquinone binding site of 
the complex, myxothiazol disrupts the electron flow from the terminal iron-sulfur 
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cluster to downstream mitochondrial complexes, leading to inhibition of the ETC. 
To confirm the hypothesis that the inhibitory effect of myxothiazol on HIF-1 
expression is due to complex I inhibition, both wild type and AOX-expressing 
cells were treated with different concentrations of myxothiazol under hypoxic 
conditions (Figure 17A). In the wild type cells, hypoxia-dependent HIF-1 
stabilization was prevented at any concentration of myxothiazol. In contrast, in 
AOX-expressing cells, HIF-1 could be detected at the lower myxothiazol 
concentrations (100nM and 250nM) but not at the higher concentration of 1µM. 
When measuring the effects of the different myxothiazol concentrations on 
mitochondrial complex I activity in mouse liver mitochondria, significant 
inhibition was observed with 500nM and 1µM, but not with lower concentrations 
of myxothiazol (Figure 17B). These results indicate that the inhibition of HIF-1 
accumulation in AOX-expressing cells by 1µM myxothiazol (as observed in 
Figure 16) is due to an inhibitory effect on complex I. In contrast, AOX 
expression prevents the inhibition of hypoxia-dependent HIF-1 stabilization by 













Figure 17. Effects of increasing myxothiazol concentrations on HIF-1 
protein stability and mitochondrial complex I activity. (A) Both HEK293T 
wild type and AOX-overexpressing cells were exposed to 1% O2 for 3 hours in 
the presence of myxothiazol (100nM, 250nM, and 1µM). HIF-1 protein 
abundance was measured by Western blotting. (B) Mitochondrial complex I 
activity was determined in mouse liver mitochondria treated with myxothiazol 
(100nM, 250nM, 500nM, and 1µM) using NADH as substrate as described under 
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3.5.6 Regulation of HIF-1α protein stabilization is likely independent of 
mitochondrial ROS produced during hypoxia 
     Our results indicate that increasing mitochondrial oxygen consumption in the 
absence of electron transport via complex III is sufficient for hypoxia-dependent 
HIF-1α accumulation. This result is in agreement with the hypothesis that ROS 
generated by complex III are not required for hypoxia-dependent HIF-1α 
accumulation. To assess the role of ROS in mediating HIF-1α stabilization 
directly, we used exogenous glucose oxidase/glucose system to produce constant 
amounts of H2O2.  Being an oxidoreductase, glucose oxidase converts glucose in 
the cultured media into D-Gluconic acid by using molecular oxygen as the final 
electron acceptor to produce H2O2 simultaneously (Figure18A) [Hayashi and 
Nakamura, 1976 and Rothberg et al., 1999] . When 143B cells were treated with 
250miliunits/ml or higher glucose oxidase concentration, toxic effects were 
observed. We therefore used a range of lower glucose oxidase concentration of 25, 
100, and 200milliunits/ml. Based on dichlorofluorescein (DCF) fluorescence 
calibration with known amounts of H2O2, addition of 100 miliunits/ml glucose 
oxidase to 143B cells over a period of 15 minutes resulted in DCF fluorescence 
that was similar to exposure of cells to 200µM H2O2. We found that glucose 
oxidase/glucose-derived H2O2 at any concentration was without effect on HIF-1 
protein accumulation during hypoxia (Figure18B). 
 
 




Figure 18. Effects of increasing doses of H2O2 produced by an exogenous 
glucose oxidase/glucose system on HIF-1 protein stability. (A) Chemical 
reaction catalyzed by glucose oxidase. (B) 143B cells were incubated at either 
21% O2 or 1% O2 for 4 hours with glucose oxidase at concentration of 25, 100 
and 200 mU/ml followed by analysis of HIF-1α by Western blotting. 
 
     To test further whether H2O2 is involved in HIF-1 stabilization, we 
retrovirally overexpressed  both cytosolic and mitochondrial-targeted catalase. 
H2O2 produced by SOD1 or other sources in the cytoplasm will be scavenged by 
the cytosolic catalase while H2O2 generated by SOD2 in the mitochondrial matrix 
will be scavenged by the mitochondria-targeted catalase (Figure 19A). Thus, 
overexpression of either catalase protein is expected to lower cellular ROS 
production without affecting oxygen consumption. The catalase-transduced cells 
had marked increased catalase protein expression (Figure 20). The cytosolic 
catalase overexpressing cells were also found to have marked increased H2O2 
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scavenging capacity, as indicated by a 70% lower DCF fluorescence compared to 
control cells (Figure 19B). However, HIF-1 protein in cells that overexpressed 
either form of catalase was still induced in hypoxia to the same degree compared 
to the control cells (Figure 20).  These results suggest that mitochondrial or 











































Figure 19. Catalase overexpressing cells have increased H2O2 scavenging 
capacity. (A) Schematic diagram of the mitochondrial ETC with mitochondrial 
(MITO-CAT) and cytoplasmic catalase (CYTO-CAT). (B) 143B control cells 
(open bar) and cytoplasmic catalase (CYTO-CAT) (filled bar) overexpressing 
cells were stained with 20μM 2’-7’-Dichlorodihydrofluorescein diacetate 
(DCFDA) dye for 15 minutes prior to H2O2 (200μM) treatment for 5 minutes. The 
difference in fluorescence before and after the H2O2 treatment was determined in 
control and CYTO-CAT cells. (n = 3, mean ± SEM). 
 
 



















Figure 20. Effect of Catalase overexpression on HIF-1 protein stability. 
143B cells overexpressing cytoplasmic or mitochondrial catalase (CYTO- CAT or 
MITO-CAT) or control vector cells were subjected to 21% O2 or 1% O2 and HIF-
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3.5.7 Hydrogen peroxide does not directly inhibit prolyl hydroxylase activity  
    According to the ROS hypothesis, increased mitochondrial superoxide released 
from complex III will be converted to H2O2 which inhibits the PHD enzyme in the 
cytoplasm, possibly by oxidizing the non-heme-bound Fe
2+
 in the PHD active site 





residues in HIF-1, leading to binding of the 
pVHL/Cul2 E3 ligase, and subsequently ubiquitination and degradation of HIF-
1. To determine directly the effect of H2O2 on the enzymatic activity of PHD, an 
in vitro PHD assay based on the specific interaction between pVHL and the 
hydroxylated proline 564 residue of HIF-1, was carried out. In this assay, the C-
terminal oxygen dependent degradation domain (ODDD) of HIF-1, containing 
PHD substrate residue proline 564, was fused to GST tag [GST-HIF-1(521-
652)-V5]  and produced as a recombinant protein from E. coli (Figure 21A) and 
purified using GSH sepharose affinity column. Cell lysate from cells 
overexpressing full length PHD2 and pVHL was used to hydroxylate the 
recombinant GST-HIF-1 protein in the presence of the PHD2 cofactor ascorbate, 
Fe
2
+ and the cosubstrate 2-oxoglutarate.  Binding of pVHL to hydroxylated HIF-
1 was used as an indicator of Pro564 hydroxylation.  Based on Figure 21B, pVHL 
was observed to bind to HIF-1 in the presence of ascorbate and 2-oxoglutarate. 
Several negative controls were carried out to demonstrate the sensitivity and 
specificity of the assay. pVHL showed reduced binding to HIF-1 in the presence 
of  the PHD inhibitor,  dimethyloxaloylglycine.  As expected, there was no 
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binding of pVHL to HIF-1  in the absence of  both cofactors (e.g. Fe2+, ascorbate) 
and cosubstrate (e.g. 2-oxoglutarate) of  PHD2 upon treatment with the Fe
2+
 
chelator deferoxamine mesylate. In addition, there was also no significant pVHL 
binding to GST-HIF-1(521-652)-V5 after Pro564 was mutated to Ala in the 
recombinant HIF-1 fusion protein (Figure 21B, right panel).  In the presence of 
50M and 200M H2O2, pVHL binding was not affected, suggesting that H2O2 
does not directly affect PHD (Figure 21B).  We also tested whether superoxide 
affects PHD activity by using xanthine/xanthine oxidase system to generate 
superoxide in vitro. Superoxide is generated as a byproduct of xanthine oxidase 
when it converts xanthine into uric acid (Figure 21C) [McCord  and Fridovich, 
1968;  Hodges et al.,  2000].   In contrast to H2O2, superoxide caused a ~50% 
reduction in binding of pVHL to HIF-1 (Figure 21D), suggesting that 
superoxide inhibits PHD activity partially. However, we cannot rule out that the 
inhibitory effect of superoxide is due to other reasons such as a conformational 
change in the VHL protein. 
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Figure 21. Hydrogen peroxide does not inhibit PHD activity.  (A) Solubility of 
wild-type GST HIF-1 (521-652)-V5 recombinant protein expressed in BL21 
cells was determined by coomassie blue staining in a small scale preparation. As 
the majority of the recombinant GST HIF-1 (521-652)-V5 protein was found in 
the soluble fraction, a large scale preparation was then carried out and the 
recombinant protein was purified using GSH sepharose affinity columns. The 
purified  GST HIF-1 (521-652)-V5 protein was then used to perform pVHL 
binding assays as indicated in Figure 21B . (B) Cell lysate of HEK293 cells 
transfected with PHD2 and pVHL was incubated with wild type or P564A mutant 
GST-HIF-1 (521– 652)-V5, immobilized on GSH agarose beads, in the presence 
of 2mM 2-oxoglutarate and 2mM ascorbate to detect pVHL binding by Western 
blotting. The reaction was performed in the presence of H2O2 (50µM and 200µM), 
dimethyloxaloylglycine (DMOG; 2mM), and deferoxamine mesylate (DFO; 
200µM) as described under “Materials and Methods.” After the incubation, the 
lysate was removed, the GSH-agarose beads were washed, and bound pVHL was 
analyzed by Western blotting. (C) Chemical reaction catalysed by xanthine 
oxidase (D) Densitometric analysis of three independent pVHL binding assays in 
the presence of 50µM or 200µM H2O2, superoxide-generating system 
xanthine/xanthine oxidase, or 2mM dimethyloxaloylglycine is presented in (B) 
(percent of untreated control; mean  S.E.). The decrease in the PHD activity in 
the presence of xanthine/xanthine oxidase compared with the untreated control 
reached statistical significance (p < 0.05), as indicated by an asterisk. 
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Although H2O2 that is converted from complex III-derived superoxide has been 
proposed to inhibit PHD under hypoxia [Guzy et al., 2005; Mansfield et al., 2005], 
we wanted to test whether cellular superoxide has any effect on PHD activity in 
cells. To this end, cells were treated with the SOD1 inhibitor 
diethyldithiocarbamate (DCC), the SOD mimetic, Mn(III)tetrakis(4-benzoic 
acid)porphyrin Chloride (MnTBAP) and the antioxidants N-acetylcysteine (NAC) 
and ascorbate, which are superoxide scavengers [Yang et al., 2008]. Lowering the 
superoxide concentration by converting superoxide to H2O2 or by scavenging 
superoxide when cells were treated with MnTBAP or NAC and ascorbate, 
respectively, did not significantly affect HIF-1 stabilization in hypoxia (Figure 
22).  This suggests that superoxide is not involved in regulating PHD activity in 
cells. In addition, when superoxide level was increased upon DCC treatment, 
there was no significant effect on the hypoxia-dependent HIF-1 stabilization 
(Figure 22). However, DCC marked increased HIF-1 protein expression in 
normoxia.  Addition of the SOD1 mimetic MnTBAP to dismutate the 
accumulating superoxide did not reverse the effect of DCC, suggesting that DCC 
increases HIF-1 protein expression in normoxic conditions independently of 
changes in the superoxide concentration. Therefore, taken together, our results 
suggest that neither H2O2 nor superoxide is involved in the regulation of PHD 
activity in vivo. 
 
 





Figure 22. Superoxide is not involved in the regulation of  PHD activity in 
cells.  HEK293 cells treated with the superoxide dismutase inhibitor 
diethyldithiocarbamate (DCC) (1mM the superoxide dismutase mimetic 
MnTBAP (100μM), the antioxidants N-acetylcysteine (NAC) (10mM) and 
ascorbate (2.5mM) were exposed to either 21% or 1% O2. HIF-1α protein 




     Mitochondria are the major consumer of cellular oxygen. Any fluctuations in 
mitochondrial respiration and in the activity of the ETC as a result of 
physiological or pathological processes will affect the amount of intracellular 
oxygen. The intracellular oxygen concentration determines the rate at which the 
PHD enzymes hydroxylate HIF-1. Thus, PHD enzymes function as oxygen 
sensors that target the HIF-1 protein for ubiquitination and degradation in 
oxygen dependent manner.  There are two opposing mechanisms as to how 
mitochondria might interact with PHD to regulate HIF-1 protein stability.  
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Studies by several groups have provided evidence that mitochondria act as 
regulators of PHD activity by regulating the intracellular oxygen availability 
[Hagen et al., 2003; Doege et al., 2005, Gong and Agani, 2005; Brown and Nurse, 
2008]. Alternatively, a number of studies have proposed that the role of 
mitochondria is to release ROS from complex III of the ETC under hypoxia 
[Brunelle et al., 2005; Guzy et al., 2005; Mansfield et al., 2005]. These complex 
III-derived ROS were reported to stabilize HIF-1 protein during hypoxic 
conditions by inhibiting the activity of PHD enzymes. 
     In this study, we tried to validate the two proposed mechanisms. We provide 
evidence that mitochondria regulate the stabilization of HIF-1 protein by 
controlling the intracellular oxygen availability and not by releasing ROS from 
complex III.  We show that the requirement of the mitochondrial ETC for 
hypoxia-dependent HIF-1 protein stabilization is not limited to complex III, 
given that inhibition at any site in the ETC exhibits the same effect of preventing 
HIF-1 protein stabilization. This effect is due to a shorter HIF-1 half life, 
which is decreased by all inhibitors to similar degree. Moreover, all of the tested 
mitochondrial ETC inhibitors produced different amount of ROS in the form of 
superoxide. Hence, there is no correlation between the effects of the various 
inhibitors on superoxide production and hypoxia-dependent HIF-1 protein 
stabilization, suggesting that superoxide may not play an important role in HIF-
1 protein stabilization.   
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     Most pharmacological and genetic intervention approaches that modify the 
mitochondrial ETC will affect both mitochondrial ROS production and oxygen 
consumption. To conclusively distinguish between the two hypotheses, we used 
approaches that differentially regulate mitochondrial oxygen consumption and 
ROS production. We demonstrate that when complex III is inhibited, 
reestablishing oxygen consumption using an artificial electron donor that provides 
electrons to complex IV or by bypassing electron transport via complex III with 
AOX is sufficient to restore hypoxia-dependent HIF-1 stabilization. Thus, 
mitochondrial ROS derived from complex III are not necessary for the regulation 
of HIF-1 protein stability. Furthermore, we did not detect  any effect on HIF-1 
protein accumulation during hypoxia when the ROS level was manipulated by 
exogenous glucose oxidase/glucose system, which produces steady amounts of 
H2O2, or by overexpressing catalase, which scavenges H2O2.  Taken together,  
these results indicate that mitochondrial or exogenous ROS are not involved in the 
stabilization of  the HIF-1 protein during hypoxia. 
     According to the ROS hypothesis, increased H2O2 released from mitochondrial 
complex III stabilizes HIF-1 during hypoxia by inhibiting PHDs [Gerald et al., 
2004]. However, we show that H2O2 does not directly affect PHD activity and this 
finding is in agreement with another study that reported that PHD enzymes have 
low sensitivity towards inhibition by H2O2 [Masson et al., 2012].  
We also observed that superoxide inhibits PHD activity partially. However, 
superoxide released from complex III is normally rapidly dismutated into H2O2 by 
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SOD2 in the mitochondrial matrix and SOD1 in the intermembrane space. 
Therefore most of the signaling function of superoxide is usually mediated by 
H2O2 [Okado-Matsumoto  and Fridovich 2001; Sturtz et al., 2001; Guzy et al., 
2005;  Mansfield et al., 2005]. Furthermore, the HIF-1 protein level was 
unaffected when the intracellular concentrations of superoxide were manipulated 
by an SOD inhibitor or an SOD mimetic. We conclude that both H2O2 and 








4.  Regulation of HIF-1 protein stability by Compound C  
4.1 Introduction and Aim of study 
     Compound C or 6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-
pyrrazolo[1,5-a]-pyrimidine, a well known inhibitor of adenosine 
monophosphate-activated protein kinase (AMPK), was identified during a high-
throughput screening for potential small-molecule candidates that inhibit AMPK 
activity [Zhou et al., 2001].  Compound C inhibits AMPK activity reversibly by 
competing with the kinase for ATP.  AMPK is known as a metabolic sensor. It is 
activated by a decrease in the cellular ATP concentration and an increase in the 
AMP concentration. AMPK functions to promote ATP synthesizing processes and 
suppress ATP consuming processes, thus maintaining cellular homeostasis 
[Laderoute et al., 2006; Hardie et al., 2012]. AMPK has been suggested to be 
involved in the regulation of HIF-1 based on the finding that Compound C 
inhibits the transcriptional activity of HIF-1 [Lee et al., 2003; Hwang et al., 2004]. 
Compound C has also been reported to inhibit HIF-1 activity during hypoxia 
independently of AMPK. This finding is supported by a genetic approach 
whereby Compound C still inhibits HIF-1 activity in hypoxia exposed mouse 
embryonic fibroblasts when the catalytic  subunit in the heterotrimeric AMPK 
complex is knocked out (Ampk1-/-2-/-) [Emerling et al., 2007]. This same group 
further showed that Compound C prevents HIF-1 protein stabilization by 
interacting with the mitochondrial ETC and suppressing mitochondrial ROS 
production [Emerling et al., 2007]. This finding is in agreement with the ROS 
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hypothesis whereby HIF-1 protein is stabilized through an increase in ROS 
generated from mitochondrial complex III during hypoxia [Brunelle et al., 2005; 
Guzy et al., 2005]. However, we have shown in chapter 3 that hypoxic-dependent 
stabilization of HIF-1 protein is independent of mitochondrial ROS [Chua et al., 
2010]. To resolve this discrepancy, we studied the mechanism through which 





















4.2.1 Compound C inhibits stabilization of HIF-1 protein during hypoxia by 
inhibiting Complex I 
4.2.1.1 Compound C inhibits stabilization of HIF-1 protein during hypoxia  
     To study the effect of Compound C on hypoxia-induced HIF-1 protein 
stabilization, 143B cells were treated with various concentrations of Compound C 
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(20µM, 40µM and 80µM) for 4 hours at either 21% or 1% O2.  At 1% O2, HIF-1 
protein was stabilized in the untreated cells. Incubation with increasing 
concentrations of Compound C at 1% O2 led to a dose-dependent decrease in 
HIF-1 protein accumulation (Figure 24). Our finding of Compound C induced 
inhibition of HIF-1 protein stabilization during hypoxia agrees with the previous 
study by Emerling et al. [2007]. 
 
Figure 24.  Compound C inhibits hypoxia-dependent HIF-1 stabilization.  
143B cells were incubated at 1% O2 for 4 hours in the presence of Compound C 
(20M, 40M and 80M). Whole cell lysates were separated by 10% SDS gel 
and probed for HIF-1. 
 
 
4.2.1.2 Compound C interacts with mitochondrial complex I  
     To better understand whether Compound C affect hypoxic-stabilization of 
HIF-1 protein via the ROS hypothesis or oxygen availability hypothesis, we 
studied the effect of Compound C on the mitochondrial ETC. To determine the 
effect of Compound C on the different mitochondrial complexes, we first 
measured the oxygen consumption polarographically in mouse liver mitochondria 
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treated with Compound C in the presence of different respiratory substrates. 
80µM Compound C was chosen as it is the concentration that most effectively 
inhibits HIF-1 protein stabilization (Figure 24).  In the presence of NADH, the 
respiratory substrate for complex I, Compound C inhibited mitochondrial 
respiration by 74.5%. Oxygen consumption resumed when succinate, a complex 
II respiratory substrate was added (Figure 25A).  These results suggest that 
Compound C inhibits complex I and not downstream mitochondrial respiratory 
complexes.  To further examine whether Compound C interact with complex II, 
III or IV, mitochondria respiring on succinate were treated with Compound C. 
Compound C did not affect succinate-dependent respiration. Thus, this confirms 
that Compound C does not interact with complex II, III or IV (Figure 25B). To 
directly investigate whether Compound C inhibits complex IV, TMPD/ascorbate, 
which supply electrons to complex IV via cytochrome c, were added. 
Mitochondria respiring on TMPD/ascorbate remained unaffected by the addition 
of Compound C (Figure 25C). Taken together, Compound C hinders 








Figure 25.  Compound C acts as an inhibitor of mitochondrial complex I.  
Mouse liver mitochondria were isolated by differential centrifugation in 
mitochondrial isolation buffer and subjected to one freeze thaw cycle before 
measurement.  Oxygen consumption of mouse liver mitochondria was measured 
with 2.5mM NADH, 5mM succinate or 0.2mM TMPD/1mM ascorbate as 
respiratory substrates and 80M Compound C,  as indicated in mitochondrial 
isolation buffer using a Clark-type oxygen electrode at 37
o
C. The results shown 




4.2.2 Compound C has no significant effect on ROS production from 
Complex I via both forward and reverse flux 
     Mitochondrial complex I (NADH: ubiquinone oxidoreductase) is one of the 
two major contributors to mitochondrial ROS production [Boveris and Chance, 
1973]. ROS from this complex originate from both forward (FET) and reverse 
electron transfer (RET), whereby the latter produces ROS in the form of 
superoxide at a higher rate [Stowe and Camara, 2009; Lambert and Brand, 2004a]. 
The flavin mononucleotide (FMN) and several iron-sulfur (Fe-S) clusters act as 
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electron carriers in complex I.  FET occurs when mitochondria are energized with 
electrons that originate from NADH (Figure 26).  During FET, electrons from 
NADH are first transferred to FMN and then move in a step-wise manner to the 
downstream carriers, which involves a series of Fe-S clusters and a bound 
ubiquinone located at the ubiquinone binding site of complex I [Grivennikova and 
Vinogradov, 2006]. Electrons are then finally transferred to downstream 
complexes via the mobile ubiquinone (CoQ) [Berg et al., 2002; Lambert and 
Brand, 2004a; Carroll et al., 2013] (Figure 26).  It has been proposed in different 
studies that complex I-derived superoxide during FET is released from either the 
FMN or the Fe-S cluster/quinone binding-site [Lenaz and Genova, 2010].  On the 
other hand, RET happens when mitochondria respire on high concentrations of 
succinate (Figure 26). Succinate acts as the respiratory substrate for complex II 
(Succinate dehydrogenase). Succinate is oxidized by FAD, a prosthetic group of 
complex II, to form fumarate.  Electrons derived from succinate oxidation are 
passed on to the mobile CoQ via the Fe-S clusters of complex II. However under 
conditions of high succinate concentrations in the absence of NADH-linked 
substrate, the electron derived from succinate oxidation are simultaneously 
transferred to complex I [Lambert and Brand, 2004b; Murphy, 2009]. These 
electrons thus move in the reverse direction, from the reduced bound ubiquinone 




The reverse electron movement continues until the pool of 
NAD
+
 is fully converted to NADH.  Significant amounts of superoxide produced 
during RET have been suggested to be released from either FMN or Fe-S clusters/ 
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reduced ubiquinone of complex I [Lambert and Brand, 2004a; Grivennikova and 
Vinogradov, 2006; Lenaz et al., 2006] . 
 
Figure 26.  Schematic diagram of Forward (FET) and Reverse Electron 
Transfer (RET) in mitochondrial complex I. During FET, electron supply is 
derived from NADH-linked substrates (glutamate and malate). Electrons are 
transferred to FMN and Fe-S clusters within complex I and then to bound 
ubiquinone (CoQ). Electrons are then finally transferred to downstream 
complexes via the mobile CoQ.  During RET, electrons from succinate are 
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transported to the mobile CoQ. The electrons are then transferred from CoQ to 
complex I. The electrons thus move in the reverse direction from reduced bound 
CoQ of complex I to NAD
+
. The reverse electron movement continues until the 
pool of NAD
+
 is fully converted to NADH.  Superoxide produced during FET or 
RET has been suggested to be released from either FMN or Fe-S clusters/ reduced 
ubiquinone of complex I. 
 
 
     To determine whether Compound C induces ROS production in the form of 
H2O2 generated by the endogenous superoxide dismutase from either forward or 
reverse electron flux, the rate of H2O2 production was measured using the HRP-
HVA assay. As a control for the assay, ROS production from both FET and RET 
was measured with the well established complex I inhibitor rotenone. In 
agreement with other studies, rotenone resulted in a moderate increase in the 
H2O2 from FET of complex I when mitochondria were energized with NADH-
linked substrates (glutamate and malate) (Figure 27A) [Herrero and Barja, 2000; 
Fato et al., 2009].  On the other hand, H2O2 production via RET was inhibited by 
rotenone when mitochondria were supplied with succinate (Figure 27B). Addition 
of Compound C did not increase ROS from either of the electron fluxes.  
Incubation with Compound C had no effect on H2O2 production via FET (Figure 
27C) and it also caused a slight decrease in H2O2 production (Figure 27D) via 
RET. 
     To further explore the effect of Compound C on ROS production in 
mammalian cells, cellular H2O2 and superoxide production were measured via 
flow cytometry and specific ROS sensitive dyes (DCFHA and DHE). No 
significant difference in both superoxide and H2O2 concentration was observed in 
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cells treated with Compound C at both low (20µM) and high (100µM) 
concentrations compared with untreated cells (data not shown). Thus, our results 
suggest that Compound C is a complex I inhibitor but has no effect on ROS 
production by complex I.  Taken together, our results indicate that Compound C 
does not mediate inhibition of hypoxia-dependent HIF-1 stabilization via 
mitochondrial ROS generated by complex I or III, as suggested by Emerling et al. 
It is likely that Compound C regulates stabilization of HIF-1 protein by altering 














Figure 27.  Compound C does not increase hydrogen peroxide production 
from both forward and reverse electron flux of complex I. 0.1mg/ml of 
isolated mouse liver mitochondria (Mito) were incubated in reaction buffer with 
either 5mM glutamate/5mM malate or 10mM succinate as respiratory substrates 
or inhibitors (5M rotenone and 20M Compound C) at 37oC. Hydrogen 
peroxide production was assessed using homovanillic acid/ horseradish 
peroxidase, as described under Materials and Methods. Mitochondria, substrates 
and inhibitors were sequentially added as shown in the figure. The results shown 
are representative of 2 independent experiments.  
 
4.3 Discussion  
    Compound C is an inhibitor of AMPK. The Ki value for Compound C 
dependent AMPK inhibition is 109nM [Zhou et al., 2001]. In contrast, we 
observed that Compound C inhibits hypoxia-dependent HIF-1 protein 
stabilization only at concentrations of 20µM or higher, this suggests that 
destabilization of HIF-1 by Compound C is independent of its effect on AMPK 
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activity. This observation is consistent with the study carried out by Emerling et al. 
[2007].  
     Compound C was demonstrated to destabilize HIF-1 by interacting with the 
mitochondrial ETC. Emerling et al. [2007] proposed that Compound C inhibits 
HIF-1 via a ROS-dependent mechanism whereby HIF-1 protein is stabilized 
through an increase in ROS generated from mitochondrial complex III [Brunelle 
et al., 2005; Guzy et al., 2005]. However, this proposed mechanism for the action 
of Compound C is contrary to our findings presented in the previous chapter, 
where we showed that the mitochondrial ETC regulates the stabilization of HIF-
1 protein independently of mitochondria-derived ROS.  
     In this study, we therefore focused on determining the mechanism through 
which Compound C interacts with the mitochondrial ETC and through which the 
inhibitor regulates the stability of HIF-1 protein. Firstly, we showed that 
Compound C inhibits both hypoxia-dependent HIF-1 stabilization and oxygen 
consumption in isolated mitochondria, which is consistent with the study by 
Emerling et al. [2007] We observed that treatment with 20µM of  Compound C . 
Next, by using specific respiratory substrates and mitochondrial inhibitors, we 
showed that Compound C interacts with mitochondrial complex I to inhibit the 
mitochondrial respiration and not with complex III as suggested by Emerling et al.  
     Mitochondrial complex I and complex III are the two major sources of ROS 
production and ROS generated from complex I originates from both forward and 
reverse electron transfer [Boveris and Chance, 1973; Stowe and Camara, 2009; 
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Lambert and Brand, 2004a]. In contrast to the findings of Emerling et al. [2007] 
that Compound C suppresses mitochondrial ROS production, we found that 
Compound C has no significant effect on ROS production from complex I via 
both forward and reverse electron flux.  
     The reasons for the different results when measuring the effect of Compound 
C on ROS levels is currently clear. One potential reason could be the use of 
different cell lines (mouse embryonic fibroblasts in the study by Emerling et al. 
[2007] and 143B cells in our study). Furthermore, to determine the effect of 
Compound C on ROS production, different methods were used. Emerling et al. 
[2007] measured cellular H2O2 production using the 2′,7′-
dichlorodihydrofluorescein diacetate (DCFH-DA) dye that becomes fluorescent 
upon oxidation by ROS. In contrast, we used enzyme-based assays with isolated 
mitochondria, which are likely to be more sensitive and specific. Of note, 
Emerling et al. [2007] only measured the effect of Compound C on whole cell 
oxygen consumption, but did not study where in the electron transport chain the 
inhibitor acts. 
     Collectively, our findings suggest that Compound C, like other mitochondrial 
ETC inhibitors, regulate HIF-1 protein stability by controlling the amount of 
cytoplasmic oxygen available for the reactivation of prolyl hydroxylases in 
hypoxia. 
     Our study also suggests that Compound C may have off-target effects, as it not 
only suppresses AMPK activity, but also inhibits mitochondrial complex I. 
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Therefore, it is possible that similar to the Compound C induced destabilization of 
HIF-1 protein during hypoxia, other reported effects of Compound C may be 




 5.  Regulation of cellular glucose metabolism by -arrestin proteins 
 
5.1 Introduction  
     Txnip has recently been identified to regulate glucose metabolism in humans 
[Parikh et al., 2007; Patwari et al., 2009].  The first indication that Txnip is 
involved in mammalian metabolism was the demonstration that the phenotype of 
the naturally occurring mouse strain HcB-19 is due to a mutation in the Txnip 
gene. The HcB-19 mouse is characterized by hypertriglyceridemia and 
hypercholesterolemia. In addition to the marked increase in triglyceride and 
cholesterol blood levels, these mice also have significantly reduced blood glucose 
concentrations and an increase in serum ketone bodies during fasting [Bodnar et 
al., 2002]. Another mouse model, Txnip null mice generated by targeted deletion, 
displays analogous metabolic phenotypes, thus confirming the importance of 
Txnip in both glucose and lipid metabolism [Chutkow et al., 2008].  There are 
several lines of evidence to suggest that Txnip plays a role in glucose metabolism. 
During gene expression profiling of glucose-dependent effects in isolated human 
pancreatic islets, Txnip gene expression was found to be highly regulated by 
glucose. [Shalev et al., 2002].  In addition, Txnip knockout mice have increased 
glucose uptake in the absence of insulin [Andres et al., 2011] while 
overexpression of the gene in cell culture studies has the opposite effect  [Patwari 
et al., 2009].  
     Mechanistically, Txnip is known to inhibit the function of the antioxidant 
protein TRX. However, Patwari and colleagues have shown that Txnip can inhibit 
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glucose uptake independently of its interaction with TRX.  Txnip with a mutated 
Cysteine 247 residue (Txnip C247S) that cannot bind TRX was still able to inhibit 
2-deoxyglucose uptake as effectively as wild type Txnip.  The ability to regulate 
glucose metabolism is not limited to only Txnip as its paralogue Arrdc4, which 
does not bind to TRX, is also capable of inhibiting both glucose uptake and 
lactate production. Through structure-function studies, these metabolic functions 
were suggested to be intrinsic to the two -arrestin domains but not the C-
terminal tail of Txnip and Arrdc4 [Patwari et al., 2009].  However, the exact 
mechanism through which Txnip and Arrdc4 decrease both glucose uptake and 
lactate production is still unknown.  There are two possible mechanisms to 
explain how the - arrestin proteins cause a decrease in glucose metabolism: they 
can either promote mitochondrial function or suppress glycolysis.   
 5.2 Txnip and Arrdc4 may inhibit cellular glucose utilization as a 
consequence of promoting mitochondrial function   
     Deletion of Txnip in mice has been reported to lead to decreased mitochondrial 
function with lower oxygen consumption rates and this was accompanied by an 
increase in cellular glucose uptake, lactate output and glycolytic ATP production 
[Yoshioka et al., 2012]. This compensatory increase in anaerobic glycolysis in 
hearts of Txnip-knockout mice was the consequence of the impaired 
mitochondrial function and has been reported to provide protection from 
ischemia-reperfusion injury. Based on these findings, Txnip and Arrdc4 may 
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inhibit cellular glucose uptake as a consequence of promoting mitochondrial 
function that result in reduced lactate production (Figure 28).    
5.2.1 Txnip or Arrdc4 might interact with lactate dehydrogenase (LDH) or 
pyruvate dehydrogenase (PDH) to promote mitochondrial pyruvate 
utilization  
     There are two important regulators, lactate dehydrogenase (LDH) and pyruvate 
dehydrogenase (PDH), which control the mitochondrial entry and utilization of 
the end product of glycolysis pyruvate. Txnip and Arrdc4 may potentially interact 
with either of these two enzymes, leading to LDH inhibition or PDH activation 
and consequently increased mitochondrial pyruvate utilization and decreased 
cellular glucose utilization (Figure 28). 
5.2.1.1 Txnip or Arrdc4 inhibit LDH activity to promote mitochondrial 
function 
     LDH converts pyruvate into lactate during anaerobic glycolysis. LDH serves to 
regenerate NAD
+
 from the reduction of pyruvate. The NAD
+
 is then utilized by 
the upstream glycolytic enzyme Glyceraldehyde 3-phosphate dehydrogenase. 
LDH thus allows for continuous cycles of glycolysis. When oxygen is available, 
pyruvate enters mitochondria to fuel maximum ATP production via oxidative 
phosphorylation and the LDH activity is low, resulting in low amounts of lactate 
production.  We hypothesized that Txnip and Arrdc4 may function to inhibit LDH, 
resulting in reduced lactate production, as observed by Patwari et al. [2009] 
(Figure 28). Increased pyruvate utilization via oxidative phosphorylation would 
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result in high ATP production and a decreased cellular uptake of glucose 
compared to cells that primarily produce ATP via aerobic glycolysis. 
5.2.1.2 Txnip or Arrdc4 enhance PDH activity to promote mitochondrial 
function 
     PDH is another possible candidate that Txnip and Arrdc4 might interact with 
to decrease glucose metabolism. PDH is a mitochondrial enzyme and is part of the 
mitochondrial pyruvate dehydrogenase complex. PDH is the rate limiting enzyme 
of the pyruvate dehydrogenase complex that converts pyruvate into acetyl-coA to 
fuel the citric acid cycle. In the citric acid cycle, NADH is produced which in turn 
is used as a substrate for the mitochondrial electron transport chain to generate 
ATP via mitochondrial oxidative phosphorylation. An increase in PDH dependent 
pyruvate utilization in mitochondria leads to secondary decrease in the glycolytic 
rate. The activity of PDH is tightly controlled by regulatory enzymes such as 
pyruvate dehydrogenase kinase (PDK) and pyruvate dehydrogenase phosphatase 
(PDP). PDH is inactive when it is phosphorylated by PDK and active when it is 
dephosphorylated by PDP [Patel and Korotchkina, 2001; Roche and  Hiromasa, 
2007]. Andres & colleagues have reported that in the absence of TXNIP, the  
level of  phosphorylated  PDH is increased markedly in isolated  soleus muscle of 
Txnip knockout fasted mice, indicating that PDH activity is inhibited by PDK. 
[Andres et al., 2011]. We hypothesized therefore that Txnip or Arrdc4 may bind 
to PDK to inhibit phosphorylation of PDH. As a result, PDH will remain active to 
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promote mitochondrial function, thus leading to lower glucose utilization (Figure 
28). 
 
5.3 Txnip or Arrdc4 may inhibit cellular glucose utilization by inhibiting 
glycolysis 
5.3.1 Txnip or Arrdc4 may interact with the glycolytic cascade to inhibit 
glycolysis directly  
     A further mechanism through which Txnip and Arrdc4 might regulate cellular 
glucose metabolism is by interacting with one of the glycolytic enzymes to 
regulate glucose metabolism. Glycolysis is tightly regulated at several important 
steps through various enzymes including hexokinase, phosphofructokinase1 
(PFK1) and pyruvate kinase. PFK1 catalyzes an important step in glycolysis in 
which fructose 6-phosphate is converted to fructose-1,6-bisphosphate. PFK1 itself 
is allosterically activated by fructose 2,6-bisphosphate (F2,6P2). We hypothesized 
that Txnip and Arrdc4 may function to lower the cellular F2,6P2 levels and render 
PFK1 less active to promote downstream glycolytic steps (Figure 28). 
5.3.2 Txnip or Arrdc4  interact with glucose transporters (GLUTs) to inhibit 
glycolysis directly  
     An alternative mechanism through which Txnip and Arrdc4 may decrease 
cellular glucose metabolism is by inhibiting cellular glucose uptake via glucose 
transporters. Glucose transporters are membrane proteins that facilitate glucose 
transport. Among the 13 members of the facilitative glucose transporters, glucose 
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transporter 1 (GLUT1) shows high affinity for glucose and is responsible for basal 
glucose uptake at the plasma membrane [Zhao and Keating, 2007]. In yeast, a 
high affinity glucose transporter located at the plasma membrane, Hexose 
transporter 6 (Hxt6), has been shown to be inactivated when it is internalized by 
Art4, an arrestin-related protein in yeast [Nikko and Pelham, 2009]. Given that 
GLUT1 is ubiquitously expressed in normal tissues and cell lines and its 
upregulation is observed in many cancer tissues and cells, we hypothesized that 
the -arrestin proteins Txnip and Arrdc4 are likely to interact with GLUT1 to 











Figure 28. Proposed mechanisms through which Txnip and Arrdc4 decrease 
glucose metabolism in mammalian cells. (A) According to the first mechanism, 
it is hypothesized that Txnip and Arrdc4 inhibit cellular glucose metabolism as a 
consequence of promoting mitochondrial function. The -arrestin proteins may 
interact with either lactate dehydrogenase (LDH) or pyruvate dehydrogenase 
(PDH) or its regulatory enzymes PDH kinase (PDK) and PDH phosphatase (PDP) 
to increase mitochondrial pyruvate utilization and decrease cellular glucose 
utilization. (B) The second mechanism proposes that Txnip and Arrdc4 decrease 
glucose metabolism independently of mitochondria by interacting with glucose 
transporter (GLUT) or the enzymes in the glycolytic cascade, such as hexokinase 






5.4 Aims of the study  
     Txnip, being a critical negative regulator of cellular glucose utilization is 
capable of regulating the Warburg effect. This effect may be of significance in 
cancer, where Txnip is frequently downregulated, thus potentially contributing to 
increased rates of aerobic glycolysis in tumor cells. Arrdc4, the paralogue of 
Txnip also inhibits cellular glucose utilization. Understanding the involvement of 
Txnip and Arrdc4 in glucose metabolism might provide more insights into 
mechanisms underlying tumorigenesis. In addition, knocking out Txnip in animal 
studies has proved to be effective in alleviating the hallmarks of diabetes namely 
hyperglycemia and glucose intolerance, making Txnip an attractive therapeutic 
target to delay the onset or progression to diabetes [Yoshihara et al., 2010]. 
Therefore, the aim of the study was to characterize the mechanism through which 
Txnip and Arrdc4 inhibit cellular glucose uptake. To this end, the following 
specific questions were addressed: 
1) To determine whether Txnip- and Arrdc4-mediated inhibition of cellular 
glucose uptake and lactate production is dependent on mitochondria 
2)  To determine whether Txnip and Arrdc4 have any effect on regulators that 
control pyruvate entry into mitochondria to promote oxidative phosphorylation 
and decrease glucose metabolism  
3)   To determine whether Txnip and Arrdc4 inhibit cellular glucose metabolism 
independently of mitochondria by interacting with the glycolytic cascade 
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4)   To determine whether Txnip and Arrdc4 decrease glucose metabolism 




















5.5.1 Txnip and Arrdc4 decrease glucose metabolism independently of 
mitochondria  
     Txnip and Arrc4 have been reported to inhibit glucose uptake and lactate 
output [Patwari et al., 2009]. To validate this, we transfected HEK293T cells with 
empty vector, Txnip Flag and Flag-Arrdc4 and measured both glucose and lactate 
concentration in their media.  After two days of transfection, striking differences 
in the media color were observed. The media of Txnip and Arrdc4 overexpressing 
cells were pink while the media of empty vector transfected cells was orange 
(Figure 30A left panel). The color change of media from red to orange in empty 
vector transfected cells indicates the acidification of the media due to lactate 
accumulation while pink media in cells expressing the -arrestin proteins 
indicates that there was less lactate accumulation.  Glucose utilization and lactate 
production was then measured in the transfected cells. As previously reported 
[Patwari et al., 2009], we observed that overexpression of either Txnip or Arrdc4 
lowered both cellular glucose utilization and lactate production. This result is 
supported by the difference in media color (Figure 30B left panels). 
Txnip has been reported to promote mitochondrial function [Yoshioka et al., 
2012]. To determine whether promotion of mitochondrial function is responsible 
for the reduced glucose utilization in the -arrestin overexpressing cells, the 
transfected cells were treated with myxothiazol. Under these conditions, 
mitochondrial oxidative phosphorylation is blocked and cellular glucose 
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utilization is solely via glycolysis, resulting in the accumulation of the end-
product lactate (Figure 29). In the presence of myxothiazol, glucose utilization 
and lactate production increased in empty vector transfected cells. This represents 
a compensatory mechanism to increase glycolytic ATP production under 
conditions of inhibited oxidative phosphorylation in order to maintain cellular 
ATP concentrations. If the inhibitory effect of Txnip and Arrdc4 on cellular 
glucose metabolism is due to promotion of mitochondrial function, the -arrestin 
proteins would be without effect in the presence of the mitochondrial inhibitor 
myxothiazol. However, it was observed that overexpression of the -arrestins 
proteins led to less media acidification even in the presence of myxothiazol 
(Figure 30A right panel). Furthermore, Txnip and Arrdc4 led to a similar decrease 
in glucose utilization and lactate production in both the presence and the absence 
of myxothiazol (Figure 30B right panels). These results indicate that Txnip and 
Arrdc4 inhibit cellular glucose utilization independently of effects on 









Figure 29. Schematic diagram illustrating glucose metabolism in mammalian 
cells via glycolysis and oxidative phosphorylation (OXPHOS) when 
mitochondrion is inhibited. Introduction of the mitochondrial complex III 
inhibitor myxothiazol prevents ATP production by OXPHOS, leading to 











Figure 30. Txnip and Arrdc4 inhibit glucose utilization and lactate 
production independent of mitochondria. HEK293T cells were transfected as 
indicated and treated with or without myxothiazol (1µM) for 6 hours. (A) 
Transfection of HEK293T  cells for  two days causes acidification of the medium 
in empty vector transfected cells but not  or markedly less in cells transfected with 
mTxnip and Arrdc4. (B) Cellular glucose utilization and lactate production rates 
were determined and expressed as percent glucose utilization or lactate production 
compared to empty vector control cells. The results shown represent the average 
of three independent experiments (mean ± S.E.M.). Statistical significance is 




5.5.2 Txnip and Arrdc4 inhibit glycolytic ATP production  
     During treatment with myxothiazol, cell death was observed in Txnip and 
Arrdc4 overexpressing cells but not in empty vector transfected cells. However in 
the absence of the mitochondrial inhibitor, overexpression of Txnip and Arrdc4 
had no effect on cell viability (Figure 31A). We hypothesized that inhibition of 
glycolytic ATP production by Txnip and Arrdc4 results in a drop in cellular ATP 
levels under the conditions of inhibited oxidative phosphorylation, consequently 
leading to the observed cell death. To determine whether Txnip and Arrdc4 
regulate glycolytic ATP production, cellular ATP concentrations were measured 
in both the presence and the absence of myxothiazol. We found that Txnip or 
Arrdc4 overexpression by itself had no effect on ATP levels compared to empty 
vector transfected cells (Figure 31B). When oxidative phosphorylation was 
inhibited with myxothiazol, empty vector transfected cells were able to largely 
maintain their ATP levels, presumably as a consequence of upregulated glycolytic 
ATP production. In contrast, cells overexpressing Txnip or Arrdc4 displayed a 
marked reduction in the cellular ATP production. The decrease in the ATP level 
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was more significant in Arrdc4 overexpressing cells, correlating with increased 








Figure 31. Effect of myxothiazol on cell viability and ATP levels of Txnip and 
Arrdc4 overexpressing cells.  HEK293T cells were transfected as indicated and 
treated with myxothiazol (1µM) for 6 hours. (A) The effect of myxothiazol on 
viability of cells is illustrated by phase contrast images taken at 20x magnification. 
(B) Relative ATP levels were measured from perchloric acid extracts of the 
transfected HEK293T cells as described in Materials and methods. The results 
shown represent the average of three independent experiments (mean ± S.E.). In 
the presence of myxothiazol, overexpression of either mTxnip and Arrdc4 
induced both cell death and a decline in relative ATP level with a statistically 
significant decrease (* p < 0.05) in relative ATP level for Arrdc4 overexpressing 
cells.  
 
     A decrease in cellular ATP concentrations can be due to inhibition of new ATP 
synthesis or faster ATP turnover. To rule out that the lower ATP concentrations in 
Txnip and Arrdc4 overexpressing cells is due to an increase in ATP turnover, 
cellular ATP utilization rates were measured. To this end, we co-treated Arrdc4 
overexpressing or empty vector transfected cells with the glyceraldehyde 3-
phosphate dehydrogenase inhibitor iodoacetate and the complex III inhibitor 
myxothiazol to rapidly block new ATP synthesis from both glycolysis and 
oxidative phosphorylation (See Figure 29).  As shown in Figure 32, the ATP 
levels in both empty vector transfected and Arrdc4 overexpressing cells declined 
rapidly at the same rate.  This indicates that the lower ATP level in Arrdc4 
overexpressing cells is not due to faster ATP turnover but a consequence of 






Figure 32. Txnip and Arrdc4 induce cell death by inhibiting glycolytic ATP 
synthesis. Empty vector or Arrdc4 overexpressing HEK293T cells were cotreated 
with iodoacetate (2.5mM) and myxothiazol (1µM) to rapidly block new ATP 
synthesis. Relative ATP levels were then measured at different time points to 
determine the relative ATP turnover. The results shown represent the average of 
three independent experiments (mean ± S.E.).  There was no significant difference 
in the relative ATP turnover of empty vector and Arrdc4 overexpressing cells.  
 
 
5.5.3 Txnip and Arrdc4 do not regulate lactate dehydrogenase (LDH) and 
pyruvate dehydrogenase (PDH) activity   
     Our results described above show that Txnip and Arrdc4 inhibit cellular 
glucose utilization directly, however, the underlying mechanism is not clear. We 
hypothesized that Txnip and Arrdc4 interact with regulatory proteins that control 
pyruvate entry into mitochondria to promote oxidative phosphorylation. We 
initially postulated that the -arrestin proteins inhibit the activity of LDH. This 





availability) and at the same time promote mitochondrial fuel oxidation. However, 
we observed that overexpression of Txnip and Arrdc4 had no effect on LDH 
enzyme activity in cell lysate (Figure 33). 
 
Figure 33. Txnip and Arrdc4 have no effect on the activity of lactate 
dehydrogenase (LDH). LDH activity was measured using lysates of cells 
transfected with empty vector and Flag-Arrdc4 overexpressing HEK293T  
 
 
We next determined whether the -arrestin proteins regulate the activity of the 
PDH enzyme. Txnip has recently been reported to regulate PDH activity by 
altering its inhibitory phosphorylation mediated by PDK [Andres et al., 2011]. 
However, we found that in HEK293T cells overexpression of Txnip or Arrdc4 did 
not affect PDH phosphorylation levels (Figure 34A). The PDH complex and the 
PDK enzymes locate to the mitochondrial matrix whereas Txnip and Arrdc4 are 
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cytoplasmic or associated with intracellular membranes. We therefore 
hypothesized that Txnip and Arrdc4 activates PDH indirectly by preventing 
translocation of PDK1 into the mitochondrial matrix. As shown in Figure 34B, 
transfected Arrdc4 localized to the cytoplasm with the strongest staining near the 
plasma membrane. PDK1 showed speckled cytoplasmic staining typical of 
mitochondria. Overexpression of Arrdc4 had no effect on the localization of 
PDK1 (Figure 34B). Taken together, these results suggest further that Txnip and 
Arrdc4 do not promote mitochondrial function by regulating mitochondrial 















Figure 34. Txnip and Arrdc4 have no effect on the activity of Pyruvate 
dehydrogenase (PDH). Transfection of cells with Txnip or Arrdc4 in the absence 
or presence of myxothiazol had no effect on (A) PDK dependent PDH 






5.5.4 Txnip and Arrdc4 lower cellular Fructose-2,6-bisphosphate levels 
independently of  PFKFB3 phosphorylation  
     Having shown that Txnip and Arrdc4 inhibit cellular glucose utilization 
independently of mitochondria, we next took a hypothesis-based approach to 
identify a potential site of action in the glycolytic cascade. F2,6P2 is an important 
regulator of glycolysis. It is the most important allosteric activator of PFK1 and is 
involved in the regulation of glycolytic flux under various physiological 
conditions. To determine the effect of Txnip and Arrdc4 on cellular F2,6P2, 
concentrations, we adapted an assay as described by Van Schaftingen et al [1982].  
Interestingly, transfection of both Txnip and Arrdc4 led to decrease in the cellular 
F2,6P2 concentration (Figure 35A) . The effect of Arrdc4 was more pronounced 
compared to that of Txnip.  This may be due to the higher expression levels of 










Figure 35. Txnip and Arrdc4 lower cellular Fructose-2,6 bisphosphate levels. 
(A)  The relative rate of Fructose-2,6 bisphosphate (F2,6P2) formation were 
measured using alkaline extracts of empty Vector, Txnip-Flag and Arrdc4-Flag 
overexpressing cells, as described under Materials and Methods. The results 
shown represent the average of three independent experiments (mean ± S.E.). (B) 
Overexpression of Txnip or Arrdc4 was confirmed by western blotting. 
 
     In subsequent experiments, we studied the mechanisms through which the -
arrestin proteins lower the F2,6P2 level. F2,6P2 is produced by 
Phosphofructokinase 2 (PFK2), a bifunctional enzyme consisting of a 6-
phosphofructo-2-kinase domain and a fructose-2,6-bisphosphatase domain that 
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function independently [Rider et al., 2004]. The 6-phosphofructo-2-kinase domain 
synthesizes F2,6P2 from F6P and ATP while the fructose-2,6-bisphosphatase 
domain catalyzes the breakdown of F2,6P2 back to fructose-6-phosphate.   Among 
all the four isoforms of PFK2 (PFKFB1-4), PFKFB3 is widely distributed and has 
the highest kinase to phosphatase activity ratio. Therefore, PFKFB3 is believed to 
be the major isoform responsible for F2,6P2 synthesis in most cells. We 
hypothesized that Txnip and Arrdc4 lower the level of F2,6P2 by interacting with 
PFKFB3. However, we were unable to detect any specific interaction of Txnip 
and Arrdc4 with PFKFB3 by coimmunoprecipitation (Figure 36).  
 
 
Figure 36. Txnip and Arrdc4 do not interact with Phosphofructokinase 2 
isoform 3 (PFKFB3). The interaction of Txnip-Flag and Flag-Arrdc4 with 
transfected PFKFB3-V5 was measured by Flag-immunoprecipitation (IP). 
PFKFB3 bound weakly to Txnip and Arrdc4. However, the detected PFKFB3 
signal largely represents non-specific binding as similar amounts of PFKFB3 




It was noted in this experiment that overexpression of PFKFB3 resulted in a 
dramatic increase in cellular F2,6P2 levels. This was accompanied by increased 
media acidification, indicative of increased glycolytic rate and lactate production 
(Figure 37Ai and 37Bi). Coexpression of Arrdc4 lowered both F2,6P2 levels  and 
media acidification, but the effect of Arrdc4 was not due to a lower PFKFB3 
expression level (Figure 37Aiii and Figure 37Biii). This suggests that Arrdc4 
regulates the activity of the PFKFB3 enzyme. 
     PFKFB3 has been reported to be activated through phosphorylation at Ser461 
[Rider et al., 2004]. To determine whether the -arrestin proteins may regulate 
PFKFB3 by inducing Ser461 phosphorylation, we constructed non-
phosphorylatable (S461A) and phosphomimetic (S461E) PFKFB3 mutants. 
Surprisingly, the activity of both mutants was not significantly different from 
wild-type PFKFB3 (Figure 37Aii and Figure 37Bii). Furthermore, Arrdc4 
overexpression lowered F2,6P2, to a similar degree with wild-type and the two 
mutant PFKFB3 enzymes. Our results indicate that Ser461 may not play a major 
role in regulating PFKFB3 activity. Our data also suggest that -arrestin proteins 




















Figure 37. Txnip and Arrdc4 do not inhibit PFKFB3 activity. (A and B) 
Empty vector or Arrdc4 overexpressing HEK293T cells were cotransfected with 
either wild type,  non-phosphorylatable PFKFB3 mutant (S461A Flag-PFKFB3) 
or phosphomimetic PFKFB3 mutant (S461E Flag-PFKFB3). (i) Colour changes 
in the culture media in the above stated cells were observed. (ii) F2,6P2 formation 
in the transfected cells was measured as described under Materials and Methods. 
iii) Overexpression of Arrdc4, wildtype or PFKFB3 mutant was confirmed by 
western blotting.  
 
 
5.5.5 Inhibition of cell viability by -arrestin proteins in the presence of 
myxothiazol is not due to lower F2,6P2 concentrations 
     As described earlier, overexpression of Txnip and Arrdc4 in the presence of 
myxothiazol results in decreased glycolytic ATP production, leading to loss of 
cell viability. We next determined whether this effect is due to the lower F2,6P2 
concentrations upon overexpression of the -arrestin proteins. To this end, two 
different siRNA oligonucleotides were used to knock down PFKFB3. If Txnip 
137 
 
and Arrdc4 cause cell death by lowering F2,6P2 concentrations in the presence of 
myxothiazol, PFKFB3 knockdown would be expected to have a similar effect. As 
shown in Figure 38B, transfection with both PFKFB3 siRNAs resulted in a much 
reduced F2,6P2 concentration. This result confirms that PFKFB3 is the major 
isoform responsible for F2,6P2 synthesis in HEK293T cells.  Despite similar 
efficiency in reducing cellular F2,6P2 levels, only PFKFB3 siRNA#1 resulted in 
lower cell viability in the presence of myxothiazol (Figure 38A). Thus, there is no 
good correlation between lowering of F2,6P2 levels and increased cell death. The 
observed cytotoxic effect of PFKFB3 siRNA#1 may be due to an off-target 
mechanism of action. In addition, we also observed that overexpression of 
PFKFB3 did not rescue Arrdc4 overexpressing cells from myxothiazol mediated 
cell death, despite markedly increasing cellular F2,6P2 concentrations (Figure 39). 
Taken together, it can be concluded that the inhibition of glucose utilization by 







Figure 38. Lowering  Fructose-2,6 bisphosphate does not cause  cell  death. 
Effect of lowering F2,6P2 level on the viability of  HEK293T cells was carried out 
by transfecting HEK293T cells with negative control siRNA or two different 
siRNAs targeted to human PFKFB3  (PFKFB3 siRNA#1  or PFKFB3 siRNA#2. 
The transfected cells were treated with myxothiazol (1µM) for 6 hours before (A) 
evaluating cell viability based on light microscopy imaging and (B) measuring of  
F2,6P2 concentrations. Cell death was observed only in HEK293T cells 
transfected with PFKFB3 siRNA#1 even though F2,6P2 levels were markedly 








Figure 39. Increasing Fructose-2,6 bisphosphate does not rescue Arrdc4 
induced cell death. The effect of increasing the F2,6P2 concentration on the 
viability of  HEK293T cells was determined by cotransfecting empty vector or 
Arrdc4 with wild type PFKFB3 (WT PFKFB3-V5). Two days after transfection, 
the cells were treated with myxothiazol (1µM) for 6 hours. In the presence of 
myxothiazol, a similar degree of cell death was observed in both Arrdc4 




5.5.6 Overexpression of Txnip and Arrdc4 lowers cellular glucose-6-
phosphate concentrations 
     A possible explanation for the reduced F2,6P2 concentrations in Txnip and 
Arrdc4 overexpressing cells is that the -arrestin proteins inhibit the glycolytic 
cascade upstream of PFK2. To test this hypothesis, we measured cellular glucose-
6-phosphate (G6P) concentrations. Overexpression of Txnip or Arrdc4 was found 
to lower the G6P levels (Figure 40). This would be expected to result in a 
decrease in fructose-6-phosphate, the substrate for PFK2, hence providing an 
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explanation for the lower F2,6P2 levels. A reduction in the cellular G6P 
concentration may be due to inhibition of hexokinase activity. However, Txnip 
and Arrdc4 were found to have no significant effect on the cellular hexokinase 
activity (Figure 41). Therefore these results suggest that the effect of Txnip and 
Arrdc4 is likely to be upstream of hexokinase at the level of glucose uptake at the 




Figure 40. Txnip and Arrdc4 lower cellular glucose-6-phosphate. Glucose-6-
phosphate (G6P) levels were measured using alkaline extracts of empty vector, 



















Figure 41. Txnip and Arrdc4 do not inhibit hexokinase activity.  (A) 
Hexokinase activity was measured using the lysates of cells transfected with 
empty vector, Txnip-Flag and Flag-Arrdc4, as described under Materials and 
Methods. A control (fresh cell lysate of empty vector transfected cells and all 
components of assay cocktail except ATP) was included to determine the 







5.5.7 Txnip and Arrdc4 reduce the plasma membrane localization of the 
glucose transporter GLUT1 
     As shown earlier, Txnip and Arrdc4 inhibit glucose utilization but not the 
glycolytic cascade. We therefore hypothesized that the -arrestin proteins 
regulate the glucose transporters to suppress glycolysis. Given the important role 
of GLUT1 in mediating glucose uptake in most cell types, we determined whether 
Txnip or Arrdc4 affect cellular levels of this glucose transporter. As shown in 
Figure 42, overexpression of Txnip and Arrdc4 did not decrease the total GLUT1 
protein concentration. We then determined the effect of the -arrestin proteins on 
the membrane localization of GLUT1 using an EGFP-tagged version of the 
glucose transporter. In the empty vector transfected cells, GLUT1-EGFP was 
predominantly expressed at the cell membrane (Figure 43). Interestingly, both 
Txnip and Arrdc4 transfection led to a marked relocalization of GLUT1 from the 
cell membrane to the cytoplasm.  In Txnip and Arrdc4 overexpressing cells, a 
large portion of GLUT1 was found in cytoplasmic aggregates. This result 
suggests that the -arrestin proteins Txnip and Arrdc4 inhibit glucose uptake by 















Figure 42. Txnip and Arrdc4 do not decrease protein abundance of the total 
endogenous GLUT1. The effect of Txnip or Arrdc4 transfection on protein 
abundance of endogenous GLUT1 in whole cell lysate of HEK293T cells was 
analyzed by immunoblotting with GLUT1 anti-serum. Overexpression of Txnip 














Figure 43. Txnip and Arrdc4 altered localization of GLUT1 at the plasma 
membrane. Empty Vector, Txnip or Arrdc4 overexpressing HEK293T cells were 
cotransfected with GLUT-1-EGFP-HA. (A) Localization of GLUT1-EGFP-HA 
was determined by fluorescence microscopy. Arrows point to GLUT1 found in 
cytoplasmic aggregates.   (B) the percentage of cells with GLUT1 present at the 
plasma membrane or in the cytoplasm was quantified in a blinded manner. The 
percentage of cells with predominantly plasma membrane or cytoplasmic 
localization of GLUT1 is indicated. The results shown represent the average of 




5.5.8 Txnip and Arrdc4 do not promote internalization of cell surface 
GLUT1 via clathrin-mediated endocytosis 
     During the course of our studies, Wu et al. [2013] reported that Txnip 
promotes the internalization of cell surface GLUT1 via clathrin mediated 
endocytosis. Clathrin is a protein that plays a major role in intracellular trafficking. 
It is composed of one heavy chain and two light chains that form a triskelion. 
Many clathrin triskelia form the clathrin coat to surround a vesicle that contains 
cargo molecules, which are recruited by adapter protein 2 (AP2).  With the aid of 
dynamin, AP2 and other accessory proteins, the clathrin coated cargo containing 
vesicle is pinched off from the plasma membrane and transported intracellularly 
[McMahon and Boucrot, 2011]. Wu et al. reported that Txnip binds to GLUT1 
and promotes GLUT1 internalization via clathrin coated pits, leading to reduced 
glucose uptake [Wu et al., 2013]. In light of our finding that both Txnip and 
Arrdc4 inhibit plasma membrane localization of GLUT1, we wanted to confirm 
the findings reported by Wu et al. [2013].  We examined the interaction between 
Txnip or Arrdc4 and clathrin heavy chain (CHC) by immunoprecipitation after 
cell lysis using the Nonidet P-40 buffer (Figure 44A) or the milder octyl-beta-
Glucoside (β-OG) buffer, as described in Wu et al (Figure 44B). However, we 
failed to detect any binding between Txnip or Arrdc4 and CHC. 
We also tested for binding between Txnip or Arrdc4 and GLUT1. However, in 
contrast to what Wu et al have reported [Wu et al., 2013], we did not detect any 
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interaction between transfected Txnip and endogenous GLUT1 while weak 
binding of Txnip and Arrdc4 to transfected GLUT1 was observed (Figure 45). As 
a positive control for the co-immunoprecipitation experiment we showed Txnip 
binds specifically to its known interaction partner thioredoxin-1. Thus, our results 
suggests that the -arrestin proteins are unlikely to internalize GLUT1 from the 













Figure  44. Txnip and Arrdc4 do not interact with clathrin heavy chain. The 
interaction of mouse Txnip (mTxnip), human Txnip (hTxnip) and Arrdc4 with 
endogenous clathrin heavy chain (CHC) was measured by Flag-
immunoprecipitation using (A) Nonidet-P40 buffer or (B) octyl-beta-Glucoside 
(β-OG) buffer. No binding between the -arrestin proteins and CHC using both 








Figure  45. Txnip and Arrdc4 do not interact with endogenous or transfected 
GLUT1. The interaction of mouse Txnip (mTxnip) and Arrdc4 with both (A) 
endogenous and (B) transfected GLUT1 was measured by Flag-
immunoprecipitation. There was weak binding between Arrdc4 and both types of 
GLUT1 while Txnip only binds very weakly to transfected but not endogenous 
GLUT1. Binding of Txnip to thioredoxin served as a positive control.  
 
 
5.5.9 Txnip and Arrdc4 prevent anterograde trafficking of GLUT1 to the 
plasma membrane 
     Our results indicate that in the presence of the -arrestin proteins the majority 
of GLUT1 accumulates intracellularly and that Txnip and Arrdc4 do not appear to 
promote internalization of GLUT1. Thus, we hypothesized that the -arrestin 
proteins prevent anterograde trafficking of GLUT1 to the plasma membrane. To 
test this alternative hypothesis, it was necessary to determine the kinetics of 
GLUT1 translocation to the cell membrane. To do this, we employed an approach 
whereby EGFP-tagged GLUT1 was expressed under control of a tetracycline-
inducible promoter. It was then possible to track GLUT1-EGFP plasma 
membrane translocation upon induction over time using confocal time-lapse 
microscopy. During the course of optimization for this experiment, we found that 
the fastest induction of the glucose transporter expression was achieved by 
pretreating GLUT1-EGFP transfected Trex293 cells with both cycloheximide and 
tetracycline for several hours to induce GLUT1-EGFP mRNA synthesis without 
the mRNA being translated. GLUT1-EGFP protein synthesis was then initiated by 
cycloheximide washout (at time zero). A western blot that shows time-dependent 
induction of GLUT1-EGFP after 10 hour induction with tetracycline plus 
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cycloheximide followed by cycloheximide washout at time zero is shown in 
Figure 46. Time dependent induction of Ubc4 expression, which was also under 
control of a tetracycline inducible promoter, served as a positive control. 
Subsequently, confocal microscopy experiments were carried out in which 
GLUT1-EGFP mRNA expression was induced for only 2.5 hours to prevent 
cytotoxicity from the cycloheximide treatment. Using this approach, time 
dependent translocation of GLUT-EGFP from the cytoplasmic site of protein 
synthesis to the plasma membrane could be observed (Figure 47). To determine 
whether Txnip and Arrdc4 inhibit GLUT1-EGFP trafficking to the plasma 
membrane, the  arrestin proteins were overexpressed and the kinetics of 
GLUT1-EGFP translocation to the plasma membrane was measured as described 
above. In empty vector transfected cells, most of the GLUT1-EGFP had moved to 
the plasma membrane by 90 minutes. At the end of 165 minutes, the majority of 
these cells showed membrane staining (Figure 47A). Interestingly, both Txnip and 
Arrdc4 transfection prevented GLUT1-EGFP from being translocated to the 
plasma membrane.  In Txnip overexpressing cells, most of the cells did not 
exhibit membrane staining at 165 minutes (Figure 47B). In the area imaged in 
Figure 47B, only two cells showed membrane staining at 165 minutes. This may 
be due to low Txnip expression levels in these cells. The inhibition of GLUT1-
EGFP plasma membrane translocation was more pronounced in Arrdc4 
overexpressing cells as no EGFP plasma membrane signal could be observed 
even after 370 minutes (Figure 47C). Therefore, these results indicate that Txnip 
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and Arrdc4 likely inhibit cellular glucose uptake by preventing anterograde 





Figure 46. Time dependent induction of GLUT1-EGFP after induction with 
tetracycline and cycloheximide followed by cycloheximide washout.Trex293 
cells were cotransfected with GLUT1-EGFP-HA pcDNA4/TO and Ubc4-HA 
pcDNA4/TO for two days. The transfected cells were then treated with 40µM 
cycloheximide and 1µg/ml tetracycline 10 hours prior to cycloheximide washout 
and treatment with tetracycline only on the third day for 1, 2, 4 and 24 hour(s). 
The cells were harvested and the expression level of both GLUT1 and the positive 
























































Figure 47. Txnip and Arrdc4 inhibit anterograde trafficking of GLUT1 to 
the plasma membrane. i) Representative time-lapse sequence of GLUT1-EGFP 
localization to plasma membrane in Trex293 cells coexpressed with (A) empty 
vector, (B) mTxnip-Flag, (C) Flag-Arrdc4 upon treatment with 1µg/ml 
tetracycline. These cells are pretreated with 40µM cycloheximide and 1µg/ml 
tetracycline for 2.5 hours prior to cycloheximide washout and treatment with 
tetracycline alone for the indicated times for image collection. Scale bar = 20µm. 
ii) Overexpression of Txnip and Arrdc4 was confirmed by Western blotting. 
 
5.6 Discussion 
     Txnip is a member of the -arrestin protein family. It was originally 
characterized as an inhibitor of TRX [Nordberg et al., 2001]. It has recently been 
identified as a regulator of cellular glucose utilization independent of its binding 
to TRX and implicated in mediating the deregulation of glucose metabolism in 
cancer and diabetes [Patwari et al., 2009; Parikh et al., 2007; Masutani et al., 
2012]. Txnip and its paralogue, Arrdc4, have been reported to inhibit glucose 
uptake, however, much less is currently known about the physiological function 
of Arrdc4 [Patwari et al., 2009].  
     In this study, we focused on the elucidation of the mechanism through which 
Txnip and Arrdc4 inhibit cellular glucose utilization.  One potential mechanism is 
the promotion of oxidative phosphorylation. ATP synthesis from oxidative 
phosphorylation is markedly more efficient compared to ATP production via the 
glycolytic cascade. Hence, less glucose is required to sustain cellular ATP levels 
when oxidative phosphorylation is highly active. Txnip has recently been reported 
to promote mitochondrial function in the myocardium. Absence of Txnip in mice 
resulted in enhanced anaerobic glycolysis, leading to the protection from 
myocardial ischemia-reperfusion injury [Yoshioka et al., 2012].  
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We show in this study that Txnip and Arrdc4 inhibit cellular glucose utilization 
independently of mitochondria, since inhibition of cellular glucose uptake and 
lactate production was maintained when mitochondrial ATP production was 
inhibited. In cells overexpressing Txnip or Arrdc4, but not in untransfected cells, 
blocking of oxidative phosphorylation led to a rapid drop in cellular ATP 
concentrations. These results strongly suggest that Txnip and Arrdc4 inhibit 
glycolytic ATP production directly. In a study by Andres et al. [2011], Txnip was 
demonstrated to regulate PDH activity by altering its inhibitory phosphorylation 
mediated by PDK. However, contrary to the report by Andres et al. [2011], we did 
not observe any effect of Txnip and Arrdc4 on the phosphorylation status of PDH. 
We also found that Txnip and Arrdc4 do not affect the activity of LDH, a 
cytosolic enzyme that control pyruvate entry into mitochondria. These results 
further support our conclusion that the -arrestin proteins do not promote 
mitochondrial function by regulating mitochondrial pyruvate utilization. 
     Next, we have show that Txnip and Arrdc4 inhibit cellular glucose metabolism 
independently of the glycolytic cascade. We found that Txnip and Arrdc4 
overexpressing cells have lower cellular levels of F2,6P2. Thus we initially 
hypothesized that Txnip and Arrdc4 decrease glucose utilization by inhibiting 
glycolysis. However, increasing the F2,6P2 level by overexpressing PFK2 isoform 
3 did not rescue Arrdc4 overexpressing cells from cell death when mitochondrial 
function is inhibited. Subsequently, we found that Txnip and Arrdc4 also decrease 
cellular G6P concentrations. Hence, we reason that the lower F2,6P2 
concentration in Txnip and Arrdc4 overexpressing cells is likely a consequence of 
157 
 
reduced cellular levels of G6P, which is the precursor of fructose-6-phosphate, the 
substrate for F2,6P2 synthesis by PFK2. Importantly, overexpression of either -
arrestin protein did not inhibit hexokinase activity. Taken together, our results 
suggested that it is unlikely for Txnip and Arrdc4 to decrease cellular glucose 
metabolism by interacting with the glycolytic cascade. 
     Since Txnip and Arrdc4 inhibit glucose consumption but not the glycolytic 
cascade, we reasoned that the -arrestin proteins most likely inhibit glucose 
uptake at the cell membrane.  We observed that Txnip and Arrdc4 inhibit glucose 
uptake by preventing plasma membrane localization of GLUT1, a result that is in 
line with the findings of a recent study by Wu et al. [2013]. These authors 
reported that Txnip promotes the internalization of cell surface GLUT1 via 
clathrin mediated endocytosis. However, we were unable to detect any interaction 
between Txnip or Arrdc4 and clathrin heavy chain (CHC). Furthermore, the 
expected strong binding between the -arrestin proteins and GLUT1 was not 
observed. Thus, our results indicate that Txnip and Arrdc4 do not appear to 
promote internalization of GLUT1. We postulated that the -arrestin proteins 
prevent anterograde trafficking of GLUT1 to the plasma membrane. We indeed 
demonstrated that the translocation of newly synthesized GLUT1 to the plasma 
membrane is inhibited by Txnip and Arrdc4. 
     In future studies, it would be interesting to investigate the mechanism behind 
the inhibition of GLUT1 plasma membrane translocation by Txnip and Arrdc4. 
The GLUT1 transporter binding protein, also known as GLUT1CBP or GIPC1, is 
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an adapter molecule that is involved in the trafficking of GLUT1 to the cell 
surface. GIPC1 interacts with the PDZ binding motif at the C-terminus of GLUT1. 
This adapter protein also forms a complex with a motor protein, myosin VI. With 
the aid of the motor domain of myosin VI, the GLUT1/GIPC1/myosin VI 
complex moves along the F-actin filament and delivers GLUT1 to the cell surface 
(Figure 48) [Reed et al., 2005]. It has been reported that blocking the interaction 
of GLUT1 and GIPC1 via mutation or deletion of the PDZ binding motif of 
GLUT1 results in a drastic decrease in cell surface GLUT1 levels. This is 
accompanied by intracellular accumulation of the glucose transporters [Reed et al., 
2005; Wieman et al., 2009]. Similarly, when GIPC1 was knocked down, a 
significant reduction in both cellular glucose uptake and surface GLUT1 levels 
were observed [Wieman et al., 2009]. Since disruption of the interaction between 
GIPC1 and GLUT1 alters the normal distribution of GLUT1 at the cell surface, 
one potential mechanism is that Txnip or Arrdc4 compete with GLUT1 for 
binding to GIPC1. With a lower amount of free GIPC1/myosin VI complex 
available to mediate anterograde trafficking of GLUT1, cellular glucose uptake 





Figure 48. Schematic diagram illustrating the trafficking of GLUT1 by 
Glucose transporter binding protein (GIPC1). (modified from [Reed et al., 
2005] (A) The interaction between GIPC1 and GLUT1 is important for the 
normal trafficking of GLUT1 to the cell surface. (B) We therefore hypothesized 
that Txnip or Arrdc4 compete with GLUT1 for binding to GIPC1. With reduced 
amount of free GIPC1/myosin VI complex available to perform anterograde 
trafficking of GLUT1, cellular glucose uptake would be reduced in the presence 
of the -arrestin proteins.  
160 
 
6.  CONCLUSIONS 
6.1 Conclusions 
     This thesis investigated mechanisms involved in the regulation of cellular 
glucose metabolism. We studied two important regulators of cellular glucose 
metabolism, the transcription factor HIF-1 and the -arrestin protein Txnip. HIF-
1 promotes glucose metabolism by transactivating a series of genes to upregulate 
glycolysis and downregulate mitochondrial activity during hypoxia. Txnip is a 
negative regulator of cellular glucose utilization. We addressed two important 
questions related to the regulation of HIF-1 stability by mitochondrial electron 
transport chain activity and the mechanism through which Txnip and the related 
-arrestin protein Arrdc4 inhibit glucose metabolism. 
 
6.1.1 Mitochondria regulate the stability of HIF-1 by controlling the 
cellular oxygen concentration independently of mitochondrial ROS  
     A functional mitochondrial ETC is required for hypoxia-dependent HIF-1 
protein stabilization. There are two hypotheses to explain this requirement. It has 
been suggested that mitochondrial complex III-derived ROS stabilize HIF-1 
protein during hypoxic conditions by inhibiting the activity of PHD enzymes 
[Brunelle et al., 2005; Guzy et al., 2005: Mansfield et al., 2005]. According to the 
alternative hypothesis, the mitochondrial ETC activity decreases the amount of 
oxygen available for the PHD enzymes, thus leading to HIF-1 protein 
stabilization [Doege et al., 2005; Hagen et al., 2003]. In the first part of the thesis, 
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the results suggested that HIF-1 protein is stabilized in hypoxia independently of 
mitochondrial ROS production from complex III. Furthermore, I also 
demonstrated that cellular oxygen availability is sufficient to regulate hypoxia-
dependent HIF-1 stabilization. Lastly, my results indicate that H2O2 and 
superoxide are unlikely to have a direct role in inhibiting the activity of PHD 
enzymes. In the second part of the thesis, I found that Compound C exerts its 
effects via the same mechanism as other mitochondrial ETC inhibitors to regulate 
the stability of HIF-1 protein. Compound C acts as a complex I inhibitor to 
increase the cellular oxygen availability, leading to reactivation of PHD enzymes 
in hypoxia. Taken together, we concluded that mitochondria regulate the stability 
of HIF-1 protein by controlling the cellular oxygen availability. 
     In conclusion, our results indicate that the mitochondrial electron transport 
chain can regulate HIF-1 accumulation by controlling the intracellular oxygen 
concentration. Of note, a number of recent studies have suggested that this 
mechanism is physiologically relevant.  
     Physiological hypoxia occurs in pancreatic β cells when they are stimulated to 
secrete insulin under conditions of high extracellular glucose concentrations. 
Upon exposure to high glucose concentrations, pancreatic β cells consume large 
amounts of oxygen to generate ATP via mitochondrial oxidative phosphorylation, 
which is required for the subsequent opening of the voltage gated calcium 
channels. The resulting calcium influx triggers exocytosis of insulin containing 
secretory granules and hence insulin secretion from the pancreatic β cells 
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[Tarasov et al., 2003]. Due to high rates of oxygen consumption by mitochondria, 
hypoxia occurs and leads to the stabilization of HIF-1 [Sato et al., 2011].  Sato 
et al. have shown that the accumulated HIF-1 inhibits insulin secretion by the β 
cells. Thus, preventing or delaying the stabilization of HIF-1 is one possible way 
to increase insulin secretion in order to improve glucose tolerance in prediabetic 
patients. 
     Relative cellular hypoxia also arises in adipose tissue of obese individuals. 
Obese patients subsequently develop chronic inflammation, which in turn causes 
obesity related insulin resistance and diabetes. Lee et al have recently identified 
HIF-1 to be a bridge that links obesity and diabetes [Lee et al., 2014]. 
Adipocytes in obese individuals are constantly exposed to high concentration of 
saturated fatty acids, which activate adenine nucleotide translocase 2, increasing 
cellular oxygen consumption and resulting in hypoxic conditions in adipocytes. 
Consequently, HIF-1 is stabilized and promotes the release of adipocyte derived 
chemokines to induce inflammation [Makki et al., 2013]. Importantly, Lee et al. 
demonstrated that knocking out HIF-1 in adipocytes of obese mice prevents the 
development of chronic inflammation, insulin resistance or diabetes. Thus 
blocking HIF-1 may be beneficial in preventing the development of diabetes. 
     Finally, there is also evidence that the regulation of the intracellular oxygen 
concentration plays a role in cancer. For instance, Cook et al. [2012] reported that 
prostate and breast cancer cells are frequently characterized by depletion or 
deletion of the mitochondrial genome. The authors reported that this leads to the 
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overexpression and activation of proto-oncogenic Ras. This effect is a 
consequence of increased intracellular oxygen concentrations, leading to 
inhibition of the hypoxia-induced degradation of 3-hydroxy-3-methyl-glutaryl-
CoA reductase (HMGR). HMGR is the rate limiting enzyme of the mevalonate 
pathway, whose activity promotes Ras maturation and activation. 
These examples highlight the importance of mitochondria-dependent regulation of 
intracellular oxygen availability for human diseases such as diabetes and cancer. 
Knowledge of the underlying mechanisms might help in designing novel 
strategies to treat these diseases. 
 
6.1.2 Txnip and Arrdc4 regulate cellular glucose by preventing anterograde 
trafficking of GLUT1 to the plasma membrane. 
     Txnip and Arrc4 have been reported to inhibit glucose uptake and lactate 
output [Patwari et al., 2009]. In the last part of my thesis I characterized the 
mechanism through which the -arrestin proteins decrease cellular glucose 
metabolism. We initially postulated that Txnip and Arrdc4 inhibit cellular glucose 
uptake as a consequence of promoting mitochondrial oxidative phosphorylation 
[Yoshioka et al., 2012]. However, my results have showed that Txnip and Arrdc4 
inhibit cellular glucose utilization independently of mitochondria. My results also 
revealed that Txnip inhibits glucose consumption but not the glycolytic cascade. 
These results suggested that Txnip and Arrdc4 inhibit glucose utilization by 
inhibiting glucose uptake. Indeed, Txnip and Arrdc4 markedly reduced the plasma 
membrane localization of the GLUT1 glucose transporter. I found that in contrast 
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to a recent report, Txnip and Arrdc4 do not promote internalization of GLUT1 but 
instead are likely to inhibit GLUT1 trafficking to the plasma membrane. In 
conclusion, my results suggest that Txnip and Arrdc4 inhibit cellular glucose 
uptake by preventing anterograde trafficking of GLUT1 to the plasma membrane. 
In future studies it will be important to identify the specific proteins that Txnip 
and Arrdc4 interact with to decrease cellular glucose metabolism. Knowing the 
molecular mechanism through which the -arrestin proteins regulate cellular 
glucose metabolism is likely to open up novel therapeutic strategies to treat 
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The transcription factor hypoxia-inducible factor-1
(HIF-1) is a master regulator of the cellular response to low
oxygen. HIF-1 protein accumulates in hypoxia due to inhi-
bition of prolyl hydroxylase enzymes, which under normoxic
conditions use molecular oxygen to hydroxylate HIF-1 on
two conserved proline residues (Pro402 and Pro564), thus tar-
geting the protein for 26 S proteasome-dependent degrada-
tion. A functional mitochondrial electron transport chain is
known to be necessary for HIF-1 stabilization in hypoxia. It
has been reported that reactive oxygen species (ROS), pro-
duced under hypoxia by complex III of the mitochondrial
electron transport chain, play a critical role in the stabiliza-
tion of the HIF-1 protein, possibly by directly inhibiting
prolyl hydroxylase enzymes. In contrast, we found that ROS
production by complex III is not required for hypoxia-in-
duced HIF-1 stabilization. Thus, reestablishing mitochon-
drial oxygen consumption in the presence of a complex III
inhibitor by using an artificial electron donor to complex IV
or by overexpressing Ciona intestinalis alternative oxidase
results in HIF-1 protein stabilization in hypoxia. Further-
more, five inhibitors that target different sites of the mito-
chondrial electron transport chain have similar effects on the
HIF-1 protein half-life in hypoxia but vary in their effects on
mitochondrial ROS production. Finally, ROS do not regulate
prolyl hydroxylase activity directly.We conclude that HIF-1
protein stabilization in hypoxia occurs independently of
mitochondrial ROS production. However, mitochondria can
modulate the cellular hypoxic response through altered res-
piratory activity, likely by regulating the cellular oxygen
availability.
Hypoxia induces a complex transcriptional program
designed to improve cellular oxygen supply and adapt cellular
metabolism to the lack of oxygen. This hypoxic response is
mediated by hypoxia-inducible factor (HIF),2 a heterodimeric
transcription factor consisting of an oxygen-regulated  sub-
unit (HIF-1 andHIF-2) and a constitutively expressed sub-
unit. The oxygen-dependent regulation of the  subunit occurs
at the level of its protein stability. At normal oxygen concentra-
tion, a family of prolyl hydroxylase (PHD) enzymes catalyzes
the hydroxylation of two conserved proline residues in HIF-1
and HIF-2 (1, 2). This reaction is dependent on both oxygen,
which is a cosubstrate, and non-heme-reduced Fe2, bound to
the catalytic center of PHD enzymes. Hydroxylation of HIF-1
and HIF-2 at either of the two proline residues creates a rec-
ognition site for binding to the Von Hippel-Lindau (pVHL)
protein. Binding of HIF-1 and HIF-2 to pVHL results in
polyubiquitination by the pVHL-associated E3 ubiquitin ligase
and degradation by the 26 S proteasome. Under hypoxic con-
ditions, lack of oxygen inhibits PHD activity, thus leading to
HIF-1 and HIF-2 protein stabilization and accumulation in
the nucleus.
The mitochondrial electron transport chain (ETC), which
consumes the vast majority of cellular oxygen and therefore
directly controls intracellular oxygen tension, is known to play
an important role in cellular oxygen sensing (3, 4). Indeed, inhi-
bition of mitochondrial respiration by pharmacological or
genetic means prevents the accumulation of both HIF-1 and
HIF-2 upon exposure of cells to hypoxia (5, 6). This effect is
due to PHD-dependent HIF-1 degradation (7). Thus, it has
been suggested that mitochondrial activity regulates the
HIF-1 protein by determining the amount of oxygen available
for PHD enzymes (7, 8).
However, given that themitochondrial ETC is also themajor
source of cellular reactive oxygen species (ROS) in most cell
types, an alternative mechanism has been proposed (9–11).
According to this model, increased amounts of ROS produced
under hypoxia by complex III of the mitochondrial ETC are
required for hypoxia-dependent HIF-1 stabilization. The
absence of a functional, ROS-producing ETC therefore pre-
vents hypoxia-dependent HIF-1 stabilization.* This work was supported by grants from the Singapore National Medical
Research Council andNational University of Singapore, the School ofMed-
icine, Academy of Finland, INSERM, the Tampere University Hospital Med-
ical Research Fund, and the Sigrid Juselius Foundation.
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Given the universal importance of the cellular hypoxic
response for normal cell physiology and the critical involve-
ment of HIF in ischemic diseases and in cancer, we studied in
detail themechanism throughwhichmitochondria regulate the
HIF-1 protein. To this end, we used a number of approaches,
including manipulations that specifically alter mitochondrial
oxygen consumption without affecting ROS production, to
show that the primary mechanism through which the mito-
chondrial ETC controls HIF-1 stability is by regulating the
cellular oxygen availability.
EXPERIMENTAL PROCEDURES
Cell Culture—Human osteosarcoma 143B cells were cul-
tured in RPMI (Roswell Park Memorial Institute) 1640 me-
dium, whereas human kidney epithelial HEK293 cells and
HEK293T cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM). Both media were supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, and 1% penicillin-strep-
tomycin (Invitrogen).
Oxygen Conditions—Hypoxic condition (1%O2, 94%N2, and
5% CO2) was achieved in a humidified variable aerobic work
station (CoyLaboratories Products,Grass Lake,MI) or a Pro-ox
110 oxygen controller andPro-ox in vitro chamber (BioSpherix,
Redfield, NY).
Immunoblotting—Cell lysis and Western blotting were car-
ried out as previously described (39). The following antibodies
were used: mouse anti--actin (Sigma-Aldrich), mouse anti--
tubulin (Invitrogen), mouse anti-HIF-1 (BD Pharmingen),
rabbit anti-alternative oxidase (AOX) (18), mouse anti-VHL
(BDPharmingen), goat anti-GST (AmershamBiosciences), and
anti-catalase (Abcam).Western blots shown are representative
of at least two independent experiments.
Detection of Cellular Superoxide—Superoxide production
was estimated using dihydroethidium. Cells were plated in
12-well plates and grown to 70% confluence and cotreated with
20 M dihydroethidium and mitochondrial inhibitors for 30
min. Subsequently, the cells were rinsed with PBS and kept in
PBS for analysis of fluorescence using a multiwell plate reader
(Molecular Devices, excitation and emission wavelengths were
520 nm and 610 nm, respectively). The validity of this assay has
previously been verified by using menadione and 2-me-
thoxyestradiol as positive controls (40).
Measurement of Oxygen Consumption—Oxygen consump-
tion was measured with a Clark-type oxygen electrode (Oxy-
graph; Hansatech) in Krebs buffer using cells at a density of
1.6 108/ml.
Generation of HEK293T Cells Expressing AOX—HEK293T
cells were infectedwith 4l of concentrated pWPI-AOX-IRES-
GFP lentiviral preparation (18, 41) leading to30% of cell sta-
bly expressing the green fluorescence as measured with
COULTEREPICS-XL_MCLTM flow cytometer and Cyflogic
1.2.1 analysis software. HEK293T-infected cells were subjected
to two successive rounds of purification, first plating the
infected population in 96-well plates at a density of one cell/well
and then subjecting each of the single clones obtained from this
seeding to limited dilution using 1/3 serial dilutions. AOX
expression in subclones was verified by polarography using a
Clark-type oxygen electrode.
Preparation of Mitochondria—Mitochondria were isolated
frommouse liver by differential centrifugation inmitochondria
isolation buffer containing 280 mM sucrose, 10 mM Tris (pH
7.4), and 1 mM EDTA.
Mitochondrial Complex I Activity—Measurement of com-
plex I activity was carried out as previously described (42) using
0.1 mg of mouse liver mitochondria. Mitochondria were sub-
jected to freeze-thawing prior to the assay.
Overexpression of Cytosolic and Mitochondrially Targeted
Catalase—Murine catalase was PCR-amplified from I.M.A.G.E.
clone (ID4241333) and inserted in the retroviral expressionvector
Puro-MaRX (a gift from Dr. David Beach). It has been previously
shown that a robust overexpression of catalase results in accumu-
lation of the protein in the cytoplasm. TheN-terminal mitochon-
drial targeting sequence of SOD2 (comprising the sequence cor-
responding to residues 1–28) was used to target catalase to
mitochondria. This construct also included a C-terminal V5
epitope tag. Retroviral particles were generated using catalase,
mitochondrial catalase-V5, or enhancedGFP (control) containing
Puro-MaRX retroviral expression vector in 293-gag-pol cells and
pseudotypedwith vesicular stomatitis virus-G. Protein expression
was assessed by immunofluorescence (enhanced GFP) or immu-
noblotting with catalase antibody.
Detection of H2O2 Scavenging Capacity—H2O2 scavenging
capacity was estimated using DCFDA. 143B cells resuspended
in Krebs buffer containing 10 mM glucose were loaded with 20
MDCFDA for 15min at 37 °C and analyzed by flow cytometry
using the fluorescein isothiocyanate (FITC) channel (logmode)
both before and after treating with 200 M H2O2 for 5 min. In
each analysis, 10,000 events were recorded.
pVHL Binding Assays—GST-HIF-1 fusion protein plasmid
was generated by inserting the HIF-1 coding sequence corre-
sponding to 521–652 amino acids into the pGEX-KG vector.
The GST fusion protein was expressed in BL21 cells and puri-
fied using GSH-agarose beads. The immobilized GST-HIF was
subjected to prolyl hydroxylation assays in the presence of cell
lysate fromHEK293 cells transfected with PHD2 and VHL and
2 mM 2-oxoglutarate and 2 mM ascorbate for 1 h at room tem-
perature. After the assay, the cell lysate was removed, and the
beads were washed 3 times using Nonidet P-40 wash buffer
(containing 0.5%Nonidet P-40, 5% glycerol, 0.5mMEDTA, and
50 mM NaCl) and washed once using PBS. pVHL bound to
GST-HIF fusion protein was analyzed by Western blotting.
Statistical Analysis—Data are expressed as the mean  S.E.
Differences in measured variables were assessed with Student’s
t test. p 0.05 was considered to be statistically significant.
RESULTS
All Inhibitors ofMitochondrial Electron Transport Have Sim-
ilar Effects on HIF-1 Protein Half-life in Hypoxia—ROS are
produced to different degrees at the various complexes of the
mitochondrial ETC. We initially determined whether any spe-
cific site within themitochondrial ETC is required for hypoxia-
dependent HIF-1 stabilization. To this end, we tested the
effects of various inhibitors of the ETC on 143B human osteo-
sarcoma cells grown under hypoxic conditions (1% oxygen) for
4 h. HIF-1 protein accumulation was prevented upon treat-
mentwith the different inhibitors (rotenone,myxothiazol, anti-
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mycin A, stigmatellin, sodium azide) at concentrations that
completely inhibit ETC activity (Fig. 1A). Thus, the require-
ment of a functional ETC is not restricted to complex III.
To examine this further, we obtained a more quantitative
measurement of the effect of the mitochondrial inhibitors by
measuring the rate at which the HIF-1 protein is degraded.
HEK293 cells were subjected to hypoxic conditions for 3 h fol-
lowed by incubation with the protein synthesis inhibitor cyclo-
heximide in the presence or the
absence of inhibitors for different
durations. In the presence of cyclo-
heximide, there was a slow gradual
decrease in the HIF-1 protein con-
centration. However, in the pres-
ence of both cycloheximide and the
complex III inhibitor myxothiazol,
HIF-1 protein was degraded at a
much faster rate (Fig. 1B). We
repeated the same experiment using
different mitochondrial inhibitors
(rotenone, antimycin A, sodium
azide, DETA-NONOate), as sum-
marized in Fig. 1C. TheHIF-1half-
life in hypoxia in control cells was
32.99 min. All inhibitors of the
mitochondrial ETC decreased the
HIF-1 half-life to similar degrees
(rotenone t1⁄2 8.94 min; myxothia-
zol t1⁄2 9.95min; antimycin A t1⁄2
5.74 min; sodium azide t1⁄2  8.59
min; DETA-NONOate t1⁄2  10.72
min). These results therefore indi-
cate that inhibition of any site in the
mitochondrial ETC inhibits hypoxia-
dependent HIF-1 protein induc-
tion by decreasing its half-life.
Next, we also tested the effects of
the inhibitors on ROS production in
both normoxia and hypoxia by
measuring the superoxide-depen-
dent oxidation of the fluorescent
dye dihydroethidium. In the
untreated cells, there was no signif-
icant increase in the superoxide
concentration in hypoxia compared
with normoxia. Of the mitochon-
drial ETC inhibitors, only sodium
azide reduced superoxide produc-
tion in both hypoxia and normoxia
significantly. There was no signifi-
cant change with nitric oxide donor
and a slight increase was observed
with the other inhibitors (Fig. 1D).
Thus, there is no correlation be-
tween the effects of the various
inhibitors on superoxide produc-
tion and hypoxia-dependent HIF-1
protein stabilization, suggesting
that superoxide may not play an important role in HIF-1 pro-
tein stabilization.
Reestablishing Oxygen Consumption in the Presence of
Complex III Inhibitor Restores Hypoxia-dependent HIF-1
Stabilization—To establish further whether the effects ofmito-
chondrial inhibitors on HIF-1 are due to inhibition of mito-
chondrial oxygen consumption or inhibition of ROS produc-
tion from complex III, we investigated the effect ofmyxothiazol
FIGURE 1. Inhibition ofmitochondrial electron transport at different sites prevents hypoxia-dependent
HIF-1 stabilization and has similar effects on HIF-1 half-life in hypoxia. A, 143B cells were incubated at
1% O2 for 4 h in the presence of the mitochondrial inhibitors stigmatellin (1 M), sodium azide (2 mM), myxo-
thiazol (1 M), rotenone (0.5 M), and antimycin A (1 M), as indicated. HIF-1 was analyzed by Western
blotting. B, after incubation at 1% O2 for 3 h in a hypoxia chamber, HEK293 cells were treated with cyclohexi-
mide (Chx, 40 M) andmyxothiazol (1 M) as indicated, within the chamber without introducing atmospheric
oxygen, and cell lysates were obtained after 5, 20, 30, and 45 min followed by immunoblotting using HIF-1
antiserum. C, summary of immunoblot analysis of HIF-1 in cell lysates of HEK293 cells incubated under the
same conditions as those described in Bwith mitochondrial inhibitors rotenone (0.5 M), myxothiazol (1 M),
antimycin A (1 M), sodium azide (2 mM) and DETA-NONOate (100 M) present. The band intensity, as deter-
mined by densitometry, was normalized to the -tubulin signal and expressed as percent of the HIF-1 abun-
dance of time zero. The results shown represent the means  S.E. (error bars) of three independent experi-
ments. The decrease in HIF-1 protein expression in mitochondrial inhibitor treated versus control cells was
statistically significant (p 0.05) for all inhibitors at 45 min, for all inhibitors except myxothiazol at 30 min, for
sodium azide and DETA-NONOate at 20min.D, HEK293 cells were incubated in either 21%O2 or 1%O2 for 3 h
followed by treatment with mitochondrial inhibitors used at the same concentration as in B and C and 20 M
dihydroethidium dye (DHE) for 30 min to measure superoxide concentration. The fluorescence results shown
represent the average of three independent experiments (mean S.E.). Only sodium azide caused a statisti-
cally significant (p 0.05) decrease in the superoxide concentration in normoxia and hypoxia (as indicated by
an asterisk).
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on HIF-1 protein accumulation in the presence of 2,2,4-tri-
methyl-1,3-pentanediol (TMPD). The complex III inhibitor
myxothiazol has been reported to inhibit complex III-depen-
dent superoxide production, whereas TMPD is an artificial
electron donor that donates electrons to cytochrome c and
complex IV downstream of complex III. As a result, oxygen
consumption is reactivated even in the presence ofmyxothiazol
as illustrated in Fig. 2A. We then determined the effect of
TMPD on hypoxia-dependent HIF-1 stabilization. TMPD by
itself had no effect on the HIF-1 protein concentration in
hypoxia (Fig. 2B). However, TMPD completely rescued myxo-
thiazol-induced inhibition of HIF-1 stabilization. This indi-
cates that in the presence of an inhibitor of complex III, rees-
tablishing oxygen consumption via complex IV is sufficient for
HIF-1 stabilization. The result suggests that electron trans-
port via complex III and superoxide derived from complex III
are not required for HIF-1 induction. Therefore, the effect of
myxothiazol is likely due to inhibition of mitochondrial oxygen
consumption.
Next, we repeated the HIF-1 half-life measurements in the
presence of TMPD. As shown in Fig. 2C, addition of TMPD
increased the HIF-1 half-life in the presence myxothiazol
from 9.95 min to 28.91 min, which is similar to the untreated
control (t1⁄2  32.99 min). A very similar trend was observed
with a different complex III inhibitor, antimycin A (increase in
the HIF-1 half-life from 5.74 min to 23.70 min in the absence
versus presence of TMPD). These results further suggested that
HIF-1 protein stabilization is independent of ROS produced
by complex III.
Alternative Oxidase-dependent Oxygen Consumption Is Suf-
ficient to Reactivate the Hypoxia Response When Complex III Is
Inhibited—AOX is amitochondrial enzyme that is expressed in
plants, some fungi, protists, and lower metazoa (12). It has two
reported physiological functions: to carry out thermogenesis
and to lower the ROS production during mitochondrial elec-
tron transport (13–16). The AOX protein is localized in the
inner mitochondrial membrane. It accepts electrons from
coenzyme Q and uses the electrons to reduce oxygen to water
directly, therefore bypassing complex III and IV. As a conse-
quence, electron transport via complex III is decreased, result-
ing in lower superoxide production from complex III via the Q
cycle while maintaining mitochondrial oxygen consumption.
We have previously shown that AOXderived fromCiona intes-
tinalis is well tolerated in mammalian cells, functional, and can
confer complex III and complex IV inhibitor-resistant respira-
tion (17–19). To genetically determine whether HIF-1 stabi-
lization is dependent on mitochondrial ROS from complex III,
we utilized HEK293T cells with stable AOX expression. We
first compared the respiratory properties of both wild type and
AOX-expressing HEK293T cells by measuring their oxygen
consumption polarographically using aClark-type oxygen elec-
trode. When subjected to myxothiazol and rotenone, respira-
tion of the wild type cells was inhibited by 75.7% and 84.8%,
respectively (Fig. 3A). However, in the AOX-expressing cells,
respiration was inhibited by only 42.8% when myxothiazol was
present (Fig. 3A). Subsequent addition of rotenone resulted in
similar inhibition (78.5%) as observed in control cells. Thus, the
AOX-expressing cells still consume oxygen even in the pres-
FIGURE 2. Reestablishing oxygen consumption under condition when
complex III is inactive is sufficient for hypoxia-dependent HIF-1 stabi-
lization. A, oxygen consumption of 143B cells was measured using a Clark-
type oxygen electrode at 37 °C. Myxothiazol (1 M) and TMPD (0.2 mM) addi-
tion is indicated. B, 143B cells were incubated at 1% O2 for 3 h with
myxothiazol in the absence or presence of TMPD. HIF-1 protein abundance
was determined by Western blotting. C, HEK293 cells were incubated at 1%
O2 for 3 h, followed by treatment with cycloheximide (Chx, 40 M) and the
complex III inhibitorsmyxothiazol (1M) and antimycinA (1M), as indicated,
in the absence or presence of TMPD. Cell lysateswere obtained after 5, 20, 30,
and 45min, followedby immunoblotting usingHIF-1 antiserum. The results
were calculated and are presented as in Fig. 1C (n  3, means  S.E. (error
bars)). With antimycin, TMPD caused a statistically significant (p  0.05)
increase inHIF-1protein expression at 20, 30, and 45min.Withmyxothiazol,
the TMPD-induced increase in HIF-1 protein expression was not statistically
significant.
Role of Mitochondria in the Regulation of HIF-1















ence ofmyxothiazol, due to their ability to bypass both complex
III and IV and utilize AOX to consume oxygen.
Next, we determined the effect of AOX protein expression
on the cellular superoxide concentration in the presence of dif-
ferentmitochondrial ETC inhibitors. AOX reduced superoxide
production in the presence of the complex III inhibitors myxo-
thiazol and antimycin A but had no effect on superoxide when
the complex I inhibitor rotenonewas present (Fig. 3B). Thus, as
expected, AOX only inhibits com-
plex III-dependent superoxide pro-
duction. To investigate whether
reestablishing oxygen consumption
under conditions where complex III
is inactive is sufficient for hypoxia-
dependent HIF-1 stabilization, we
treatedwild type andAOX-express-
ing HEK293T cells with mitochon-
drial inhibitors under hypoxic con-
ditions. In wild type cells, HIF-1
protein accumulation was pre-
vented in the presence of inhibitors
of complex I, III, and IV (Fig. 3C).
In AOX-expressing cells, HIF-1
induction was also inhibited with
complex I inhibitor, rotenone. This
result is expected because rotenone
inhibits electron transport up-
streamofAOX. In contrast, antimy-
cin A and sodium azide had no
inhibitory effect on HIF-1 ex-
pression in AOX-expressing cells.
These cells still consume oxygen via
the AOX protein, but do not pro-
duce increased superoxide because
electron transport via complex III is
prevented. These results suggest
that mitochondrial ETC regulates
HIF-1 stability by controlling
intracellular oxygen but not ROS
concentration.
Unexpectedly, HIF-1 expres-
sion was still significantly inhibited
when AOX-expressing cells were
treated with myxothiazol. Myxo-
thiazol is also a complex III inhibi-
tor. Therefore, its inhibitory effect
on hypoxia-dependent HIF-1 ac-
cumulationwould be expected to be
reversed when AOX is expressed
and oxygen can be consumed inde-
pendently from complex III. A pos-
sible explanation for this finding is
that the concentration of 1 M
myxothiazol that was used is high
enough to inhibit complex I also.
Indeed, it has been previously
reported that at higher concentra-
tions myxothiazol also functions as
complex I inhibitor (see Ref. 20). To confirm this hypothesis,
both wild type and AOX-expressing cells were treated with dif-
ferent concentrations ofmyxothiazol under hypoxic conditions
(Fig. 3D). In the wild type cells, hypoxia-dependent HIF-1 sta-
bilization was prevented at any concentration of myxothiazol.
In contrast, in AOX-expressing cells, HIF-1 could be detected
at the lower myxothiazol concentrations (100 nM and 250 nM)
but not at the higher concentration of 1 M. When measuring
FIGURE 3. AOX expression reactivates the hypoxic response when complex III is inhibited. A, both
HEK293T wild type and AOX-overexpressing cells were treated overnight in the presence of 2 mM pyruvate to
ensure maximum AOX activity, followed by measurement of oxygen consumption in the presence of the
mitochondrial inhibitorsmyxothiazol (1M)or rotenone (0.5M), as indicated.B, HEK293Twild type (openbars)
and AOX-overexpressing (filled bars) cells were treated with the mitochondrial inhibitors rotenone (0.5 M),
myxothiazol (1 M), and antimycin A (1 M) and 20 M dihydroethidium dye (DHE) for 1 h to measure cellular
superoxide concentrations. The fluorescence results shown are expressed in relative fluorescence units (RFU)
and represent the average of two independent experiments (mean S.E. (error bars)). C, HEK293T wild type
and AOX-overexpressing cells were exposed to 1% O2 for 3 h in the presence of the mitochondrial inhibitors
myxothiazol (1 M), antimycin A (1 M), sodium azide (5 mM), and rotenone (0.5 M). HIF-1 was detected by
Western blotting. D, both HEK293T wild type and AOX-overexpressing cells were exposed to 1% O2 for 3 h in
the presencemyxothiazol (100 nM, 250 nM, and 1M). HIF-1 protein abundance was determined byWestern
blotting. E, activity of mitochondrial complex I was determined in mouse liver mitochondria treated with
myxothiazol (100 nM, 250 nM, 500 nM, and 1 M) using NADH as substrate as described under “Experimental
Procedures.”
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the effects of the differentmyxothiazol concentrations onmito-
chondrial complex I activity in mouse liver mitochondria, sig-
nificant inhibition was observed with 500 nM and 1 M, but not
with lower concentrations of myxothiazol (Fig. 3E). The results
indicate that the inhibition of HIF-1 accumulation in AOX-
expressing cells by 1 Mmyxothiazol (as observed in Fig. 3C) is
due to an inhibitory effect on complex I. In contrast, AOX
expression prevents the inhibition of hypoxia-dependent HIF-
1 stabilization by concentrations ofmyxothiazol which specif-
ically inhibit complex III.
Regulation of HIF-1 Protein Stabilization Is Likely Inde-
pendent ofMitochondrial ROS Produced during Hypoxia—Our
results indicate that increasing mitochondrial oxygen con-
sumption in the absence of electron transport via complex III is
sufficient for hypoxia-dependent HIF-1 accumulation. To
assess the role of ROS in mediating HIF-1 stabilization
directly, we used glucose oxidase/glucose to produce constant
amounts of H2O2. At glucose oxidase concentrations of 250
milliunits/ml and higher, toxic effects on 143B cells were
observed. We therefore used a range of lower glucose oxidase
concentration of 25, 100, and 200 milliunits/ml. Based on
dichlorofluorescein fluorescence calibration with known
amounts ofH2O2, addition of 100milliunits/ml glucose oxidase
to 143B cells over a 15-min period resulted inDCF fluorescence
that was similar to exposure of cells to 200 M H2O2. We
found that glucose oxidase/glucose-derived H2O2 at any con-
centration was without effect on HIF-1 protein accumulation
during hypoxia (supplemental Fig. S1A). To test further
whether H2O2 is involved in HIF-1 stabilization, we retrovi-
rally overexpressed both mitochondria-targeted and cytosolic
catalase in 143B cells. The catalase-transduced cells had mark-
edly increased catalase protein expression and H2O2 scaveng-
ing capacity (supplemental Fig. S1B). However, HIF-1 protein
in cells that overexpressed either form of catalase was still
induced in hypoxia to the same degree despite lower amounts
of mitochondrial ROS release (supplemental Fig. S1B). These
results suggest that mitochondrial or exogenous ROS are not
involved in the stabilization of the HIF-1 protein.
Hydrogen Peroxide Does Not Directly Inhibit Prolyl Hydrox-
ylase Activity—According to the ROS hypothesis, increased
mitochondrial superoxide released from complex III will be
converted to H2O2 which inhibits the PHD enzyme in the cyto-
plasm, possibly by oxidizing the non-heme-bound Fe2 in the
PHD active site (3). PHD enzymes in the presence of oxygen
hydroxylate Pro402 and Pro564 residues in HIF-1, leading to
binding of the pVHL/Cul2 E3 ligase and consequently ubiquiti-
nation and degradation of HIF-1. To determine directly the
effect of H2O2 on the enzymatic activity of PHD, an in vitro
PHD assay was carried out using cell lysate tomimic physiolog-
ical conditions. In this assay, the C-terminal oxygen-dependent
degradation domain of HIF-1 containing proline 564 was
fused toGST [GST-HIF-1(521–652)-V5] and immobilized on
GSH agarose beads. Cell lysate containing PHD2 and pVHL
was used to hydroxylate the recombinant GST-HIF-1 protein.
Binding of pVHL to hydroxylated HIF-1 was used as an indi-
cator of Pro564 hydroxylation. pVHL bound to HIF-1 in the
presence of the PHD cosubstrate 2-oxoglutarate and the cofac-
tor ascorbate but showed reduced binding in the presence of
the PHD inhibitor dimethyloxaloylglycine. As expected, there
was no binding of pVHL to HIF-1 upon treatment with the
Fe2 chelator deferoxamine mesylate in the absence of 2-oxo-
glutarate and ascorbate. There was also no significant pVHL
binding to GST-HIF-1(521–652)-V5 after mutation of Pro564
to Ala in the recombinant HIF-1 fusion protein (Fig. 4A, right
panel). In the presence of 50 M and 200 M H2O2, pVHL
binding was not affected, suggesting that H2O2 does not
directly inhibit PHD (Fig. 4A). We also tested whether super-
oxide affects PHD activity by using xanthine/xanthine oxidase
as a superoxide-generating system. In contrast to H2O2, super-
oxide caused an50% reduction in binding of pVHL toHIF-1
(Fig. 4B), suggesting that superoxide inhibits PHD activity par-
tially. Although H2O2, after conversion from complex III-de-
rived superoxide, has been proposed as the mediator that
causes PHD inhibition under hypoxia (10, 11), we wanted to
test for any effect of cellular superoxide on PHDactivity in cells.
To this end, cells were treated with SOD1 inhibitor diethyldi-
thiocarbamate (DCC), the SOD mimetic MnTBAP and the
FIGURE 4. Hydrogen peroxide does not directly inhibit PHD activity. Cell
lysate of HEK293 cells transfected with PHD2 and pVHL was incubated with
wild type or P564A mutant GST-HIF-1(521–652)-V5 immobilized on GSH
agarose beads in the presence of 2mM 2-oxoglutarate and 2mM ascorbate to
detect pVHL binding byWestern blotting. The reaction was performed in the
presence of H2O2 (50M and 200M), dimethyloxaloylglycine (DMOG; 2mM),
and deferoxaminemesylate (DFO; 200M) as described under “Experimental
Procedures.” After the incubation, the lysate was removed, the GSH-agarose
beads were washed, and bound pVHL was analyzed by Western blotting.
Densitometric analysis of three independentpVHLbindingassays in thepres-
ence of 50 M or 200 M H2O2, superoxide-generating system xanthine/xan-
thine oxidase, 2 mM dimethyloxaloylglycine is presented in B (percent of
untreated control; mean S.E. (error bars)). The decrease in the PHD activity
in the presence of xanthine/xanthine oxidase compared with the untreated
control reached statistical significance (p 0.05), as indicated by an asterisk.
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antioxidants N-acetylcysteine and ascorbate which are known
to scavenge superoxide (21). Reducing the superoxide concen-
tration via increased conversion of superoxide to H2O2 by
MnTBAP or treatment of cells with the N-acetylcysteine and
ascorbate did not significantly affect the hypoxia-dependent
HIF-1 stabilization (supplemental Fig. S2), suggesting that
superoxide is not required. When using DCC to inhibit SOD1,
we also observed no significant effect onHIF-1 stabilization in
hypoxia. However, DCC markedly increased HIF-1 protein
expression in normoxia (supplemental Fig. S2). This effect of
DCCwas not reversed when adding SODmimeticMnTBAP to
dismutate the accumulating superoxide, suggesting that DCC
increases HIF-1 protein expression in normoxia via a super-
oxide-independent mechanism. Therefore, taken together, our
results suggest that neither H2O2 nor superoxide is involved in
the regulation PHD activity in vivo.
DISCUSSION
At a given atmospheric oxygen concentration, the intracel-
lular oxygen concentration varies widely in different human
tissues as a function of both oxygen supply (i.e. tissue oxygen-
ation) and oxygen consumption. Given that mitochondria con-
sume more than 95% of cellular oxygen, it can be assumed that
themitochondrialmetabolic activity in a cell is amajor factor in
regulating the cellular hypoxic response. Thus, fluctuations in
mitochondrial respiration, for instance due to altered meta-
bolic activity (e.g. resting versus contractingmuscle cells) or due
to intracellular signaling events mediated via NO and CO
(which both can inhibit the terminal oxygen acceptor in the
mitochondrial ETC, cytochrome c oxidase), may play an
important role in regulating HIF-1 stability. Furthermore,
mitochondrial ETC activity is reduced under pathological con-
ditions, such as in genetic mitochondrial ETC complex defi-
ciencies or under conditions of septic shock, and the inability of
cells to elicit an appropriate hypoxic response may contribute
to the pathology in these conditions. Studies by several groups
have indeed provided strong evidence that by regulating intra-
cellular oxygen availability for HIF-1 PHD enzymes, mito-
chondria are important regulators of the cellular hypoxic
response (7, 8, 22, 23). Alternatively, a number of studies have
proposed that the role of mitochondria is to release ROS,
derived from complex III of the ETC, under hypoxic conditions
(9–11). The complex III-derived ROS were reported to be
required for hypoxia-dependent HIF-1 stabilization, and this
effect has been suggested to be due to ROS-mediated inhibition
of PHD enzymes. In this study, we evaluated the validity of the
two proposed mechanisms by using a number of approaches
that differentially affect mitochondrial oxygen consumption
and ROS production.
In this study, we provide evidence that mitochondria regu-
late HIF-1 protein accumulation by controlling the intracel-
lular oxygen availability and not by releasing ROS from com-
plex III. Thus, we show that all ETC inhibitors tested, regardless
of which complex they inhibit, decrease the HIF-1 protein
half-life under hypoxia to a very similar degree. This suggests
that inhibition at any site in the ETC has the same effect on
HIF-1 degradation under hypoxia. On the other hand, the
inhibitors are known to have varying effects on superoxide pro-
duction at complex III and had different effects on the cellu-
lar superoxide concentrations. This suggests that effects on
mitochondrial superoxide production are unlikely to
account for the stimulation of HIF-1 degradation by the
mitochondrial inhibitors.
Conflicting reports have been published on whether hypoxia
increases or decreases cellular ROS. Although a number of
reports demonstrated increased ROS under hypoxia from
mitochondrial (24, 25) or nonmitochondrial sources (26),
numerous studies reported that decreased oxygen availability
in hypoxia leads to lower ROS concentrations (27–33). Results
in which antioxidant compounds or enzymes were used to pre-
vent ROS-dependent effects on HIF-1 are equally contradic-
tory. Therefore, in this study we used approaches that would
specifically change mitochondrial oxygen consumption rates
without affecting ROS production. Previous studies supporting
the ROS hypothesis relied partially on the inhibitory effects of
the ETC inhibitors rotenone andmyxothiazol on both hypoxia-
dependentHIF-1 stabilization andhypoxia-inducedROSpro-
duction (5, 10, 34, 35). However, these ETC inhibitors are not
well suited because they also inhibitmitochondrial oxygen con-
sumption. Here, we demonstrate that in the presence of inhib-
itors of complex III, reestablishing oxygen consumption by
using an electron donor that provides electrons to complex IV
or by bypassing complex III with AOX is sufficient for hypoxia-
dependent HIF-1 stabilization. Thus, electron transport via
complex III- and complex III-mediated superoxide production
is not required for HIF-1 stabilization. We also did not detect
a direct inhibitory effect of H2O2 on PHD activity. Although
superoxide caused partial inhibition of PHD activity, superox-
ide released from complex III is quickly converted to H2O2 via
SOD1 in themitochondrial intermembrane space and SOD2 in
the mitochondrial matrix. Thus, most signaling functions of
superoxide, including the proposed inhibition of prolyl hy-
droxylases, are believed to be due to its conversion into H2O2
(10, 11). Finally, we also found thatmanipulating cellular super-
oxide production using a SOD1 inhibitor or SOD mimetic was
without effect on hypoxia-dependent HIF-1 stabilization.
Various studies have shown that ROS, either added exog-
enously or produced by manipulating the activity of intracellu-
lar ROS-producing or -inactivating enzymes, can under certain
conditions stabilize HIF-1. However, this by itself does not
provide proof that mitochondria-derived ROS are required for
hypoxia-dependent HIF-1 stabilization. In support of a com-
plex III- and ROS-mediated regulation of HIF-1 in hypoxia,
several studies have used different pharmacological and genetic
approaches. For instance, a number of studies have relied on the
mitochondria-targeted antioxidant MitoQ to inactivate super-
oxide produced by complex III in hypoxia (35, 36). However,
more recent studies suggest that in addition to its antioxidant
function, this compound also inhibits mitochondrial oxygen
consumption (35) and can under certain conditions give rise to
ROS via redox cycling (37, 38). Similarly, a number of genetic
approaches using ETC-deficient Rho0 cells, siRNA-mediated
knockdown of the Rieske iron-sulfur protein of complex III (10,
11), loss of cytochrome c (11), and complex I-deficient Chinese
hamster fibroblast CCL16-B2 cells (9) are expected to inhibit
both mitochondrial oxygen consumption and superoxide pro-
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duction, thus could not distinguish between the two potential
mechanisms. In a different geneticmodel used byBell et al. (36),
cells deficient in cytochrome b were shown to produce in-
creased amounts of ROS in hypoxia and havemarkedly reduced
mitochondrial oxygen consumption, yet are still able to stabi-
lize HIF-1 in hypoxia. Although we are currently unable to
explain this discrepancy with our data, none of the data pre-
sented in the current study support a role ofmitochondrial ROS
in hypoxia-induced HIF-1 stabilization. Thus, we did not
observe an increase in cellular superoxide in hypoxia and found
no effect onHIF-1whenROSwere reduced or increased using
different approaches. We also found no evidence for H2O2-de-
pendent inhibition of PHD activity. We observed that even
though differentmitochondrial inhibitors varied in their effects
on superoxide production, they all had very similar effects on
HIF-1 protein half-life in hypoxia. Finally, reestablishing
mitochondrial oxygen consumption under conditions where
complex III remains inhibited is sufficient to induce HIF-1
stabilization in hypoxia. Therefore, our results do not support a
role for complex III-derived ROS in hypoxia-dependent
HIF-1 stabilization. In contrast, the data presented in this
study indicate that themitochondrial oxygen consumption rate
is the main determinant of HIF-1 stability in hypoxia. Mito-
chondrial regulation of the intracellular oxygen concentration
may thus be a major mechanism that regulates the cellular
hypoxic response.
In conclusion, our study characterizes the mechanism through
which mitochondria regulate hypoxia-dependent HIF-1 stabili-
zation.Weprovide furtherevidence that inhibitingcellularoxygen
consumption prevents HIF-1 accumulation in hypoxia and that
this is the result of increased cellular oxygen availability. The
increased oxygen concentration leads to activation of oxygen-de-
pendent prolyl hydroxylase enzymes that target the HIF-1 pro-
tein for ubiquitination and proteasome-dependent degradation.
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CHUA et al. Supplementary Material 
SUPPLEMENTARY FIGURE LEGENDS  
Fig. S1.  HIF-1α  protein stabilization is not altered by modulating intracellular ROS 
(a) 143B cells were incubated at either 21% O2 or 1% O2 for 4 hours with glucose oxidase at 
concentration of 25, 100 and 200 mU/ml followed by analysis of HIF-1α by Western 
blotting. 
 
(b) 143B control cells (open bar) and cytoplasmic catalase (CYTO-CAT) (filled bar) 
overexpressing cells were stained with 20 μM 2’-7’-Dichlorodihydrofluorescein diacetate 
(DCFDA) dye for 15 min  prior to H2O2 (200 μM) treatment for 5 min.  
The difference in fluorescence before and after the H2O2  treatment was determined in 
control and CYTO-CAT cells. (n = 3, mean ± SEM). 143B cells that overexpressed with 
cytoplasmic or mitochondrial catalase (CYTO- CAT or MITO-CAT) or control vector 
cells were subjected to 21% O2 or 1% O2 and HIF-1α was detected by Western blotting. 
 
Fig. S2. Superoxide is not involved in the regulation PHD activity in vivo 
              HEK293 cells treated with diethyldithiocarbamate (DCC) (1 mM), MnTBAP  
              (100 μM), N-acetylcysteine (NAC) (10 mM) and ascorbate (2.5 mM) were     
              exposed to either 21% or 1% O2. HIF-1α protein abundance was determined    
              by Western blotting. 























































Compound C prevents Hypoxia-Inducible Factor-
1a protein stabilization by regulating the cellular
oxygen availability via interaction with
Mitochondrial Complex I
Yee Liu Chua and Thilo Hagen*
Abstract
The transcription factor Hypoxia-Inducible Factor-1a is a master regulator of the cellular response to low oxygen
concentration. Compound C, an inhibitor of AMP-activated kinase, has been reported to inhibit hypoxia
dependent Hypoxia-Inducible Factor-1a activation via a mechanism that is independent of AMP-activated kinase
but dependent on its interaction with the mitochondrial electron transport chain. The objective of this study is
to characterize the interaction of Compound C with the mitochondrial electron transport chain and to
determine the mechanism through which the drug influences the stability of the Hypoxia-Inducible Factor-1a
protein.
We found that Compound C functions as an inhibitor of complex I of the mitochondrial electron transport chain
as demonstrated by its effect on mitochondrial respiration. It also prevents hypoxia-induced Hypoxia-Inducible
Factor-1a stabilization in a dose dependent manner. In addition, Compound C does not have significant effects on
reactive oxygen species production from complex I via both forward and reverse electron flux.
This study provides evidence that similar to other mitochondrial electron transport chain inhibitors, Compound
C regulates Hypoxia-Inducible Factor-1a stability by controlling the cellular oxygen concentration.
Findings
Compound C has been reported to inhibit hypoxia
dependent Hypoxia-Inducible Factor-1a (HIF-1a) stabi-
lization by interacting with the mitochondrial electron
transport chain (ETC) and suppressing mitochondria
generated reactive oxygen species [1]. This finding coin-
cides with the hypothesis that increased reactive oxygen
species (ROS) released from mitochondrial complex III
during hypoxia stabilize HIF-1a [2-4]. However our
recent findings showed that the mitochondrial electron
transport chain controls the stability of HIF-1a during
hypoxia independently of reactive oxygen species pro-
duction [5]. We therefore studied the mechanism
through which Compound C interacts with the ETC in
detail.
Effect of Compound C on hypoxia-induced HIF-1a protein
stabilization
We first determined the effect of Compound C on
hypoxia-induced HIF-1a protein accumulation. 143B
cells from ATCC (ATCC number: CRL-8303) were
incubated at either 21% or 1% O2 for 4 hours in the
presence of Compound C (20 μM, 40 μM and 80 μM)
and then analyzed using immunoblotting. At 1% O2,
HIF-1a protein is stabilized in untreated control cells.
This is due to inhibition of prolyl hydroxylases which in
the presence of oxygen hydroxylate HIF-1 a and there-
fore target it for proteasomal degradation. The treat-
ment with increasing concentrations of Compound C at
1% O2 caused a dose dependent decrease in HIF-1 a
protein accumulation (Figure 1A). The result confirms
that Compound C inhibits hypoxia induced HIF-1 a
protein stabilization [1].
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Effect of Compound C on mitochondrial respiration
To study the effects of Compound C on the mitochon-
drial ETC, we measured the oxygen consumption in 0.5
mg of mouse liver mitochondria with a Clarke-type oxy-
gen electrode. Mitochondria were subjected to one
freeze-thaw cycle before the measurement and NADH
(2.5 mM) was used as the respiratory substrate for com-
plex I. Treatment of mitochondria with 80 μM Com-
pound C inhibited respiration by 74.5%. Oxygen
consumption resumed when the respiratory substrate
for complex II, succinate (5 mM) was added, as illu-
strated in Figure 1B. These results suggest that Com-
pound C is an inhibitor of complex I and does not
inhibit downstream complexes. To determine if
Compound C interacts with complex II, III or IV, Com-
pound C was added to mitochondria respiring on succi-
nate. Compound C did not inhibit succinate dependent
oxygen consumption (Figure 1C) and therefore does not
interact with complex II, III or IV. To directly test if
Compound C is an inhibitor of complex IV, 0.2 mM
2,2,4-trimethyl-1,3-pentanediol (TMPD)/1 mM ascor-
bate was added. TMPD is an artificial electron donor
that transfers electrons from ascorbate to complex IV
via cytochrome c. Compound C had no effect on the
oxygen consumption when TMPD/ascorbate was used
as the respiratory substrate (Figure 1D). These results
imply that Compound C inhibits mitochondrial respira-


































































Figure 1 Compound C acts as an inhibitor of mitochondrial complex I and inhibits hypoxia-dependent HIF-1 a stabilization. A. 143B
cells were incubated at 1% O2 for 4 hours in the presence of Compound C (20 μM, 40 μM and 80 μM). Whole cell lysates were separated by
10% SDS gel and probed for HIF-1a. B-D. Mouse liver mitochondria were isolated by differential centrifugation in mitochondrial isolation buffer
containing 280 mM sucrose, 10 mM Tris (pH7.4) and 1 mM EDTA as described in [8] and subjected to one freeze thaw cycle before
measurement. Oxygen consumption of mouse liver mitochondria was measured with 2.5 mM NADH, 5 mM succinate or 0.2 mM TMPD/1 mM
ascorbate as respiratory substrates and 80 μM Compound C in mitochondrial isolation buffer using a Clark-type oxygen electrode at 37°C. The
results shown are representative of 2 independent experiments.
Chua and Hagen BMC Research Notes 2011, 4:117
http://www.biomedcentral.com/1756-0500/4/117
Page 2 of 4
Effect of Compound C on ROS production from isolated
mouse liver mitochondria
Mitochondrial respiratory complex I is one of the two
main sites that are capable of producing ROS within the
ETC [6]. ROS from complex I can be derived from both
forward and reverse electron flux. To determine whether
ROS are produced from either of the electron fluxes in
the presence of Compound C, the rate of hydrogen per-
oxide (H2O2) production was measured. In this assay, 0.1
mg/ml of isolated mouse liver mitochondria were added
to 2 ml of reaction buffer (containing 125 mM KCl, 2
mM KH2PO4, 1 mM MgCl2, 20 mM HEPES, 0.1 mM
EGTA pH7.4) in the presence of 0.1 mM homovanillic
acid, 0.5 μM horseradish peroxidase and different
respiratory substrates at 37°C. The rate of H2O2 produc-
tion was measured fluorometrically at Ex/Em 312/420
nm using a Perkin Elmer LS-55 fluorescence spectro-
meter. In the presence of glutamate and malate, addition
of the well-established complex I inhibitor rotenone
resulted in a moderate increase in the H2O2 production
from complex I via the forward electron flux (Figure 2A).
As expected, H2O2 production via reverse electron flux
was inhibited by rotenone when the mitochondria were
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Figure 2 Compound C does not increase hydrogen peroxide production from both forward and reverse electron flux of complex I. 0.1
mg/ml of isolated mouse liver mitochondria were incubated in reaction buffer with either 5 mM glutamate/5 mM malate or 10 mM succinate
as respiratory substrates or inhibitors (5 μM rotenone and 20 μM Compound C) at 37°C. Hydrogen peroxide production was assessed by
homovanillic acid/horseradish peroxidase. Mitochondria, substrates and inhibitors were sequentially added as shown in the figure. The results
shown are representative of 2 independent experiments.
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Compound C was without effect on H2O2 production via
the forward electron flux (Figure 2C). H2O2 production
via the reverse electron flux was also not increased but
showed a slight decrease (Figure 2D).
To measure the cellular H2O2 and superoxide produc-
tion in mammalian cells, fluorescence of the 2’,7’-
dichlorofluorescein (DCFDA) and dihydroethidium
(DHE) dye, respectively, were monitored by flow cyto-
metry. No significant difference in both the H2O2 and
superoxide concentration was observed in cells treated
with Compound C (at concentrations up to 100 μM)
compared with untreated cells (data not shown). Taken
together, the results suggest that Compound C mediated
inhibition of hypoxia dependent HIF-1a stabilization is
not due to inhibition of complex III derived ROS as pre-
viously suggested [1] but likely due to an effect on mito-
chondrial oxygen consumption.
Conclusions
The aim of this study was to determine the mechanism
through which Compound C inhibits the stabilization of
the HIF-1 a protein in hypoxia. We provide evidence
that Compound C acts as a complex I inhibitor that
affects the stabilization of the HIF-1 a protein indepen-
dently of ROS production. Our results suggest that
Compound C, like other mitochondrial ETC inhibitors,
regulates HIF-1 a stability by controlling the cellular
oxygen concentration leading to increased cellular oxy-
gen availability and reactivation of prolyl hydroxylases in
hypoxia [5,7].
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Reveals Targeting of Microtubules as the Major Mechanism








Mol Canc2-Methoxyestradiol (2ME2) is an anticancer agent with antiproliferative, antiangiogenic, and proapop-
totic effects. A major proposed mechanism of drug action is the disruption of the microtubule skeleton,
leading to the induction of cell cycle arrest and apoptosis. In addition, other mechanisms of action have
been proposed, including the generation of reactive oxygen species (ROS), inhibition of hypoxia-inducible
factor (HIF), and interference with mitochondrial function. In this study, we used a selection of 2ME2
analogues to conduct structure activity analysis and correlated the antiproliferative and proapoptotic ac-
tivity of the various analogues with their effects on different drug targets. A good correlation was ob-
served between drug activity and effects on microtubule function. In contrast, our results indicate that
effects on ROS, HIF, and mitochondria are unlikely to contribute significantly to the cellular activity of
2ME2. Thus, our data indicate that the structural requirements for inducing ROS and inhibition of com-
plex I of the mitochondrial electron transport chain were different from those required for proapoptotic
drug activity. Furthermore, antioxidant treatment or overexpression of catalase did not inhibit the cellular
activity of 2ME2 in epithelial cancer cells. Inhibition of HIF required much higher concentrations of 2ME2
analogues compared with concentrations that inhibited cell proliferation and induced apoptosis. Our re-
sults thus provide a better insight into the mechanism of action of 2ME2 and reveal structural require-
ments that confer high cellular activity, which may aid future drug development. Mol Cancer Ther; 9(1);
224–35. ©2010 AACR.Introduction
2-Methoxyestradiol (2ME2) is a naturally occurring
metabolite of 17β-estradiol with antiproliferative, antian-
giogenic, and proapoptotic activity (1, 2), and is consid-
ered to have potential clinical benefit in the treatment of
cancer. 2ME2 does not interact with the estrogen recep-
tors. Its major target is believed to be the cellular micro-
tubule skeleton. 2ME2 has been shown to inhibit the
polymerization of tubulin in vitro, thus disrupting normal
microtubule function (3). However, at therapeutic doses
in vivo, the drug is likely to act by impairing microtubule
dynamics (4, 5). Given that rapid microtubule dynamics
are essential for the correct assembly and function of the
mitotic spindle, 2ME2 activates the spindle assembly
checkpoint and causes metaphase arrest, and as a conse-
quence, inhibition of cell proliferation and induction of
cellular apoptosis (6, 7).ffiliation: Department of Biochemistry, Yong Loo Lin School
, National University of Singapore, Singapore
Chua and Y.L. Chua contributed equally to this paper.
ding Author: Thilo Hagen, National University of Singapore,
Drive, Singapore, 117597 Singapore. Phone: 65-6516-3686;
79-1453. E-mail: bchth@nus.edu.sg
8/1535-7163.MCT-09-1003
erican Association for Cancer Research.
er Ther; 9(1) January 2010In addition to the inhibition of microtubule dynamics
and induction of cell cycle arrest, the proapoptotic action
of 2ME2 has also been linked to the stimulation of cellu-
lar reactive oxygen species (ROS) production, resulting in
the release of cytochrome c from the mitochondria and
activation of caspases (8–13). Specifically, 2ME2 has been
reported to inhibit superoxide dismutase enzymes (8).
However, a subsequent study documented that 2ME2-
induced superoxide production is not due to superoxide
dismutase inhibition and suggested the existence of an
alternative mechanism (14). We and others have shown
that 2ME2 and related compounds are inhibitors of com-
plex I of the mitochondrial electron transport chain
(15, 16). Given that in the majority of cell types, the mi-
tochondrial electron transport chain is the major source
of cellular ROS, this drug target may be responsible for
2ME2-induced superoxide production. Other complex I
inhibitors, such as rotenone or 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine, have been shown to cause
the production of ROS and induce cellular apoptosis, lead-
ing to neuronal cell death (17). Thus, 2ME2-dependent dis-
ruption of mitochondrial function may be an alternative
mechanism for its proapoptotic effects.
2ME2 has also been reported to inhibit hypoxia-induc-
ible factors (HIF; ref. 18). HIF is a transcription factor re-
sponsible for mediating the adaptation of cells and
tissues to low oxygen concentrations by upregulating
Structure Activity Analysis of 2-Methoxyestradiol Analoguesgenes involved in angiogenesis and glycolysis (19). HIF is
a heterodimer comprised of an oxygen-regulated α sub-
unit (HIF-1α or HIF-2α) and a constitutively expressed β
subunit (HIF-1β). The oxygen-dependent regulation of
HIF-1α and HIF-2α occurs at the level of their protein sta-
bility. HIF-1α and HIF-2α are normally constitutively hy-
droxylated at two proline residues by oxygen- and
oxoglutarate-dependent prolyl 4-hydroxylases (20, 21).
Prolyl hydroxylation targets these proteins for ubiquitina-
tion by the pVHL-associated E3 ubiquitin ligase, resulting
in 26S proteasome-mediated degradation. At low oxygen
concentrations, prolyl hydroxylase activity is inhibited, re-
sulting inHIF-1α andHIF-2α protein accumulation. 2ME2
was shown to inhibit hypoxia-induced HIF-1α protein ac-
cumulation (18). This effect was reported to be indepen-
dent of oxygen-regulated HIF-1α protein stability, but
due to inhibition of new HIF-1α protein synthesis. Inhibi-
tion of HIF-1α translation by 2ME2 was found to be
caused by the disruption ofmicrotubules, although the ex-
act mechanism is currently unclear.
It has been suggested that the antiangiogenic effect of
2ME2 is a consequence of HIF inhibition (18). Various
studies have also shown the importance of HIF-1α in cell
proliferation in vitro and in vivo. Thus, knockout of HIF-
1α resulted in the inhibition of the proliferation of colon
cancer cells (22, 23), mouse embryonic stem cells (24), and
immortalized mouse embryonic fibroblasts (25). HIF-1α
deficiency has also been reported to promote apoptosis
in mouse embryonic fibroblasts and pancreatic cancer
cells (26, 27). However, in other models, such as in xeno-
grafted embryonic stem cells, HIF-1α increased apoptosis
(24). Given the role of HIF-1α in cell proliferation and ap-
optosis, it is possible that the antiproliferative and proa-
poptotic effects of 2ME2 are mediated via HIF-1α
inhibition. However, there are contradictory results in
the literature as to whether 2ME2-mediated HIF-1α inhi-
bition occurs at therapeutic drug concentrations.
In an effort to gain a better understanding of the con-
tribution of the different 2ME2 targets to antiproliferative
and proapoptotic drug effects, we used a number of dif-
ferent structural analogues and correlated their cellular
apoptosis-inducing effects with their effects on different
drug targets. Our results indicate that targeting of micro-
tubules is the major mechanism of action of 2ME2,
whereas induction of cellular ROS or disruption of mito-
chondrial function are unlikely to be important contribu-
tors to drug action in epithelial cancer cells. Inhibition of
HIF-1α requires supratherapeutic concentrations and
does not correlate well with effects on microtubules.
Our studies also reveal interesting differential structural
requirements for the effects on different drug targets.Materials and Methods
Growth Inhibition
MTT assays were done as previously described (28).
GI50 values were calculated with GraphPad Prism usingwww.aacrjournals.orgnonlinear regression (sigmoidal dose-response variable
slope curve fit).
Immunofluorescence
MCF7 and HCT116 cells were grown on glass coverslips
and treated with 25 μmol/L of 2ME2 analogues for 12 h.
Cells were fixed using 4% formaldehyde and permeabi-
lizedwith 0.2%TritonX-100 for 10min.After blockingwith
5% fetal bovine serum, the coverslips were incubated with
mouse anti–α-tubulin followedbygoat anti-mouse second-
ary antibody tagged with FITC. Coverslips were mounted
onto glass slides using Vectashield (Vector Laboratories)
containing 4′,6-diamidino-2-phenylindole to label nuclei.
Immunoblotting
Cell lysis and Western blotting was carried out as pre-
viously described (29). The following antibodies were
used: mouse anti–α-tubulin (BD Transduction Laborato-
ries), mouse anti–HIF-1α (BD Transduction Laboratories),
mouse anti-FLAG (Sigma), rabbit anti–poly(ADP)-ribose
polymerase (PARP; Cell Signaling Technology), mouse
anti-p53 (Sigma), and rabbit anti-catalase (Abcam). The
Western blots shown are representative of at least two in-
dependent experiments.
HIF Luciferase Gene Reporter Assay
Cells in 12-well plates were transfected for 24 h with
0.2 μg of pGL3-HRE plasmid containing the hypoxia re-
sponse element (HRE) from the phosphoglycerate kinase
promoter (a kind gift from Dr. Kaye Williams). Cells were
treated with DMSO or 25 μmol/L of 2ME2 analogues
and incubated under normoxic or hypoxic conditions.
Luciferase reporter activity was measured using the
Steady-Glo luciferase assay reagent (Promega).
Tetracycline-Inducible Mutant HIF-1α Cells
The T-Rex system (Invitrogen) was used to generate a
cell line with tetracycline-inducible expression of P402A/
P564A mutant full-length HIF-1α-FLAG (COOH-termi-
nal 2× FLAG tag). Single clones were isolated using zeo-
cin selection. Tetracycline-dependent protein expression
was confirmed by immunoblotting.
Detection of Cellular Superoxide
Superoxide production was estimated using dihy-
droethidium. Cells were plated in 12-well plates and
grown to 70% confluence and cotreated with dihydroethi-
dium and 2ME2 analogues for 1 h. Subsequently, the cells
were rinsed with PBS and kept in PBS for analysis of fluo-
rescence using a multiwell plate reader (Molecular De-
vices), excitation and emission wavelengths were 520
and 610 nm, respectively.
Overexpression of Cytosolic and Mitochondrially
Targeted Catalase
Murine catalase was PCR-amplified from I.M.A.G.E.
clone (ID 4241333) and inserted in the retroviral expres-
sion vector Puro-MaRX. It has been previously shown that
a robust overexpression of catalase results in the accumu-
lation of protein in the cytoplasm. The NH2-terminalMol Cancer Ther; 9(1) January 2010 225
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of the sequence corresponding to residues 1–28) was
used to target catalase to the mitochondria. This con-
struct also included a COOH-terminal V5 epitope tag.
Retroviral particles were generated using catalase, mito-
chondrial catalase-V5, or enhanced green fluorescent
protein (control) containing Puro-MaRX retroviral ex-
pression vector in 293-gag-pol cells and pseudotyped
with vesicular stomatitis virus-g protein. Protein expres-
sion was assessed by fluorescence (EGFP) or immuno-
blotting with catalase antibody.
Preparation of Mitochondria and Measurement of
Oxygen Consumption
Mitochondria were isolated from mouse liver by differ-
ential centrifugation in mitochondria isolation buffer con-
taining 280 mmol/L of sucrose, 10 mmol/L of Tris (pH
7.4), and 1 mmol/L of EDTA. Oxygen consumption
was measured with a Clark-type oxygen electrode (Oxy-
graph, Hansatech) in mitochondria isolation buffer using
0.5 mg/mL of mitochondria with substrates and other
additions as indicated in the figure legends.
Drug Analogues
2ME2 and the analogues used were obtained from En-
treMed, Inc. The synthesis of the analogues is described in
a series of articles which have been submitted for publica-
tion. The preclinical activity of ENMD-1198, which is cur-
rently being tested in a phase 1 oncology trial in patients
with solid tumors, has been described in refs. (30, 31).
Results and Discussion
Modifications in the 3- and 17-Position Are
Important for Antiproliferative and Proapoptotic
Drug Effects
To determine the effects of the various 2ME2 analo-
gues on cell proliferation, MTT assays were done in
the colon cancer cell line HCT116 and the breast cancer
cell line MCF7. In HCT116 cells, 2ME2 had the strongest
inhibitory effect with a GI50 value of 0.8 μmol/L, fol-
lowed by ENMD-1269, ENMD-1198, and ENMD-1189
(see Fig. 1). In MCF7, the greatest inhibition was ob-
served with ENMD-1198 (GI50 of 0.4 μmol/L), followed
by 2ME2, ENMD-1269, and ENMD-1189. ENMD-1151,
which has a 2-amino group, but is otherwise identical
to 2ME2, had only small antiproliferative or cytotoxic
effects in the MTT assays in both cell lines, confirming
the importance of the 2-methoxy group. Similarly,
ENMD-1147, which is identical to 2ME2 except for the
presence of a 17-hydroxy group in the α-configuration,
had low activity compared with 2ME2. This indicates
that the modification in the 17-position is of great im-
portance for drug activity and that both 17β-hydroxy
and 16,17-olefin groups confer activity. Finally, ENMD-
1506, which has a 3-carboxy group, exhibited no inhib-
itory effect. This may be due to the inactivity of this
analogue. However, because the drug also had no activ-Mol Cancer Ther; 9(1) January 2010ity in any of the other cellular assays (see below), it
seems likely that the 3-carboxy group prevents efficient
uptake by cells. Our previous studies have shown that
the modification at the 3-position is of great importance
for drug activity, as an analogue lacking a modification
in the 3-position (17β-hydroxy, 2-methoxy, and 3H-estra-
diol) had markedly reduced activity compared with
2ME2 and ENMD-1198 (data not shown). Thus, both a
3-hydroxy (in 2ME2 and ENMD-1269) and a 3-carbamide
group (in ENMD-1198 and ENMD-1189) could confer
high drug activity.
We also determined the ability of the various analo-
gues to induce apoptosis by measuring nuclear frag-
mentation and cleavage of the caspase 3 substrate
PARP. After 24-hour treatment of cells with 2ME2 ana-
logues at a concentration of 25 μmol/L, marked drug-
induced cell rounding and cell death were observed
with 2ME2, ENMD-1189, and ENMD-1269, whereas
the other analogues did not cause cell toxicity
(Fig. 2A; data not shown). When the drugs were added
at a low cell density, we also observed marked toxicity
with ENMD-1198, consistent with the MTT results
above (data not shown). ENMD-1198 has previously
been shown to be highly active in different cell lines
as well as in vivo (30, 31). The reason and significance
for the lack of a proapoptotic effect with ENMD-1198
at higher cell density is currently not clear, but is likely
related to drug metabolism. Nuclear fragmentation was
apparent with 2ME2, and to a somewhat lesser extent,
with ENMD-1189 and ENMD-1269 in both HCT116
and MCF7 cells (Fig. 2B; Table 1). No effect was ob-
served with the other analogues. When measuring
drug-induced PARP cleavage after treating the cells
for 36 hours with 25 μmol/L of the various analogues,
2ME2 and ENMD-1269 were found to have the stron-
gest effect (Fig. 2C). PARP cleavage induced by
ENMD-1189 was somewhat less severe whereas the
other analogues did not cause consistent cleavage of
PARP. These results indicate that there generally was
a good correlation between inhibitory activity of the
analogues in the MTT assays and their ability to induce
apoptosis, consistent with the proposed mechanism of
action of cell cycle arrest due to disruption of microtu-
bule dynamics followed by apoptosis.
Effects of 2ME2 Analogues on Chromatin
Condensation
2ME2 at high concentration has been reported to depo-
lymerize microtubules by binding to the colchicine bind-
ing site of tubulin (3). At low therapeutic concentrations,
2ME2 inhibits microtubule dynamics, which leads to in-
hibition of the formation of the mitotic spindle apparatus,
and consequently, to the arrest of cells in metaphase
and induction of apoptosis (4, 5, 7). Therefore, the accu-
mulation of cells in metaphase was measured by deter-
mining the mitotic index, measured as the percentage
of cells with chromatin condensation. HCT116 cells were
treated with 2ME2 analogues for 12 hours, fixed withMolecular Cancer Therapeutics
Structure Activity Analysis of 2-Methoxyestradiol Analoguesparaformaldehyde and the nuclei were labeled with
4′,6-diamidino-2-phenylindole. Chromatin condensation
was determined by cell counting. ENMD-1269 showed
the strongest effect (36% of cells with chromatin con-
densation compared with 0.5% in the DMSO-treated
control), followed by 2ME2 (32%) and ENMD-1189
(20.5%). None of the other compounds induced signifi-
cant chromatin condensation compared with the control
(ENMD-1147, 1.5%; ENMD-1151, 3%; ENMD-1198, 0.5%;
ENMD-1506, 1.5%). To rule out that the drug-induced
chromatin condensation observed after 12 hours waswww.aacrjournals.orgdue to the induction of caspase-dependent apoptosis,
cells were cotreated with the pan-caspase inhibitor
zVAD-FMK. Very similar results were obtained when
zVAD-FMK was present (DMSO, 3%; ENMD-1269,
40%; 2ME2, 34.5%; ENMD-1189, 31%), indicating that
chromatin condensation was likely a direct cause of
microtubule disruption and cell cycle arrest. The results
indicate that there is a very good correlation between
analogues that cause chromatin condensation after
12 hours and those that induce apoptosis at 24 and
36 hours. Immunofluorescence staining of HCT116Figure 1. Structure of 2ME2 and analogues,
and growth inhibition. GI50 and SEM values
(bottom of the structures) represent the
averages of four (HCT116) and three (MCF7)
experiments, respectively. Note that in
ENMD-1147, the 17-hydroxy group is in the
α configuration.Mol Cancer Ther; 9(1) January 2010 227
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228cells for α-tubulin revealed that similar to paclitaxel (a
microtubule-stabilizing drug that served as a positive
control), 2ME2 induced the appearance of multipolar
spindles (Fig. 2D), as previously reported (7). In con-
trast, multipolar spindles were not observed with the
other 2ME2 analogues (data not shown), suggesting that
this is a unique property of 2ME2.
The Proapoptotic Activity of 2ME2 Is Not Due to
Induction of Cellular Production of ROS
Several studies have reported that 2ME2 induces the
production of ROS, specifically of superoxide. The induc-Mol Cancer Ther; 9(1) January 2010tion of superoxide or its conversion into H2O2 has been
implicated as the mechanism through which 2ME2 exerts
cytotoxicity (11–13). We therefore determined the effect of
2ME2 analogues on cellular superoxide concentrations
by measuring the superoxide-dependent oxidation of
the fluorescent dye dihydroethidium. Treatment of
HCT116 cells with the known superoxide-inducing
agents menadione and antimycin A caused a robust in-
crease in dihydroethidium fluorescence (Fig. 3A), thus
validating our measurements. 2ME2 at 50 μmol/L in-
duced only a moderate increase in cellular superoxide
(39 ± 13% increase compared with control). Cells trea-MFigure 2. 2ME2, ENMD-1189, and
ENMD-1269 induce apoptosis in
MCF7 and HCT116 cells. A, HCT116
cells were treated with 25 μmol/L of
2ME2 analogues for 24 h. Light
microscopy pictures were taken at
×20 magnification. B, HCT116 cells
were grown on coverslips and
treated with 2ME2 analogues for
36 h. Cells were fixed with
paraformaldehyde and nuclei labeled
with 4′,6-diamidino-2-phenylindole.
C, cells were treated with 2ME2
analogues at a concentration of
25 μmol/L for 36 h, followed by
immunoblotting of cell lysates using
the indicated antibodies. The PARP
antibody detects both the full-length
and cleaved forms. D, 2ME2 and
paclitaxel induce multipolar mitotic
spindles. HCT116 cells were grown on
coverslips and treated with 2ME2
analogues and paclitaxel for 12 h. Cells
were fixed and immunostained with
α-tubulin antibody.olecular Cancer Therapeutics
Structure Activity Analysis of 2-Methoxyestradiol Analoguested with ENMD-1151 showed the strongest production
of superoxide of all 2ME2 analogues (204 ± 54% in-
crease compared with control). ENMD-1189 and
ENMD-1269 also induced high levels of superoxide,
ENMD-1147 had intermediate effects, and no signifi-
cant increase in superoxide production was observed
in cells treated with ENMD-1198 and ENMD-1506.
ENMD-1151 has an amino group in the 2-position,
but is otherwise identical to 2ME2, thus suggesting
that the 2-methoxy group is not required for superox-
ide production and may in fact have an inhibitory ef-
fect. In contrast, the 2-methoxy group is absolutely
required for the antiproliferative and proapoptotic
drug effects, given that both 17β-estradiol and
ENMD-1151 do not significantly affect cell growth or
cell death. The lack of cytotoxic effects with ENMD-
1151 also suggested that induction of superoxide is
not a major mechanism of action of 2ME2. To confirm
this, cells were treated with the antioxidant N-acetyl-
cysteine, which did not exert a protective effect to-
wards 2ME2-induced cell death (Fig. 3B). Cellular
superoxide is normally converted into H2O2, which ex-
erts many of the toxic effects of superoxide produced
in the mitochondria. We used retroviral gene transduc-
tion to overexpress cytosolic or mitochondrially targeted
catalase which detoxifies cellular H2O2. Highly signifi-
cant overexpression of catalase compared with endoge-
nous protein concentrations was achieved (Fig. 3C).
However, this had no effects on 2ME2- and ENMD-
1189–induced cell death (Fig. 3D). Taken together, these
results suggest that the induction of cellular ROS is
not a major mechanism of action for 2ME2 in epithelial
cancer cells.
α-Configuration of the 17-Hydroxy Group
Increases Drug Interaction with Complex I of the
Mitochondrial Electron Transport Chain
2ME2 and related compounds have been reported
to inhibit complex I of the electron transport chain
(15, 16). To determine the effects of the 2ME2 analo-www.aacrjournals.orggues on the mitochondrial electron transport chain, ox-
ygen consumption was measured by polarography in
mouse liver mitochondria. To allow use of mem-
brane-impermeable NADH as a substrate for complex
I, mitochondria were subjected to a freeze-thaw cycle.
When using drug concentrations of 50 μmol/L and
NADH as the respiratory substrate, treatment with
ENMD-1147 was found to cause the greatest inhibition
of oxygen consumption (69.2% inhibition; Fig. 4A).
2ME2, ENMD-1151, and ENMD-1189 had intermediate
inhibitory effects, whereas only small or nonsignificant ef-
fects were observed with ENMD-1198, ENMD-1269, and
ENMD-1506.
Given that ENMD-1147 had the strongest inhibitory ef-
fect, we further studied the mechanism through which it
interacts with the mitochondrial electron transport chain.
Electrons that enter the electron transport chain at com-
plex I are transferred to molecular oxygen via respiratory
complexes III and IV. Therefore, the inhibitory effect of
ENMD-1147 in the presence of NADH as a substrate
(Fig. 4B) could be due to inhibition of complex I, III, or
IV. When using succinate as a respiratory substrate, suc-
cinate-derived electrons are transported via complex II,
III, and IV. ENMD-1147 did not inhibit succinate-depen-
dent oxygen consumption (Fig. 4B), ruling out interaction
of the drug with complex II, III, or IV and implicating an
interaction with complex I as the cause for respiratory in-
hibition. Consistent with this, inhibition of NADH-depen-
dent oxygen consumption by ENMD-1147 could be
reversed upon the addition of succinate (Fig. 4C). The in-
hibition of complex I by ENMD-1147 was found to be
dose-dependent (IC50 of 47 μmol/L; Fig. 4D). Further-
more, the inhibitory effect of ENMD-1147 could be par-
tial ly reversed by washing the mitochondria in
mitochondria isolation buffer after drug treatment.
ENMD-1147 at a concentration of 200 μmol/L inhibited
mitochondrial oxygen consumption initially by 86.6%
compared with the untreated control. After washing, the
inhibitory drug effect decreased to 38.6% compared with
the control, suggesting reversible binding of the drug to
complex I.
ENMD-1147 differs from 2ME2 only in the configura-
tion of the 17-hydroxy group (α-configuration in
ENMD-1147 and β-configuration in 2ME2). Thus, our
results indicate the unique activity of the 17-α-hydroxy
group towards mitochondrial complex I. The com-
pounds bearing a 17β-hydroxy group, 2ME2, ENMD-
1189, and ENMD-1151 had intermediate inhibitory
effects, whereas the compounds with the 16,17-olefin
group had only low activity. As shown above, the α-
configuration of the 17-hydroxy group significantly
reduced the cytotoxic activity of the compound, indicat-
ing that interference with mitochondrial function is not
involved in the cytotoxic effects of 2ME2. Inhibition of
mitochondrial complex I is therefore unlikely to be an
undesired “side effect” of potent proapoptotic 2ME2
analogues. Taken together, our findings indicate thatTable 1. The percentage of cells with nuclear
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Figure 3. The proapoptotic effect of 2ME2 analogues is independent of cellular ROS. A, HCT116 cells were treated with 50 μmol/L of 2ME2 analogues,
1 μmol/L of antimycin A, or 150 μmol/L of menadione (positive controls), and 20 μmol/L of dihydroethidium dye (DHE) for 1 h. Columns, mean fluorescence
results from three independent experiments; bars, SEM. B, HCT116 cells were treated with 20 μmol/L of 2ME2 and 10 mmol/L of N-acetylcysteine
(NAC) for 36 h, followed by immunoblotting of cell lysates using the indicated antibodies and imaging of cells. C and D, catalase, mitochondrially targeted
catalase, or EGFP (control) were retrovirally transduced into HCT116 and MCF7 cells. Overexpression of catalase or mitochondrially targeted catalase was
confirmed by immunoblotting with catalase antibody (C). The nonspecific band (NS) detected by the catalase antibody served as a loading control.
D, HCT116 cells were treated with 20 μmol/L of 2ME2 or ENMD-1189 for 24 h.
Chua et al.
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Figure 4. Effect of 2ME2 analogues on mitochondrial respiration. Mouse liver mitochondria were isolated as described in Materials and Methods and
subjected to freeze thawing. A, the rate of oxygen consumption in the presence of respiratory substrate NADH was measured before and after the addition
of 50 μmol/L of 2ME2 analogues. The percentage of inhibition with the 2ME2 analogues compared with the control represents the average of three
independent experiments. B–D, oxygen consumption was measured with NADH and succinate as respiratory substrates and 100 μmol/L of ENMD-1147.
E, dose-response of the inhibition of mitochondria with ENMD-1147, using 2.5 mmol/L of NADH as substrate.
Structure Activity Analysis of 2-Methoxyestradiol Analogues
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232the modification in the 17-position is an important struc-
tural determinant of the cellular activity of 2ME2 analo-
gues towards different targets.
Different complex I inhibitors have been shown to
induce ROS production originating from electron trans-
port in the mitochondria. We have therefore previously
suggested that 2ME2-dependent superoxide production
is also due to its interaction with complex I (15). How-
ever, comparison of the effects of the different 2ME2
analogues on cellular superoxide production and on
complex I activity reveals only a partial correlation. It
is possible that upon analogue binding to complex I,
inhibition of electron transport and induction of leak-
age of electrons that reduce molecular oxygen to super-
oxide is not proportional. Alternatively, it is also
possible that other mechanisms contribute to the
2ME2-induced production of cellular superoxide.
Effects of 2ME2 Analogues on HIF-1α
To investigate the potency of the various 2ME2 analo-
gues for inhibition of HIF, we first measured hypoxia-
induced HIF transcriptional activity using luciferase gene
reporter assays (Fig. 5). As expected, incubation of cells un-
der hypoxic conditions (1% oxygen) for 6 hours resulted inMol Cancer Ther; 9(1) January 2010a marked increase in reporter activity (14.7-fold increase in
MCF7 and 31.6-fold increase in HEK293). Treatment with
the various 2ME2 analogues at 25 μmol/L revealed that
ENMD-1189 had the strongest inhibitory effect in both cell
types (69.4% and 60.8% inhibition in MCF7 and HEK293
cells, respectively). 2ME2 also exhibited clear inhibitory
effects (65.3% and 33.9% inhibition in MCF7 and HEK293
cells, respectively), whereas ENMD-1147 and ENMD-1151
had weak effects. No significant inhibition was observed
with the other analogues. In control experiments using a
luciferase plasmid lacking the HRE, none of the 2ME2 ana-
logues caused a significant decrease in luciferase activity
(Fig. 5A and B, right), which indicated that the observed
drug effects were not nonspecific due to toxicity.
We next determined the effect of the 2ME2 analo-
gues on hypoxia-induced HIF-1α protein accumulation
(Fig. 6). As expected, incubation of MCF-7 and HEK293
cells at 1% oxygen resulted in a marked stabilization of
HIF-1α protein. At drug concentrations of 25 μmol/L, on-
ly treatment with ENMD-1189 caused a clear decrease in
HIF-1α protein accumulation compared with the hypoxia
control in both cell lines (45% decrease in MCF-7 cells and
41% in HEK293 cells; Fig. 6A). None of the other analo-
gues showed reproducible effects on HIF-1α.Figure 5. Effect of 2ME2 analogues on HIF transcriptional activity. MCF7 (A) and HEK293 (B) cells transfected with pGL3-HRE (left) or empty pGL3
(right) were subjected to hypoxia in the presence of 2ME2 analogues for 6 h, followed by the measurement of luciferase luminescence (columns, mean; bars,
SEM; n = 3).Molecular Cancer Therapeutics
Structure Activity Analysis of 2-Methoxyestradiol AnaloguesFigure 6. Effect of 2ME2 analogues on hypoxia-induced HIF-1α protein accumulation. A, cells were incubated at 1% oxygen in the presence of 25 μmol/L of
2ME2 analogues for 6 h and analyzed by immunoblotting. Representative Western blots (top). Densitometric analysis of three independent experiments
was done by expressing the density of HIF-1α in the drug-treated samples, corrected for α-tubulin density, as a percentage of the hypoxia control sample
(bottom). B, HEK293 cells with tetracycline-inducible expression of P402A/P564A mutant HIF-1α-FLAG (mutHIF-1α-FLAG) were transfected with
pGL3-HRE. After 24 h, mutant HIF-1α expression was induced with 1 μg/mL of tetracycline for 6 h followed by measurement of mutHIF-1α-FLAG protein
accumulation using immunoblotting with FLAG antibody and luciferase activity. C, HCT116 cells were incubated at 1% oxygen in the presence of
25, 50, and 100 μmol/L of 2ME2 analogues or 1 μmol/L of myxothiazol for 4 h.Mol Cancer Ther; 9(1) January 2010www.aacrjournals.org 233
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234Our results obtained with ENMD-1189 and 2ME2 indi-
cated stronger effects on HIF transcriptional activity com-
pared with effects on HIF-1α protein accumulation in
hypoxia. These results suggest that the drugs may affect
HIF transcriptional activity independently of regulating
HIF-1α protein abundance. To examine this further, we
used a HEK293 cell line that was stably transfected with
P402A/P564A mutant HIF-1α under the control of a tet-
racycline-inducible promoter. Expression of this protein
is expected to be independent of posttranscriptional reg-
ulation of its protein synthesis, which is likely to be me-
diated via the HIF-1α 5′- and 3′-untranslated regions, as
well as oxygen-dependent regulation of its stability,
which is dependent on the hydroxylation of Pro402
and Pro564. Cells were treated with tetracycline in the
presence or absence of 2ME2, ENMD-1189, or ENMD-
1269. Treatment of cells with tetracycline in normoxia
resulted in the induction of the mutant HIF-1α protein
and a 2.9-fold increase in HIF transcriptional activity in
the absence of 2ME2 analogues (Fig. 6B). Treatment
with ENMD-1189 had no effect on mutant HIF-1α pro-
tein induction, but reduced HIF transcriptional activity
by 37.4%. In contrast, no significant decrease in tran-
scriptional activity was observed with 2ME2 and
ENMD-1269, although both drugs caused an increase
in mutant HIF-1α protein expression. These results sug-
gest that ENMD-1189, the most potent inhibitor of en-
dogenous HIF-dependent transcription (see Fig. 5),
exerts at least part of its effect by directly inhibiting
HIF transcriptional activity independently of regulating
HIF-1α protein.
Our results show relatively small inhibitory effects of
2ME2 and its analogues on hypoxia-induced HIF-1α
protein accumulation and transcriptional activity in
MCF7 and HEK293 cells. To determine if higher concen-
trations of 2ME2 analogues could induce more robust
HIF-inhibitory effects, we incubated HCT116 cells under
hypoxic conditions for 6 hours in the presence of 25, 50,
or 100 μmol/L of the drugs (Fig. 6C). At 25 μmol/L,
only ENMD-1198 caused a slight reduction in HIF-1α
protein induction. At 50 μmol/L, only ENMD-1198
and 2ME2 had small inhibitory effects, whereas 1
μmol/L of myxothiazol, an inhibitor of the mitochon-
drial electron transport chain with established potent
HIF-inhibitory effects, completely prevented hypoxia-
induced HIF-1α protein accumulation (Fig. 6C, top).
At 100 μmol/L, ENMD-1198 exhibited consistently very
strong inhibition of hypoxia-induced HIF-1α stabiliza-
tion. ENMD-1269 had intermediate effects, whereas
the other analogues caused weak or no inhibition.
A number of studies have reported more potent HIF
inhibitory effects, whereas relatively high 2ME2 concen-
trations were also required in other reports. The differ-
ences may be related to cell types and drug exposure
times (although we have also only observed small effects
upon 24 hours of drug treatment in HCT116 cells). De-
spite the differences with some previous studies, our re-
sults indicate that in the cell types used in this study,Mol Cancer Ther; 9(1) January 2010considerably higher doses of 2ME2 and its analogues
were required to inhibit HIF-1α compared with the con-
centrations that exerted antiproliferative and proapopto-
tic effects. Furthermore, there was no good correlation
between the antiproliferative and proapoptotic effects
and the inhibition of HIF. Thus, ENMD-1269, which po-
tently inhibited cell proliferation and induced apoptosis,
was without significant effect on HIF-1α protein and
transcriptional activity when used at the same concentra-
tion. HIF inhibition is therefore unlikely to contribute to
the in vitro cellular activity of 2ME2. However, it remains
possible that HIF inhibition occurring in vivo plays a role
in the antiangiogenic effects of 2ME2 or ENMD-1198.
With respect to the mechanism of 2ME2-dependent HIF
inhibition, it has been previously reported that disruption
of microtubules leads to the inhibition of HIF-1α protein
synthesis (18). Alternatively, 2ME2-induced production of
ROS or inhibition of mitochondrial respiration may lead
to the inhibition of HIF-1α protein stabilization in hypoxia
(32–36). We did not observe a good correlation of effects
on HIF-1α with any of these drug actions. ENMD-1269,
which had potent effects on microtubules, ENMD-1151,
which was the strongest inducer of superoxide, and
ENMD-1147, which had the strongest activity towards
mitochondrial complex I, all had no significant effects
on hypoxia-induced HIF-1α protein accumulation at their
effective drug concentrations. This suggests the existence
of an alternative mechanism(s) through which 2ME2 and
some of its analogues inhibit the HIF transcription factor.
Our data suggest that direct inhibition of HIF transcrip-
tional activity may at least partially be involved.
In summary, our results suggest that targeting of mi-
crotubules is the major mechanism of action of 2ME2,
whereas the other reported targets of 2ME2, i.e., the in-
duction of cellular ROS, disruption of mitochondrial
function, and inhibition of HIF, are unlikely to be impor-
tant contributors to drug action in epithelial cancer cells.
Inhibition of HIF-1α requires supratherapeutic concentra-
tions and does not correlate well with effects on microtu-
bules, raising doubts about both its significance in
epithelial cancer cells and the previously reported mech-
anism of 2ME2-induced HIF-1α inhibition. Our studies
also reveal that in addition to the 2-methoxy group, mod-
ifications in both the 3- and 17-positions are important
determinants of drug activity, and our findings may aid
in future drug development.
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